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ABSTRACT OF DISSERTATION  
 
 
 
DISSECTING THE BIOSYNTHESES OF GILVOCARCINS AND RAVIDOMYCINS  
             
       Gilvocarcin V (GV) and ravidomycin (RMV) exhibit excellent antitumor 
activities in the presence of near-UV light at low concentration maintaining a low in vivo 
cytotoxicity. Although, the exact molecular mechanism for in vivo actions of these 
antibiotics has yet to be determined, a [2+2] cycloaddition reaction of the vinyl side chain 
with DNA thymidine residues in addition to the inhibition of topoisomerase II and DNA-
histone H3 cross-linking are reported for the GV’s mechanism of action. Such activities 
have made these molecules interesting candidates for the biosynthetic investigation to 
generate analogues with improved activity/solubility. Previous biosynthetic studies have 
suggested that the GV biosynthetic pathway involves a number of synchronously 
occurring transformations leading to the oxidative C-C bond cleavage and other 
intriguing biosynthetic reactions, such as the vinyl side chain formation, methylations, C-
glycosylation and dehydrogenation. Although gene inactivation results identified many 
candidate genes whose corresponding enzymes are involved in these biochemical 
transformations, their exact functional roles and the identity of their natural substrates 
remained elusive. To provide more insights into these complex biochemical 
tranfrormations, three specific aims were set up. 
  
Specific aim 1 was to clone and characterize the RMV biosynthetic gene cluster. 
Through the comparison of GV cluster with the RMV cluster, the genes encoding the 
biosynthesis of sugar and tetracyclic aromatic moieties were identified. RavGT, the sole 
glycosyltransferase of the RMV cluster has demonstrated to have unprecedented sugar 
donor substrate flexibility, transferring an amino-pyranose sugar as well as a neutral 
furanose sugar. 
 Specific aim 2 was to characterize all of the TDP-D-ravidosamine biosynthetic 
enzymes. The aim also included to a one-pot enzymatic synthetic protocol for the routine 
production of TDP-D-ravidosamine. 
 
 Specific aim 3 focussed on a total enzymatic synthesis of defucogilvocarcin M 
(defucoGM), the polyketide-derived core of GV and RMV. This aim clearly identified 
the minimal enzymes required to biosynthesize the complex architecture of defucoGM 
from the simple building blocks acetate and malonate. In addition, the GV-pathway 
enzyme GilR was fully characterized. Through in vitro studies, GilR was shown to 
catalyze the dehydrogenation of hemiacetal moiety of the penultimate intermediate 
pregilvocarcin V to the lactone moiety of GV at the last step. 
  
Keywords: Gilvocarcin V, Ravidomycin V, enzymatic total synthesis, deoxysugar 
biosynthesis, dehydrogenase 
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Section One: Background 
Polyketides 
Polyketides represent one of the major classes of natural products. The polyketide class 
covers a heterogenous group of compounds such as macrolides, enedyines, anthracyclines, 
angucyclines, polyenes, macrolactams and polyethers (1). They are ubiquitous in nature spanning 
from prokaryotes such as bacteria to eukaryotes such as plants, mollusks and insects. Their exact 
roles in the context of their original biological system are not fully known yet, however, it is 
believed that these secondary metabolites serve as pigments, virulence factors, infochemicals or 
as defense weapons. Many of these compounds or their derivatives have become clinically useful 
pharmaceutics such as antibiotics, immunosuppressants, antiparasites, cholesterol-lowering 
agents, and antitumor agents, while others are infamous toxins or virulence factors (2). 
Antibacterial agents, such as oxytetracycline (1), erythromycin A (5), and the rifamycin 
derivative rifampicin (9), monensin (6), the antifungal agent amphotericin B (7), the cholesterol 
lowering agent lovastatin (3), the immunosuppressant FK506 (4), the antitumor agents 
doxorubicin (2), and mithramycin (8) etc. represent some of the clinically used polyketides 
(Figure 1.1). Because of their tremendous structural diversities and pharamacological relevance, 
much attention has been paid in the last few decades to access synthetic routes for these natural 
products or derivatives thereof. Despite remarkable progress in chemical synthetic techniques 
over the past decades, the total synthesis of many polyketides is still very challenging due to 
their vast structural complexities and diversities, although they are assembled from the simplest 
building blocks acetate or propionate (1). This led to the emergence of a new research area called 
“Combinatorial Biosynthesis” which utilizes the synthesis of natural products or derivatives 
thereof modifying nature’s original synthetic strategies and tools. Different types of polyketides 
and their biosynthetic routes are briefly discussed below.  
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Figure 1.1 Representative examples of polyketide drugs. 
 
Biosynthesis of polyketides 
Polyketides biosyntheses are catalyzed by complexes of mono-or multi-functional 
enzymes called polyketide synthases (PKSs). The genes encoding these enzymes are usually 
organized in clusters, presumably to facilitate a coordinated regulation of expression of multiple 
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enzymes required for the many steps in these specialized biosynthetic pathways (3). The 
biosynthetic genes are also associated with resistance genes and export genes to prevent the 
producer organisms from self-intoxication of their own products. The chemistry associated with 
PKSs is closely related to the well studied fatty acid synthases (FASs). Both pathways do not 
only share a common biosynthetic logic, but they also share common building blocks such as 
acetyl-coenzyme A (acetyl-CoA) and malonyl-CoA (4). Decarboxylative Claisen thioester 
condensations of an activated starter unit with malonyl-CoA or malonyl-CoA-derived extender 
units generate β-ketoester intermediates. This process requires β-ketoacyl synthase (KS), 
acylcarrier protein (ACP) and an optional malonyl/acyltransferase (MAT/AT). During fatty acid 
biosynthesis, every elongation step follows β-ketoreduction, dehydration and enoyl reduction 
catalyzed by ketoreductase (KR), dehydratase (DH) and enoyl reductase (ER), respectively, to 
yield a fully saturated acyl backbone. In contrast, each polyketide chain extension cycle is 
followed by full, partial or no reduction steps giving rise to a complex pattern of 
functionalization (Scheme 1.1). Unlike FASs, PKSs are more promiscuous, use a variety of 
building blocks and can also generate products with various chain lengths. In both pathways, the 
carbon backbone continues to grow until a defined length is achieved, and the fully grown 
products cleave off from the thioester-bound substrates of the enzyme complexes. 
Based on the assembly line enzymes, their mode of actions and architectures, PKSs are 
divided into three major categories known as type I, type II and type III (5). Type I PKSs consist 
of large multifunctional enzyme complexes where each enzyme has a catalytic domain and a 
carrier protein domain organized like beads on a string (6). Such assembly lines are further 
divided into two different systems, such as modular and iterative. In the modular system, each 
module consists of optional β-keto processing domains (KR, DH, ER) in addition to a set of KS, 
AT and ACP domains. These catalytic and carrier domains are used only once as the growing 
chain passes from N-terminal to C-terminal. The number of modules thus reflects the number of 
cycles catalyzed by a particular type I PKS and the presence of KR, DH and ER domains 
determines the degree of β-keto reduction in each module. In general, the number of modules 
and the number of catalytic domains in each module corresponds to the overall architecture of 
the PKSs product, thus making it possible to predict the product structure through the analysis of 
catalytic domains of PKSs or vice versa (1). The PKS of the erythromycin biosynthesis 
represents the proto-typical PKS (Scheme 1.2). 
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Scheme 1.1 Fatty acids (A) and polyketide (B) biosyntheses. Route X and route Y represent biosynthesis 
of unreduced and fully/partially reduced polyketides. 
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Scheme 1.2 Erythromycin A biosynthesis, 6-DEB: 6-deoxyerythronolide B. 
The cluster is composed of three open reading frames (ORFs), namely DEBS1 (eryAI), 
DEBS2 (eryAII) and DEBS3 (eryAIII) with a total of six modules and a loading domain (3, 7, 8). 
The biosynthesis starts with the loading of a starter unit propionyl-CoA to the holo-ACP domain. 
The KS domain of module 1 self acylates with the extender unit (methylmalonyl-CoA). 
Decarboxylative condensation between the ACP-tethered starter unit and the extender unit 
results in the formation of a diketide. The reduction of the keto group by the KR domain results 
in the formation of a hydroxyl group at the C-3 position. The AT domain of module 1 catalyzes 
the transfer of the growing chain from the loading ACP to the ACP of module 1. The process 
continues until the designated chain length is achieved. The final task of the PKS is to disconnect 
the mature PKS product from the ACP in module 6. This is achieved by thiosterase domain of 
eryAIII, which catalyzes an intramolecular lactone formation, where the hydroxyl group at C3 
serves as a nucleophile to the carbonyl carbon of the thioester resulting in the formation of 6-
erythronolide B (10). However, there are several other type I PKSs, where a module is used more 
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than once, some domains are skipped or the modules lack AT domains. In such AT deficient 
PKSs, standalone ATs load starter or extender units to ACPs in trans fashion (9, 10). Such 
iterative type I PKSs are usually found in fungi. The lovastatin PKS is a typical example (11, 
12). In these PKSs, KR, DH and ER domains are optionally used in every round of chain 
elongation as in lovastatin biosynthesis (Scheme ). How this is controlled is not yet fully 
understood. 
 
Scheme 1.3 Lovastatin biosynthesis. The intermediate undergoes intramolecular Diels-Alder reaction to 
establish a decalin moiety of lovastatin. 
Iteratively operating type II PKSs are more common in prokaryotes. Unlike type I PKSs, 
a minimal set of enzymes are used iteratively to generate poly β-keto thioester. Ketoacyl 
synthases [KSα and KSβ (chain length factor, CLF)] and ACP constitute the minimal PKS 
(Scheme 1.4) (13). However, other enzymes, such as, ketoreductases (KRs) and cyclases (CYCs) 
and aromatases (AROs) work with the minimal PKS in an enzymatic complex to control the 
folding, cyclization and aromatization pattern of the nascent polyketide chain. The type II PKS 
system responsible for the actinorhodin (11) biosynthesis was first reported from Streptomyces 
coelicolor (14). Doxorubicin (2) (Scheme 1.), gilvocarcin V (GV, 12), landomycin A (13) and 
tetracycline (14) are other examples of type II PKS-derived antibiotics (Figure ). Acetyl-CoA or 
propionyl-CoA are used as starter units, whereas malonyl-CoA is used for chain elongation. 
Type II PKSs are usually found in actinomycetes with an exception of a few other Gram-
negative bacteria (15, 16). 
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Scheme 1.5 Type II PKS-catalyzed biosynthesis of doxorubicin. 
Iterative type III PKSs do not require any ACP-bound extender units for chain elongation 
and utilize acyl-CoA substrates directly (Scheme 1.). Biosynthesis of the plant product 
naringenin chalcone (15) through a sequential addition of 3 molecules of malonyl-CoA to a p-
coumaryl-CoA starter unit represents a typical type III PKS catalysis. These enzymes are known 
as stilbene/chalcone synthases, and are found in plants and bacteria as well as in fungi (17-19). In 
addition to these three general types of polyketides, there are mixed type polyketide synthases, 
such as type I-type II, type I-type III, FAS-PKS hybrid or PKS-NRPS (non-ribosomal peptide 
synthases) (1). 
 
 
Scheme 1.6 Type III PKS-mediated biosynthesis of naringenin chalcone 
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Post-PKS tailoring reactions 
The products of PKSs or PKS-conjugates usually undergo a series of tailoring events 
such as glycosylation, methylation, oxidation, reduction, prenylation and halogenations to 
generate biologically active compounds. Such tailorings cause tremendous change to the 
pharmacological property of the parent polyketides, such as solubility or binding ability of the 
drug to a receptor. Erythromycin A represents such a typical example where the PKS-product (6-
DEB) has no activity, but oxygenation and glycosylations reactions change it into a powerful 
antibacterial agent (20). On the other hand, post-PKS tailoring reactions provide a unique 
platform to design natural product derivatives through pathway engineering, also known as a 
type of “combinatorial biosynthesis” (21). This typically involves targeted gene inactivation, 
gene replacement, homologous/heterologous expression of the genes or site-directed mutagenesis 
techniques, or combinations. Preparation of mithramycin analogues with altered sugar pattern 
through the expression of various deoxysugar biosynthetic constructs, preparation of 
ketopremithramycins and combinatorial biosynthesis of urdamycins are some of several 
examples of such a combinatorial biosynthetic approach (22-27). Some common post-PKS 
tailoring reactions, which are observed in various natural product biosynthetic pathways, and are 
relevant to this work, are briefly discussed in the following section. 
Glycosylation 
Glycosylation is known to be one of the most important post-PKS tailoring reactions 
because it not only modulates biological activity of the molecule, but can also provide self-
resistance to the producer organism. Activation of 6-DEB by glycosylation, and inactivation of 
oleandomycin or erythromycin A by addition of glucose to their desosamine moieties are typical 
examples (28). Glycosylation usually occurs in the later stages of a biosynthetic pathway and the 
reaction typically involves an enzyme or rarely two enzymes known as glycosyltransferases 
(GTs) which use NDP-activated sugars as donor substrates and an acceptor substrate. The 
transfer of the sugar to the acceptor substrate yields O-, N-, S- or C- glycosidic bonds. These 
glycosyltransferases are grouped into ~90 sequence-based families (29). However, three 
dimensional structures of all of the reported GTs fall into two major folds, GT-A and GT-B (21, 
29). Glycosylation chemistry involves a GT-mediated nucleophilic attack of the acceptor 
substrate at the anomeric carbon of the donor substrate, with the simultaneous release of the 
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nucleotide diphosphate, either in an SN2-fashion or via an oxocarbenium-ion-intermediate (if the 
activating group leaves prior to the glycosidic bond formation) (Scheme 1.7) (30). Although 
glycosylations have long been believed to be unidirectional, Thorson et. al. have recently 
demonstrated that some natural product O-glycosylation reactions in fact are reversible (31).  
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Scheme 1.7 Proposed mechanism for inverting type O-GTs. The figure is adapted from Rohr et al 2002 
(30). 
Most of the C-glycosides from microbial secondary metabolites have the sugar attached 
ortho or para to an electron rich functional groups (e.g. -OH) of the aromatic moiety. Such 
functional groups create higher electron density at the ortho- or para- position, making it possible 
to attack at the anomeric centre of the sugar (Scheme 1.) as in the case of urdamycin A and GV 
(32, 33). However, exact mechanisms for C- or N-glycosylations are still obscure. Based on the 
stereochemical change at the anomeric carbon of the sugar, GTs are further classified into two 
groups; inverting GTs and retaining GTs. Most of the secondary metabolite producer 
actinomycete GTs fall into the inverting type of GT-1 family. 
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Scheme 1.8 A hypothetical mechanism for C-glycosylation. 
In the past few decades, a variety of GTs have been identified from various secondary 
metabolite biosynthetic pathways. Most of these GTs have relatively strict substrate specificities. 
However, some others appeared to operate on a variety of sugar donor substrates. Those GTs 
with inherent broad substrate specificities are of special interest as they can be utilized to 
generate a variety of unnatural derivatives of natural products with potentially better therapeutic 
indices. Generation of an array of tetracenomycins, steffimycins and aranciamycins using a 
variety of sugar donor substrates with promiscuous ElmGT, StfGT and AraGT, respectively, 
highlights the potential application of such GTs in combinatorial biosynthesis (34-40). In 
addition, point mutation or domain swapping or saturation mutagenesis can be carried out to 
improve promiscuity of the GTs of interest. Generation of various unnatural glycosides through 
the modification of OleD (glycosyltransferase from oleandomycin biosynthetic pathway)(41-43) 
and generation of prejadomycin C-glycosides through the expression of UrdGT2 into LndE 
minus mutant are some representatives of such endeavors (44). These results clearly show the 
tremendous application of GTs to rationally design natural product glycosides through 
combinatorial biosynthesis.  
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Deoxysugar biosynthesis 
Sugar moieties of most of the microbial natural products are often deoxygenated to 
various extents prior to their attachment to the aglycones. Deoxygenation of hexose sugars 
usually begins with conversion hexose-1-phosphate into its nucleotide diphosphate (NDP) 
derivative by NDP-hexose-nucleotidyl transferases (45). The dedicated enzymes utilize NTP 
(ATP, CTP, GTP, UTP or TTP) as a source of NDP. While TDP-activations are the most 
dominant in microbial deoxysugar biosynthetic pathways, GDP- and UDP-activations were also 
reported. The aminopentose moiety of calicheamicin and L-lyxose-derived moiety of avilamycin 
are examples of UDP-α-D-glucose-derived deoxysugars (46, 47). Similarly, deoxysugar moieties 
of nystatin and amphotericin B are derived from GDP-mannose (48). NDP-hexose-4,6-
dehydratase catalyzes a redox reaction that deoxygenates the C-6 carbon and oxidizes C-4 
carbon of the activated sugar to generate NDP-4-keto-6- deoxy-D-hexose (18). The product 
serves as a common intermediate for all of 6-deoxysugar pathways. Formation of various TDP-
deoxysugars through 18 is shown in the Scheme 1.9 (49).  
 
Scheme 1.9 Biosyntheses of 6-deoxysugars through the common intermediate (18) 
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Oxygenation 
The products of PKSs often undergo a series of oxidations such as hydroxylations, 
epoxidations, anthrone oxidations, desaturations, Baeyer-Villiger monooxygenation, etc. which 
are usually needed for their biological activities (21). Typically, these reactions are catalyzed by 
a large family of enzymes, oxygenases. Based on the number of oxygen atoms incorporated into 
the substrate, they are further classified as monooxygenases (extracts one O-atom from an O2-
molecule) and dioxygenases (utilizes both O-atoms of an O2-molecule). Most of the 
monooxygenases utilize reduced NADPH as reducing equivalents and catalyze hydroxylations, 
epoxidations or Baeyer-Villiger oxidations, whereas dioxygenases result in the production of 
peroxides or dioxetanes, which further rearrange or react to yield diols (Scheme 1.10) (21). 
Scheme 1.10 Structural diversity introduced by oxygenases (adapted from Rohr et al. 2002) (21). 
Cytochrome P-450 monooxygenases (CYP450s) constitute a very large and diverse 
family of hemoproteins. They can be one-component (reductase activity associated with the 
enzyme) or two-component (requires another enzyme called ferredoxin reductase) enzymes. 
Stereospecific hydroxylation and epoxidation are the most common CYP450 catalyzed reactions 
observed in post-PKS modifications. PikC-mediated hydroxylation of narbomycin (24) in the 
pikromycin (25) biosynthetic pathway is a good example of an CYP450 (Scheme 1.) (50). Like 
GTs, broader substrate specificity of CYP450s can be exploited for the generation of novel 
natural product analogues. This approach was successfully used to generate several analogues of 
pikromycin and erythromycin (51-53).  
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Scheme 1.11 Hydroxylation of narbomycin by PikC. 
Baeyer-Villiger monooxygenases (BVMOs) involved in secondary metabolite 
biosynthetic pathways are rapidly growing. MtmOIV from mithramycin, (54) CmmOIV from 
chromomycin, (55) JadH from jadomycin, (56) GilOI from gilvocarcin (57) are proved/proposed 
examples of such enzymes. BVMOs are flavin-dependent and catalyze the typical Baeyer-
Villiger oxidation reaction, i.e. the insertion of an oxygen atom in cyclic ketone to form a 
lactone. The reaction requires NADPH for reducing molecular oxygen. Despite the hundreds of 
reports on BVMOs and their synthetic applications, MtmOIV is the only BVMO whose natural 
substrate and mechanism of catalysis is characterized. MtmOV catalyzes the conversion of 
premithramycin B (26) to premithramycin B-lactone (27), which eventually opens up to yield 
mithramycin DK, the penultimate intermediate of the mithramycin biosynthetic pathway 
(Scheme 1.) (54, 58). Mechanistically, two electrons and two protons are transferred from 
NADPH to FAD generating FADH transiently. The reduced flavin immediately receives an 
atmospheric oxygen molecule to generate a reactive peroxyflavin ion. Nucleophilic attack of the 
ion on the ketone carbon followed by the migration of the C-C bond generates a lactone. Other 
flavin-dependent monooxygenases are PgaE, PgaM (59), and even cofactor-free anthrone 
oxygenases such as TcmH (21), AknX (60), JadG (61) are known. Most of these catalyze simply 
hydroxylations and their number is steadily growing.  
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 Scheme 1.12 MtmOIV-catalyzed Baeyer-Villiger oxidation of premithramycin B. 
 
Scheme 1.13 Mechanism of BVMO catalysis. 
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Methylation 
Methyltransfer reactions are among the most common post-PKS tailoring reactions, 
observed in the biosynthesis of a variety of bioactive microbial secondary metabolites. N-, C- or 
O-methylations of PKS products occur through the activity of corresponding methyltransferases 
(MTs) in a regioselective manner. These enzymes require S-adenosyl methionine-(SAM) as the 
methyl donor source, and function in various quaternary structural forms. For example, while 
carminomycin 4-O-MT (DauK) from Streptomyces sp. strain C5, which methylates 
carminomycin to daunorubicin, functions in the tetrameric form (62, 63), emodin O-MT (64) and 
tetracenomycin-O-MT (TcmO) (65) work in homohexameric and homodimeric forms, 
respectively. MTs are widely used for combinatorial biosynthetic approaches. Methylation of 
anthracyclines rhodomycin D and 13-carboxy-13-deoxycarminomycin by DauC are 
representative of such example (66). Methylations are also involved in the biosynthesis of 
deoxysugars such as L-mycarose, D-desosamine, etc. (36, 67, 68). The identification of the 
bifunctional methyltransferase/cyclase TcmN from the tetracenomycin biosynthetic pathway 
shows the evolutionary diversity of this family of enzymes (69). 
Antitumor antibiotics gilvocarcin V and ravidomycin V 
GV (12) produced by Streptomyces griseoflavus Gö 3592 represents the most important 
member of benzo[d]naptho[1,2-b]pyran-6-one anticancer antibiotics (70, 71). The compound 
was first isolated by Nakano et al. in 1981 from Streptomyces gilvotanareus (72-74). It exhibits 
high potency against tumor cell lines at low concentration with a low in vivo toxicity. In addition, 
GV serves as an antiviral and an antibacterial agent (71,75,76). These properties made this 
molecule particularly interesting for the biosynthetic investigation and for the development of its 
analogues with improved activity through combinatorial biosynthesis. It has been reported that 
GV promotes a [2+2] cycloaddition reaction of the C-8-vinyl side chain with DNA thymidine 
residues in addition to the inhibition of topoisomerase II (77-79). A recent report of GV-
promoted cross-linking between DNA and histone H3 is particularly remarkable (80). However, 
the exact molecular mechanism for the in vivo action of GV is yet to be determined. Despite an 
early success on total synthesis of gilvocarcins (V, M and E), none of their analogues have ever 
been synthesized (81-84). The structural complexity of GV and a costly and laborious synthetic 
process could be understood as a part of the hurdle for generating new GV derivatives. 
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The GV producer Streptomyces griseoflavus also produces minor amounts of gilvocarcin 
M (GM, 12-b). Both compounds have an identical tetracyclic aromatic moiety linked to D-
fucofuranose through C-4 glycosidic linkage, but GM has a methyl group at C-8 position instead 
of the vinyl group of GV. This answers the question why GM is far less photoactive as compared 
to the GV indicating the crucial role of the vinyl side chain in conferring biological activity (77). 
Several other analogues of GV, such as the ravidomycins (RMs, 28, 29), chrysomycins (CMs, 
32, 32-a), FE35A (30) and B (31) (85), BE 12406 A (38) and B (39) (86, 87), Mer 1020 dA-D 
(33-36) (88) and polycarcin V (37) have been isolated from various actinomycete species 
(Figure 1.) (89). They are different from GV in their deoxysugar moieties, but members of the 
so-called gilvocarcin class compounds (71). Unlike GV (12) or most of the gilvocarcin class 
compounds, 38 and 39 have O-glycosidically linked sugars.  
RMV (28) is a potent antitumor and antibacterial antibiotic isolated from the culture 
broth of Streptomyces ravidus (90). RMV shows a broad range of biological activities (91). It is 
about two fold more active than GV against varieties of gram-positive (MICs = ≤.0.06 μg mL-1 
and 0.12 – 4 μg mL-1 in the presence and in the absence of visible light, respectively) and gram 
negative (MICs = 64 - >128 μg mL-1 and ≥ 0.5 μg mL-1 in the presence and in the absence of 
visible light, respectively) bacteria (92). Such activities could be attributed to RMV’s role in 
inhibiting DNA and RNA synthesis. RM shows remarkable activity against P38 leukemia cell 
lines both in vitro and in vivo in mice (85, 93). 
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Figure 1.3 Gilvocarcins, ravidomycins and related antibiotics. 
However, cytotoxicity of RMV (28) was reported for human colon carcinoma cell lines 
(92). In addition, RMV (28) has been reported as a potent inhibitor of human topoisomerase II 
(94). Like GV, the exact mechanism of action of RMV at the molecular level is still unclear. 
However, photoactivated antitumor and antibacterial activities of GV (12) and RMV (28), and 
their common coumarin-based backbone indicate their similar mechanism of actions. Although, 
there is no direct experimental report on activity comparison of RMV with the other analogs, 
reports in the literature indicated RMV to be the most active compound against tumor cell lines 
(93). This is a clear indication that the more hydrophilic amino sugar moiety has a crucial role in 
the biological activities. Such amino compounds also provide better formulation and delivery 
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options in their salt forms (95). Structure activity relationship (SAR) of the RMV analogues 
generated through chemical modification suggested that 2′- and 4′-hydroxyl groups of the D-
ravidosamine subunit are essential for the biological activities. However, its inherent cytotoxicity 
hindered its further development as an anticancer drug necessitating the generation of new 
analogues with better pharmacological profiles. 
Biosynthetic investigations of gilvocarcin V and ravidomycin V 
Incorporation studies of gilvocarcins, ravidomycins and chrysomycins showed that the 
unique backbone originates from acetate and propionate, and the pathway involves a C-C bond 
cleavage and an oxidative rearrangement of an angucyclinone (96-98). However, the exact 
intermediates involved, mode of oxidative rearrangement and other post-PKS tailoring reactions 
were largely unclear. Recently, Rohr et al. have isolated the complete gene cluster for GV 
biosynthesis in a single cosmid, namely cosG9B3. Heterologous production of GV in S. lividans 
TK24 clearly showed that the cosmid harbors the entire GV biosynthetic locus (71). The 
sequencing of the cluster revealed the presence of anticipated PKS genes (gilABCFKPQ), four 
putative oxygenases (encoded by gilOI, OII, OIII, OIV), a C-glycosylransferase (encoded by 
gilGT), a methyltransferase gene (gilMT), an oxidoraductase gene (gilR) and several other genes 
of unknown function such as gilNLVM besides putative repressor and resistance genes (Figure 
1.). 
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Figure 1.4 GV biosynthetic gene cluster (the figure was taken directly from Rohr et al. 2003) (71). 
 In an effort to figure out the mode of the oxidative C-C bond cleavage, all of the 
pathway oxygenases were inactivated in cosG9B3 individually or sequentially. Thus, the 
generated mutant cosmids were heterologously expressed in S. lividans TK24. Homo-
rabelomycin (48) and 2,3-dehydro-homo-UWM6 (41) were identified as major metabolites from 
the culture broth of ∆GilOIV or ∆GilOIV∆GilOII and ∆GilOI∆GilOII∆GilOIV or ∆GilOI 
mutants, respectively (Scheme 1.) (56,57). Similarly dehydro-homo-rabelomycin (49) was 
isolated from a ∆GilOII mutant. In none of these compounds, a C-C bond cleavage occurred, 
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which indicated that all of the oxygenases are necessary for the C5-C6 bond cleavage of the 
hypothetical intermediate 42. Identification of similar compounds through the inactivation of 
homologous oxygenases of the jadomycin pathway showed that both jadomycin A (44-c) and 
GV (12) biosynthetic pathways share common intermediates prior to their C-C-bond cleavages 
(Scheme 1.) (30, 61). Interestingly, a cross complementation of the ∆GilOI mutant strain with 
JadH and of the ∆gilOIV mutant with JadF restored the production of GV. However, GV 
production was not restored when jadG was expressed into the ∆GilOII strain (56). This 
indicated that both pathways share at least two functionally identical oxygenases and might have 
identical modes of oxidative C-C bond cleavage. GilOII and JadG might have functions unique 
to the GV and jadomycin pathways, respectively. Identification of a GV biosynthetic 
intermediate, pregilvocarcin V (47), from the ∆GilR mutant provided indirect proof that the GV 
biosynthesis involves an acid-aldehyde intermediate (44). While non-enzymatic incorporation of 
L-isoleucine to this intermediate, followed by spontaneous decarboxylation and oxidation 
resulted in the production of jadomycin A (Scheme 1.) (99, 100), C-C bond rotation, O-
methylations, vinyl side chain formation, glycosylation, and oxidation were necessary to 
generate GV (Scheme 1.). However, the exact mechanism of such oxidative ring opening for 
both pathways was remain undetermined. 
Rohr et al. further inactivated several other genes and analyzed the metabolites 
accumulated by the resulting mutants. Inactivation of GilGT completely halted the production of 
GV and accumulated defuco-GV (50) (33). The production of GV was restored by 
complementing the mutant with a GilGT-expression plasmid. Similarly, gilvocarcin E (12-a) was 
accumulated as the major metabolite of the ∆GilOIII mutant. These results clearly showed that 
GilGT and GilOIII were involved in C-glycosylation and C-8-vinyl side chain formation, 
respectively.  
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Scheme 1.14 Proposed pathway for GV biosynthesis. 
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Scheme 1.15 Biosynthetic pathway of jadomycins A and B. 
None of the compounds isolated from the mutant strains were converted into GV when fed to a 
culture of the ∆GilOIV mutant. This indicated that the accumulated compounds were 
biosynthetic shunt products, thus, making the substrate of GilGT and GilOIII elusive. 
Gilvocarcin V production was completely abolished when gilM (unknown gene) was inactivated 
and the production was restored when the mutant was complemented with a gilM-expression 
construct (101). The mutant accumulated the shunt product, homo-rabelomycin (48), as the 
major metabolite and also produced an other yet uncharacterized minor compound. This clearly 
showed that GilM was a crucial enzyme for the GV biosynthesis, although its exact functional 
role was not clear. Expression of gilMT-deleted cosmid in S. lividans TK24 did not accumulate 
any metabolites. However, GilM and GilMT were proposed to catalyze C-C bond rotation and 
methylation of phenolic hydroxyl groups (45→47), respectively.  
D-fucofuranose is rarely found in glycosylated natural products. Its biosynthesis was of 
particular interest for its unique ring-contraction chemistry as this sugar residue was crucial for 
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the biological activity of the GV. Inactivation of one of the potential deoxysugar biosynthetic 
gene gilU (ketoreductase) resulted in the accumulation of a new GV derivative, 4′-hydroxy-GV 
(51), with an improved biological activity (102). The results provided a clear proof that GilU 
stereospecifically reduced the 4-keto group of 18 (Scheme 1.9) to generate TDP-D-fucose, which 
further undergoes yet unknown ring-contraction and glycosylation steps to yield the D-
fucofuranose moiety of GV. 
Summary 
Polyketides constitute one of the largest group of natural products with diverse structures 
and biological activities. Structural and functional knowledge gained about their biosynthetic 
machineries at the genetic and molecular levels over the past few decades has made the 
nucleotide sequence based rational design of new polyketides possible. In this context, 
generation of thousands of new natural products through combinatorial biosynthesis has largely 
been appreciated, which is otherwise not possible through traditional/modern chemical synthesis. 
With an aim to develop a photo-activated antitumor drug, our lab has been focusing on the 
biosynthesis of GV and combinatorial biosynthetic approach to generate new GV derivatives for 
structure activity relationships (SAR) studies. In this context, GV biosynthesis has been 
extensively studied through gene inactivation experiments. Analyses of metabolites from various 
mutants produced several new gilvocarcin derivatives/intermediates. This helped outline the 
functional roles of the individual gene products. However, cross feeding experiments showed 
that none of the isolated compounds appeared to be GV biosynthetic intermediates, except pre-
GV (47, the principal metabolite of the GilR-minus mutant) thus, making the exact biosynthetic 
intermediates and the sequence of biosynthetic events elusive. Given the fact that combinatorial 
biosynthesis of new derivatives requires an in depth understanding of the involved biosynthetic 
enzymes and their orchestrations, this study was focused on characterizing individual GV 
biosynthetic enzymes in vitro. The results would provide more insights into the intriguing 
chemistry involved in GV biosynthesis, especially in the post-PKS tailoring events, such as 
oxidative rearrangement, C-glycosylation, O-methylation, lactone formation etc. As discussed 
earlier, glycodiversification provides a unique means to generate GV/RMV analogues, but this 
requires flexible glycosyltransferases (GTs) and a library of NDP-sugars (42,43). Unfortunately, 
there was only a handful of C-GTs known that have marginal substrate promiscuity (32,44,102) 
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and no other C-GT that was capable of transferring amino or branched sugars were reported so 
far, except the Med-ORF8 which utilizes TDP-angolosamine as the donor substrate (103). In this 
context, cloning, sequencing and characterization of the ravidomycin biosynthetic gene cluster 
could provide an additional opportunity to expand the combinatorial biosynthetic toolbox to 
further investigate or to design/generate GV/RMV analogues through combinatorial 
biosynthesis. Comparison of the two (GV/RMV) gene clusters would also help sort out the 
genes, whose products catalyze the chemistry unique to each pathway, for instance, the genes 
involved in contracting the D-furopyranose to D-fucofuranose moiety of GV. 
Specific aims 
The objectives of this study were to elucidate the functional role of post-PKS tailoring 
enzymes involved in the biosynthesis of GV (12) and RMV (28) and to evaluate their substrate 
specificities; a prerequisite for the successful utilization of a combinatorial biosynthesis approach 
towards generating new GV analogues. To achieve this goal, the following three specific aims 
were addressed: 
Specific aim 1: Clone and characterize RMV biosynthetic gene cluster.  
Through the comparison of the GV and RMV gene cluster, genes responsible for the 
biosynthesis of the sugar and the tetracyclic aromatic moieties can be identified for both 
compounds. In addition, ravidomycin biosynthetic enzymes could provide additional tools to 
generate GV/RMV analogues through combinatorial biosynthesis. 
Specific aim 2: Characterize all of the 4-O-acetyl-TDP-D-ravidosamine biosynthetic 
enzymes.  
Characterization of the putative 4-O-acetyl-TDP-D-ravidosamine biosynthetic genes can 
provide valuable insights into the biosynthetic pathway of the sugar moiety of RMV. Successful 
reconstitution of the sugar pathway in vitro could provide a means to generate the natural sugar 
donor substrate of the RMV C-GT for in vitro evaluation. In addition, the intermediates of the 4-
O-acetyl-TDP-D-ravidosamine biosynthetic pathway can be tested as sugar donor substrates for 
RavGT or GilGT.  
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Specific aim 3. Demonstrate a total enzymatic synthesis of defucogilvocarcin M 
(defucoGM), the common polyketide-derived core of GV and RMV. 
 This aim can identify a minimal set of enzymes required to biosynthesize defucoGM 
from the anticipated pathway intermediate prejadomycin. Alternatively, a successful 
reconstitution of the GilPKS and post-PKS enzymes could demonstrate the biosynthesis of 
relatively complex defucoGM from simple building blocks, such as acetate and malonate. The 
results would provide more insights into the GV post-PKS tailoring reactions and will also 
provide a framework for the further study of substrate specificities of the involved enzymes. 
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Section Two: Cloning, sequencing and characterization of ravidomycin biosynthetic gene 
cluster 
Results 
Cloning, sequence analysis and organization of the ravidomycin gene cluster  
A library screening strategy was taken to clone the ravidomycin (RMV) biosynthetic gene 
cluster. A genomic library of Streptomyces ravidus (S. ravidus) was constructed in the pOJ446 
E.coli-Streptomyces shuttle vector (104). Like gilvocarcin V (GV), biosyntheses of the 
polyketide core and the sugar moiety of RMV (28) required type II PKS enzyme keto-acyl 
synthase α (KSα) and a deoxysugar biosynthetic enzyme NDP-sugar 4,6-dehydratase, 
respectively. Therefore, their corresponding genes were used to probe the genomic library. The 
primers based on conserved residues of gilA (encodes KSα in GV pathway) (71), and its 
homologues from the National Center for Biotechnology Information (NCBI) nucleotide 
sequence database resulted in the expected amplifications from S. ravidus genomic DNA. 
Similarly, a part of NDP-glucose-4,6-dehydratase gene was amplified using the previously 
reported forward and a newly generated reversese primers (see appendices) (105). The cosmid 
library was screened for positive colonies using a digoxigenin (DIG)-labelled KSα gene probe. 
The positive colonies were then subjected to a second round of hybridization with DIG-labeled 
TDP-glucose 4,6-dehydratase gene probe (Figure 2.1). The hybridization was further confirmed 
through southern blot analysis (Figure 2.2). Out of approximately 2000 colonies screened, four 
different colonies from the S. ravidus library hybridized with both probes. However, restriction 
analyses of the cosmid DNA from two colonies revealed identical digestion pattern. One of the 
positive cosmids namely cosRav32 was sequenced via a shotgun approach. Bioinformatics 
analyses of the cosRav32 sequence in public databases revealed a cluster of 35 open reading 
frames (ORFs). The ravidomycin gene cluster was flanked by ORFs encoding functions 
obviously irrelevant for RMV (28) biosynthesis. The organization of the cluster and the putative 
function of the genes are summarized in Figure 2.3 and Table 2.1, respectively. The nucleotide 
sequence data have been deposited in the EMBL nucleotide database under the accession number 
FN565485. 
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Figure 2.1 Colony hybridization of S. ravidus genomic library using KSα and TDP-glucose-4,6-
dehydratase gene probes. Twelve colonies including no. 12, 32, 65 and 40 were hybridized with the both 
probes. 
 
 
 
 
Figure 2.2 Southern blot of hybridization of the isolated cosmids with KSα and 4,6-dehydratase gene 
probes. Numbers on the top of the figures represents the DNA sample isolated from the corresponding no. 
of positive E. coli colony. A: hybridization of BamHI digested cosmid DNA with 4,6-dehydratase gene 
probes. B: hybridization of BamHI digested cosmid DNA with 4,6-dehydratase gene probes. DNA 
samples from colony 12, 32, 40 and 65 were selected for the hybridization with KSα gene probe. 
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Biosynthesis of the polyketide backbone 
Nine genes in the RMV cluster were identified to be involved in the biosynthesis of the 
polyketide-derived backbone. The encoded proteins of ravA, ravB and ravC displayed typical 
homologies to the various minimal PKS enzymes [ketoacyl synthases (KSα), chain length 
determinants (KSβ or CLF) and the acyl carrier protein (ACP), respectively], typical of a type II 
PKS system and were flanked by two oxygenase genes (ravOIII and ravOIV). RavA and RavB 
exhibited 79% and 78% identity to UrdA (KSα) and JadA (KSβ) from the urdamycin and 
jadomycin biosynthetic pathways, respectively (106, 107). 
 
 
Figure 2.3 A gene cluster for ravidomycin biosynthesis: the black filled arrows indicate biosynthetic 
genes; gray arrows represent regulatory genes and blank arrows represent genes of enzymes with 
unknown functions. 
 
Like other Ksα/Ksβ heterodimers, RavA contained a conserved amino acid motif STGCTSGLD 
including the active site cysteine (108), but RavB had a glycine residue in place of the cysteine. 
The product of ravC displayed 86% identity to JadC from the jadomycin pathway (107). 
Interestingly, an additional ACP encoded by (ravC1) was also found in between two cyclase 
genes (ravG and ravK). The encoded amino acid sequence of ravC1 exhibited 68% and 61% 
identities to KinC (AH012623) and JadC from the kinamycin and jadomycin pathways, 
respectively. Both ACPs had a conserved LG(X)DS motif including the serine residue for 
attachment of  the 4′-phosphopanthetheine arm (109).  Despite their close homologies, these 
ACPs might be specific for the selection and priming of a starter unit, either acetate or 
propionate. In contrast, only one ACP has been reported for many other well characterized type 
II PKS clusters including those of aclacinomycin A (110),  doxorubicin (111)  and even the most 
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closely related GV (71). Unlike other typical type II PKS clusters, the putative ketoreductase 
gene ravF was stand alone at the end of the RMV cluster. The deduced amino acids of ravF 
exhibited strong similarities to various angucycline PKS associated ketoreductases such as 
SimA6 (77%  identity), UrdD (72%) and AknA (72%) of the simocyclinone (112), urdamycin A 
(106) and aklavinone (113) biosynthetic pathways, respectively. Therefore, we hypothesized that 
RavF reduces the 9-keto position of the growing polyketide chain to generate a secondary 
alcohol which later dehydrates during cyclization and aromatization of the first ring. Two 
putative cyclase genes, ravK and ravG, were separated by ravC1. The product of ravG displayed 
76% amino acid identitiy to the cyclase (Schp9) of Sch 47554 biosynthetic pathway (114), 
whereas the product of ravK showed 61%, 60% and 58% identities to the bifunctional 
dehydratases/cyclases from the oviedomycin (OvmA) (115), Sch 47554 (SchP4) (114) and 
griseusin (Orf4) (116) biosynthetic pathways, respectively. The homologues of ravG and ravK 
were also found in the GV cluster. Based on the amino acid similarities, we hypothesized that 
RavG and RavK are involved in several cyclizations and dehydrations steps required to install an 
aromatic angucyclinone intermediate (40). Located downstream of ravY, genes ravP and ravQ 
were translationally coupled and their encoded proteins exhibited similarity to malonyl 
CoA:ACP transacylase (MAT) and acyltransferase (AT), respectively. Given the fact that Type 
II PKS often recruits MAT from the fatty acid pathway (117), the presence of two such enzymes 
in the RMV gene cluster was unique. However, there was such precedence in the GV 
biosynthetic cluster as well. Homology search showed that RavP was similar to various type II 
PKS-associated MATs such as PgaH (118) (51% identity), Aur1M (119) (49%) and GilP (71) 
(45%). These homologous enzymes assist loading of the starter/extender unit, preferentially 
malonyl-CoA to the ACP. However, the product of ravQ resembled various other ATs such as 
AknF (110) (45% identity), FrnK (120) (46%) and EncL (121) (40%) DpsD (122) and GilQ 
(39%), which were involved in the biosyntheses of aromatic polyketides with the starter units 
other than acetate. Therefore, we favored RavQ to be responsible for the selection of propionate 
as a starter unit, which turns into the vinyl side chain of 28. GilP might self load and then 
transfer acetyl-CoA to the ACPs RavC/RavC1.  
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Table 2.1 Orfs of the RMV gene cluster and proposed function of their corresponding enzymes 
Orfs Size[a] of 
corresponding 
enzyme 
ID/SM 
(%)[b] 
Closest homologous 
enzyme 
Nucleotide 
accession no. 
Proposed function of 
product 
ravX 106 94/100 PaaB, S. clavuligerus ZP_03184882 Phenylacetic acid 
degradation protein 
ravX1 325 92/94 PaaA, S. clavuligerus ZP_03184883 Phenylacetate-CoA 
oxygenase 
ravX2 270 65/79 S.  pristinaespiralis YP_002198855 Unknown 
ravX3 65 - - - Hypothetical protein 
ravF 261 77/87 SimA6, S. 
antibioticus 
AAK06787 Ketoreductase 
ravX4 161 66/79 S. griseus YP_001826336 Regulatory protein 
ravV 107 30/48 GilV, S. griseoflavus ABE03981 Hypothetical protein 
ravH 189 55/67 GilH, S. griseoflavus AAP69587 NADPH-dependent 
FMN reductase 
ravOI 503 57/67 JadH, S. venezuelae AAV52248 Monooxygenase 
ravG 108 76/83 schP9, S. sp. SCC 
2136 
CAH10118 Cyclase 
ravC1 82 68/79 KinC, S. 
murayamaensis 
AAO65348 Acyl carrier protein 
ravK 315  ovmA, S. antibioticus CAG14969 Aromatase/cyclase 
ravOIV 520 48/58 lndM2,  S. 
globisporus 
AAT64432 Monooxygenase 
ravA 423 79/86 UrdA,  S. fradiae CAA60569 
 
Ketoacyl synthase α 
(KS α) 
ravB 401 71/84 S. venezuelae AAB36563 Ketoacyl synthase β 
(KS β) 
ravC 86 62/75 S. venezuelae AAB36564 Acyl carrier protein 
ravOIII 394 70/80 GilOIII, S. 
griseoflavus 
AAP69584 Cytochrome P-450 
monooxygenase 
ravY 72 43/63 Nocardia farcinica 
IFM 10152 
YP_116742 Ferredoxin 
ravP 323 51/64 PgaH, S. sp. PGA64 AAK57533 Malonyl-CoA acyl 
carrier protein 
transacylase 
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ravQ 330 45/55 AknF, S.galilaeus BAB72049 Acyltransferase 
ravJ 289 42/53 SchP11, S. sp. SCC 
2136 
CAH10120 Unknown 
ravX5 208 56/74 S. violaceoruber CAA09631 Regulatory protein 
ravE 328 77/85 S. sviceus YP_002205670 NDP-glucose 4,6-
dehydratase 
ravD 355 79/88 S. sviceus YP_002205669 NDP-glucose synthase 
ravX6 55 - - - Hypothetical protein 
ravGT 379 46/66 GilGT, S. 
griseoflavus 
AAP69578 C-glycosyltransferase 
ravNMT 265 56/71 SnogX, S. nogalater CAA12020 N,N-
dimethyltransferase 
ravIM 156 47/69 Burkholderia 
phymatum 
YP_001858530 NDP-6-deoxy-3, 4-
keto-hexulose 
isomerase 
ravAMT 369 60/75 Saccharopolyspora 
erythraea 
YP_001103001 Aminotransferase 
ravMT 339 51/66 S. tubercidicus AAT45298 O-methyltransferase 
ravOII 231 68/77 GilOII, S. 
griseoflavus 
AAP69583 Anthrone 
Monooxygenase 
ravRM 776     
 N-terminal 
535 aa, 
54/67; S. galilaeus ABI15166 Dehydrogenase 
 C-terminal, 
241 aa 
41/58 GilM, S. griseoflavus AAP69591 Unknown 
ravX7 126 - - - Hypothetical protein 
ravW 247 37/46 Arthrobacter 
aurescens TC1 
YP_950015 N-acetyltransferases 
ravX8 564 59/74 S. griseus YP_001827711 Hypothetical protein 
[a]: number of amino acids; [b]: identity/similarity; aa: amino acids 
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 Scheme 2.1 Proposed pathway for the biosynthesis of RMV (28), involving enzymes encoded by the 
cloned RMV gene cluster 
 
Post-PKS tailoring enzymes 
 As expected, the post-PKS tailoring enzymes encoded by the RMV cluster were similar 
to those of the GV counterpart. Four different oxygenases (encoded by ravOI, OII, OIII and OIV) 
were scattered throughout the cluster. Homology searches in the databases showed that the 
products of ravOI and ravOIV resembled the flavin adenine dinucleotide (FAD)-dependent 
monooxygenases. RavOIV displayed its identity/similarity to LndM2 (48%/58%) from the 
landomycin, OvmOII (47%/56%) from the oviedomycin,(123) PgaM (46%/58%) from the 
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gaudimycin,(59) JadF (46%/55%) and JadH (42%/54%) from the jadomycin(61) and GilOI 
(35%/47%)  and GilOIV (29.8%) from the GV pathways (57). Similarly, SimA7 (124) 
(61%/73%), OvmOI (115) (60%/72%), PgaE (125) (58%/71%), JadH (61) (57%/67%), GilOI 
(71) (42%/55%) and GilOIV (30% identity) were the closer homologues of RavOI.  Here, it was 
important to note that most of these homologues were proposed or characterized to have dual 
oxygenation and dehydration activities, and they all act on angucyclinones. Recent results 
showed that both JadF and GilOIV catalyze identical reactions, i.e. 2,3-dehydration of 40 and 
hydroxylation at the C-5 position of 41 despite the very different pathway end products (scheme 
2.1) (56). Similarly JadH and GilOI were also shown to have identical activities: both catalyze 
4a,12b dehydration of 42, and may also be involved in C-C bond cleavage presumably through 
Baeyer-Villiger monooxygenation of the C-6 carbonyl. Based on these similarity studies, we 
proposed that RavOIV and RavOI were functionally identical to GilOIV and GilOI of the GV 
pathway, respectively. The start codon of ravOI was transcriptionally coupled with ravH that 
encodes a 189 aa-protein showing its similarity (55%-61% identity) to the various NADPH-
dependent FAD/FMN reductases including the recently characterized GV pathway counterpart 
GilH (102). We assumed that RavH might generate the reduced coenzyme (FADH) from 
NADPH and FAD to provide reducing equivalents for the oxidative cascade catalyzed by RavOI 
or RavOIV. The encoded sequence of ravOII showed its closest homology to GilOII (68%/77%) 
of the GV pathway besides other putative anthrone oxygenases. Like GilOII in the GV pathway, 
RavOII might introduce a hydroxyl group at the naphthalene moiety of 44 which then would 
react with the aldehyde to generate a hemiacetal 46. The encoded product of ravOIII exhibited 
similarity to various cytochrome-P450 monooxygenases with GilOIII of the GV pathway being 
the closest homologues (70%/80%).  Through inactivation of the corresponding gene, we 
previously showed that GilOIII is involved in the vinyl side chain formation of GV (33). 
Therefore, a similar role of RavOIII in RMV biosynthesis could be safely assigned. Careful 
sequence analyses revealed a small ORF ravY whose start codon was translationally coupled to 
the stop codon of ravOIII. The product of ravY shared moderate identity (40%-50%) to various 
putative ferredoxin proteins in the database. Since most of the cytochrome-P450 
monooxygenases require ferredoxin as an electron carrier to fulfill their oxidative activities, we 
propose that the product of ravY might serve as an electron carrier for RavOIII. The lack of such 
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a gene in the GV cluster was not surprising as there were many such precedents, where 
ferredoxin proteins are located outside the secondary metabolite biosynthetic gene clusters. 
 Unlike stand alone gilM and gilR of the GV cluster, the homologous genes in the RMV 
cluster were fused to a larger ORF namely ravRM, whose N-terminal protein sequence showed 
similarity to GilR and whose C-terminal protein sequence was similar to GilM. Through both in 
vivo and in vitro studies, GilR was shown have a dehydrogenase activity which converts the 
hemiacetal moiety of preGV (47) to the lactone moiety of GV (12) (see section 4) (56, 126). 
Gene deletion experiments showed that GilM was necessary for GV biosynthesis.(101) 
However, its exact role was not fully known. Homology searches of GilM revealed a SAM-
binding domain and showed its similarity to SAM-depedent methyltransferases from various 
organisms. This indicated that GilM might be a methyltransferase responsible for methylating 
one of the phenolic hydroxyl groups (C10-OH or C12-OH) of 46 during GV biosynthesis. In this 
context, we propose RavRM to be a bifunctional enzyme capable of catalyzing identical 
reactions of GilR and GilM.  Like GilMT, the product of ravMT displayed similarity to various 
O-methyltransferases indicating its potential role in the methylation of the remaining hydroxyl 
group of 46.  
Genes for deoxysugar biosynthesis and attachment 
 A total of six genes encoding deoxysugar biosynthetic enzymes were identified in the 
RMV cluster. RavD and ravE appear to be translationally coupled. The product of ravD and 
ravE resembled the various NDP-glucose synthases and NDP-glucose-4,6-dehydratases from 
Streptomyces sps, respectively. RavD displayed 76%, 75% and 71% identity to MtmD, GilD and 
StrD of the mithramycin (127), GV (71) and streptomycin (128) deoxysugar biosynthetic 
pathways, respectively. Similarly, RavE showed 73%, 72% and 69% identity to MtmE, GilE and 
StrE of these pathways, correspondingly. This suggested that RavD might be a NDP-hexose 
synthase that catalyzes the first step of the NDP-ravidosamine biosynthesis and RavE catalyzes 
the follow-up step to generate NDP-4-keto-6-deoxy-D-glucose (18, Scheme 2.2). Start and stop 
codons of the rest of the proposed ravidosamine biosynthetic genes ravNMT, ravIM, ravAMT 
were translationally coupled. RavIM represented a unique gene of the RMV cluster which 
displayed its closest similarity to putative WxcM (bifunctional sugar isomerase/N-
acetyltransferase) domain-containing proteins from various bacteria such as Burkholderia 
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phymatum, Silicibacter sp. TM1040 and Desulfococcus oleovorans. Genetic analyses showed 
that the WxcM protein from Xanthomonas campestris pv. campestris catalyzes isomerization of 
TDP-4-keto-6-deoxy-D-glucose (18) to TDP-3-keto-6-deoxy-D-galactose and also acetylates the 
amino group of TDP-3-amino-3,6-dideoxy-D-galactose (56) during lipopolysaccharide (LPS) 
biosynthesis (129). RavIM also showed its close similarity to the NDP-hexose-3,4-
ketoisomerases such as (ORF2) (130) (51%/68%, identity/similarity) and  Tyl1a (131) 
(35%/54%) from the mycaminose biosynthetic pathway. Similarly, RavIM also exhibited 39% 
identity and 60% similarity to the FdtA from Aneurinibacillus thermoaerophilus. FdtA has been 
shown to catalyze TDP-4-keto-6-deoxy-D-glucose (18) to TDP-3-keto-6-deoxy-D-galactose (55) 
during the biosynthesis of a surface layer 3-acetamido-3,6-dideoxy-α-D-galactose moiety of the 
bacterial surface glycan chain (132), whereas Tyl1a acts on the same substrate but generates the 
product TDP-3-keto-6-deoxy-D-glucose (53) with an equatorial-facing hydroxyl group at C-4 
position instead. We propose that RavIM catalyzes the isomerization reaction identical to that of 
FdtA (Scheme 2.2) generating an axial hydroxyl group at 4-position, which later is acetylated in 
RMV. If this hypothesis is true, RavIM would be the first enzyme from a secondary metabolite 
biosynthetic pathway to have such an activity.  
 The product of ravAMT was similar to EryC1(133) (60%/75%), OleN2 (134) 
(61%/73%) and DesV (135) (59%/71%). All of these homologous enzymes were pyridoxal-5-
phosphate (PLP)-dependent and were proposed/characterized to catalyze amino transfer from an 
amino acid, preferably L-glutamate, to the carbonyl carbon of a deoxysugar intermediate (135, 
136). Therefore, we propose that RavAMT serves as an aminotransferase which converts 55 to 
56 using L-glutamate as an amino donor during TDP-D-ravidosamine biosynthesis. The encoded 
amino acid sequence of ravNMT showed significant similarity to the various deoxysugar N-
methyltransferases including SnogX (56%/71%) and SnogA (57%/70%) from TDP-L-
nogalamine (137) and to other deoxysugar N,N-dimethyltransferases, e.g. DesVI  (55%/71%) 
and OleM1 (53%/68%) from  TDP-D-desosamine pathways, respectively (68, 136). Both of 
these N,N-dimethyltransferases transfer a methyl group from S-adenosyl methionine (SAM) to 
the amino nitrogen twice, in an iterative fashion.                  
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Scheme 2.2 Proposed pathways for the biosyntheses of 4′-O-acetyl-NDP-D-ravidosamine, and NDP-D-
mycaminose. 
In context of RMV biosynthesis, we assumed that RavNMT catalyzes a similar reaction 
(56→19) utilizing the product of RavAMT as the substrate. RavW was the only candidate 
enzyme that could acetylate the 4-hydroxyl group of 19. The product of ravW shows modest 
similarity to GCN-5 related N-acetyltransferase (GNAT)-family enzymes which catalyze the 
transfer of an acetyl group from acetyl-CoA to the primary amine of a variety of acceptor 
substrates and function in diverse pathways of prokaryotes and eukaryotes. Like ATs, PKS-
associated GNATs were reported to catalyze the conversion of malonyl-CoA to acetyl-CoA and 
then transfer the product to the thiol group of holo-ACPs directly (138). Regarding the functional 
role of RavW, there could be three possible scenarios: i) RavW functions as AT; ii) RavW 
catalyzes N-acetylation of 56 where the acetyl group then migrates to the 4′-hydroxyl group 
(57→58); iii) RavW might serve as an acetyltransferase which catalyzes direct O-acetylation of 
19 before or after the establishment of the C-C-glycosidic bond. The presence of two ATs in the 
RMV cluster and lack of an RavW homologue in the GV cluster made the first possibility less 
likely. The suspected N to O-acyl-shift was not observed previously when preparing TDP-3-
acetamido-3,6-dideoxy-D-galactose enzymatically (see section 3) (132). This made the second 
option less possible. However, we could not rule out this possibility as the closely related 
antibiotic FE35B (31) contains an 3-acetamido and 4-O-acetyl groups. The presence of 
significant amount of deacetylravidomycin V (29) in the culture broth of S. ravidus indicated 
acetylation of the 4′-OH group as the last step of the deoxysugar biosynthesis prior to or after the 
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attachment of the sugar. Therefore, we favored the third possibility. However, further 
experiments were necessary to clarify these issues. 
 The glycosyltransferase (GT) that establishes C-glycosidic linkage between the 
aromatic backbone and amino sugar of RMV was particularly interesting from the biosynthetic 
point of view as it could be used for combinatorial biosynthesis. We identified a 
glycosyltransferase encoding gene (ravGT) upstream of ravNMT. The deduced amino acid 
sequence of ravGT exhibited similarity to various O- and C-glycosyltransferases involved in 
secondary metabolite biosyntheses, such as LanGT2 (47%/67%), GilGT (46%/66%), Med-ORF8 
(48%/65%) and UrdGT2 (42%/60%) from GV, landomycin, medermycin and urdamycin 
biosynthetic pathways, respectively (103,139,140). Unlike GilN of the GV cluster, there was no 
other GT homologue that could potentially be involved in or assist C-glycosylation in the RMV 
pathway. Therefore, we assumed that RavGT might be sufficient to catalyze the attachment of 
ravidosamine or 4′-O-acetyl-ravidosamine to 46, establishing a C-C bond. Here, it was important 
to note that UrdGT2, GilGT, SaqGT5 and IroB were the only C-glcosyltransferases characterized 
at a functional level (33, 141, 142). The former three enzymes used NDP-deoxysugars as donor 
substrates, whereas the latter used UDP-glucose. Given the fact that sugar donor substrate 
flexibility of a GT determines its potential applicability to generate novel molecules through the 
glycodiversification, we were curious to explore the flexibility of RavGT. The ∆GilGT mutant 
strain (S. lividans TK24/cosG9B3-GilGT¯), where the gilGT gene was deleted in-frame was the 
ideal host to test the flexibility of RavGT (33). This strain harbored the entire GV gene cluster 
except the glycosyltransferase (encoded by gilGT) thus providing a yet unknown sugar acceptor 
substrate and TDP-D-fucofuranose. Therefore, we attempted cross complementation of the 
GilGT-minus mutant with a ravGT expression construct, (pRavGT). The constitutive expression 
of the cloned gene was maintained by the presence of erythromycin resistant gene promoter 
(ermEP*). Interestingly, complementation of the mutant with pRavGT restored gilvocarcin E 
production, however GE (12-a) was produced instead of GV (12) (Figure 2.4). Accumulation of 
GE instead of GV was not surprising as the activity of GilOIII was suppressed in the GilGT-
minus mutant due to a polar effect (33).  
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Figure 2.4  HPLC analyses of metabolites generated through the complementation of ∆GilGT strain. 
Trace A : standard GE (12-a); trace B : metabolites [homorabelomycin (48); defucoGE (50-a)]from 
∆GilGT strain; trace C : metabolites [GM (12-b); GE (12-a); defucoGE (50-a)] from  ∆GilGT-pRavGT 
strain. 
UrdGT2 was reportedly the only known C-GT to have flexibility with regard to both, sugar 
donor and acceptor substrates (32, 44). More recently, the generation of 4′-hydroxygilvocarcins 
through the inactivation of ketoreductase (GilU) has demonstrated the flexibility of GilGT 
regarding its donor substrate in the GV pathway. However, GilGT could not accept a variety of 
amino sugars or branched sugars as donor substrates (unpublished results). Our current results 
provided the first example of a C-glycosyltransferase that could utilize both five-membered 
TDP-D-fucofuranose (22) and the six-membered aminosugar TDP-D-ravidosamine (19)  as sugar 
donor substrates. 
Genes encoding regulatory and resistance enzymes, or enzymes of unknown function 
 RavX4 and ravX5 represent two regulatory genes whose encoded amino acid sequence 
resembled transctriptional regulatory proteins from different Streptomyces sps. The function of 
six other orfs (ravX2, X3, J, X6, X7, X8) could not be assigned through homology studies. The 
products of ravX and X1 were homolog to the phenylacetic acid degradation pathway enzymes 
and were not related to RMV biosynthesis. Located at the right and left ends, the products of 
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ravX and ravX8 showed similarity to hypothetical proteins indicating the end of the cluster at 
both sides.  
Heterologous production of deacetylravidomycins in S. lividans TK24 
Analysis of the DNA sequence of cosRav32 indicated that the cosmid was harboring all 
of the necessary genes for the production of RMV. This prompted us to attempt the heterologous 
expression of the entire RM cluster in S. lividans TK24. Such expression would utilize all of the 
naturally occurring promoters, regulatory, resistance and the RMV biosynthetic genes. The 
cosmid was introduced in S. lividans TK24 through a well-established E. coli : Streptomyces 
inter generic conjugation protocol (143).  The yellowish green exconjugants obtained on the 
plate were introduced to liquid culture for metabolite production.  HPLC analysis showed that 
there were at least six new metabolite peaks in the culture broth of the S. lividans 
TK64/cosRav32 as compared to the control strain S. lividans TK64/pOJ446. UV spectra, 
retention time in HPLC and ESI-MS spectra comparison revealed that four of the six peaks 
represent 2,3-dehydroUWM6 (41-a, 2 mg L-1), 2,3-dehydro-homo-UWM6 (41, 20 mg L-1), 
preGM-o-quinone (42-d, 0.2 mg L-1) and preGV-o-quinone (42-c, 1.3 mg L-1) (Figure 2.5). The 
other two peaks (eluted at Rt.= 6.6 min and 7.1 min) exhibit UV spectra typical to that of 
ravidomycin with a slight  hypsochromic shift of one of the maxima from 392 nm to 380 nm. 
This indicated that the C-8 vinyl side chain of 28 might be replaced by a saturated ethyl or 
methyl group. Low resolution ESI-MS analyses further showed that the mass of the first 
compound (MW, [M+H]+ = 510  in positive APCI and [M-H]¯= 508 in the negative APCI MS) is 
14 amu less than that of the second (MW, [M+H]+ = 524 in positive APCI and  [M-H]¯ 522 in 
negative APCI MS) indicating their real molecular weights to be 509 and 523 amu, respectively. 
This clearly showed that these compounds differ from each other by a single methylene group (-
CH2-) likely at the C-8 position, and unlike 28, the 4′-O-acetyl group may be absent in both 
compounds. The molecular formula of the latter compound obtained through high resolution EI-
MS (C29H33NO8, 523.2207 g mol-1) matched perfectly with the predicted molecular formula of 
deacetylravidomycin E (29-b). However, poor production (< 50 μg L-1) of these metabolites 
hindered a larger scale isolation for NMR analysis. Given the fact that ancymidol serves as an 
effective CYP450 inhibitor, and that a homologue of a CYP450 (GilOIII) is involved in the vinyl 
side chain formation of GV, compound 29-b could be obtained by inhibiting this enzyme of S. 
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ravidus as well. As expected, the fermentation of S. ravidus in the presence of ancymidol 
revealed a new metabolite in the HPLC-MS, whose retention time and mass were identical to 
that of 29-b isolated from S. lividans TK64/cosRav32. About 2 mg of the compound was isolated 
using preparative HPLC and its structure was analyzed through NMR spectroscopy and HR-MS 
spectrometry. When the 1H NMR of 29-b was compared with that of 28 (RMV), all signals were 
observed, except for the vinyl and 4′-O-acetyl protons which typically appear at δ 5.5-7.0 ppm 
and δ 2.0-2.5 ppm, respectively. Instead, an additional triplet (δ 1.32 ppm) and quartet (δ 2.83 
ppm) signals were observed. This was a clear indication of the presence of an ethyl side chain at 
the C-8 position, thereby confirming its structure (see NMR data in the materials and methods 
section). The structure of the compound was further confirmed by 13C NMR analysis. Based on 
these observations, we also proposed the structure of the minor compound to be 
deacetylravidomycin M (29-a).  
The results clearly show that the isolated cluster covers most of the genes required for the 
biosynthesis of RMV. However, the marginal accumulation of 29-b (deacetylRME) instead of 
28, and the accumulation of 41, 41-a, 42-c and 42-d in large amounts was surprising. Gene 
inactivation, complementation and in vitro assay results have suggested that 41 and 41-a are 
biosynthetic intermediates of the GV and jadomycin pathways, respectively (30, 56, 57, 61). This 
hypothesis might be true for the RMV biosynthesis as well, where RavOI, RavOII and RavOIV 
could convert 41 to 46 through a series of oxidative reactions including a C-C bond cleavage 
(Scheme 2.1).  
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Figure 2.5  HPLC analyses of the metabolites: Trace A; metabolites extracted from S. lividans TK24-
cosRav32, trace B; standard deacetylravidomycin E (29-b); deacetylravidomycin M (29-a); 2,3-dehydro-
homo-UWM6 (41); 2,3-dehydroUWM6 (41-a); pregilvocarcinV-o-quinone (42-c); pregilvocarcin M-o-
quinone (42-d) 
 
The accumulation of these intermediates indicated that there could be some disturbances 
in the oxygenase activities (particularly, the conversion of 41→45). However, the lack of an 
acetyl group at the 4′-position of the sugar residue and the vinyl side chain at the C-8 position in 
the products suggested that the proposed acetyltransferase (encoded by ravW) and CYP450 
(encoded by ravOIII) are not functioning. This raised two questions: i) were these genes 
functionally inactive and the real functional genes were somewhere outside of the sequenced 
region? or ii) was the expression of  these genes negatively regulated in the heterologous host? 
To clarify this issue, a ravOIII expression construct (pRavOIII) was generated using a pEM4 
vector, into which the gene was expressed under the control of the erythromycin resistance gene 
promoter (ermEP*). This construct was then used to complement the ∆GilOIII strain (S. 
5.00 10.00 15.00 20.00 25.00
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lividansTK24/cosG9B3-GilOIII¯) that harbors the entire GV cluster except GilOIII, and 
accumulates GE (12-a) and some other biosynthetic shunt products, mainly rabelomycin (48-a) 
and homorabelomycin (48). Interestingly, expression of ravOIII in the ∆GilOIII mutant resulted 
in the conversion of GE (12-a) to GV (12) (Figure 2.6). This demonstrated without any 
ambiguity that ravOIII encodes the functionally active enzyme responsible for the vinyl side 
chain formation of RMV. The incomplete conversion could be due to the imperfect fitting of 
RavOIII to the other GV biosynthetic enzymes. Therefore, we suspected that expression of 
ravOIII might have been negatively regulated during the heterologous expression of cosRav32. 
Our attempts to prepare RavW in vitro repeatedly failed due to insolubility of the enzyme. 
Further investigation including an in vitro characterization of this enzyme would help assign its 
exact functional role.  
Comparison of the GV and RMV gene clusters 
One of the major goals of this study was to identify the genes involved in the biosynthesis 
of the D-fucofuranose moiety of GV through the comparative analysis of the two clusters. 
Reflecting on their structural similarities, similar sets of PKS and post-PKS biosynthetic genes 
were found in both clusters with the exception of an additional ACP (encoded by ravC1) and the 
fused ORF ravRM in the RMV cluster. GilD/ravD and gilE/ravE represented the early 
deoxysugar biosynthetic genes for both of the D-fucofuranose and 4′-O-acetyl-ravidosamine 
moieties. As discussed earlier, the products of RavIM, ravAMT, ravNMT and ravW could 
potentially catalyze the follow-up steps to biosynthesize the 4′-O-acetylravidosamine moiety of 
RMV (see section 3).  No homologues of gilU, gilN and gilL were identified in the RMV cluster 
indicating their unique roles in GV biosynthesis, likely in GV’s deoxysugar moiety (D-
fucofuranose). While the product of gilU was known to catalyze the conversion of TDP-4-keto-
6-deoxy-D-glucose (18) to TDP-D-fucopyranose (67), GilN and GilL are the only candidate 
enzymes, possibly responsible for the sugar ring contraction that leads to the conversion of 67 to 
D-fucofuranose (22) (Scheme 2.2) (102). Whether this ring contraction takes place before or after 
glycosylation remains unclear. 
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Figure 2.6 HPLC analyses of the metabolites generated through the complementation of ∆GilOIII strain: 
trace C; from the S. lividans TK24-cosG9B3-GilOIII¯ mutant; trace D:  from the S. lividans TK24-
cosG9B3-GilOIII¯ mutant strain after complemented with pRavOIII. 12, 12-a, 48 and 48-a represent GV, 
GE, homo-rabelomycin and rabelomycin, respectively. 
 
Discussion 
Glycosylated natural products have diverse biological activities. Because C-glycosides 
are resistant to glycosidase activity, they are more promising for therapeutic use than O-
glycosides. In the past decades, several dozen secondary metabolite biosynthetic gene clusters 
from microorganisms have been cloned, sequenced and fully/partially characterized. The 
majority of these investigations were focused on O-glycosylated products. Gilvocarcins, 
urdamycins, Sch 47554, Sch 47555 (114), saquamycin Z, geltamycin B were the only C-
glycosylated angucyclines whose gene clusters had been cloned. They all harbor neutral 
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deoxysugar moieties. Similarly, the medermycin cluster represented the sole type II-PKS derived 
secondary metabolite with a C-glycosidically linked amino sugar (D-angolosamine). In this 
context, the identification of the sugar moiety related biosynthetic genes in addition to the 
defucoGV biosynthetic genes of the RMV cluster was very significant. Production of 
ravidomycin derivatives in the heterologous host S. lividans TK24 clearly showed that the 
isolated gene cluster is sufficient for the biosynthesis of deacetylravidomycin E (29-b). Because 
RavGT utilizes an amino sugar, presumably TDP-D-ravidosamine as the donor substrate, it could 
be a valuable tool to generate novel RMV analogues with diverse amino sugars, such as 
angolosamine, desosamine, or daunosamine. The partial complementation of the GilGT-minus 
mutant with RavGT was a clear indication of such a possibility. This was the first report of a C-
glycosyltransferse that utilizes chemically very different deoxysugars (a neutral TDP-D-
fucofuranose and a basic TDP-D-ravidosamine). However, further investigations on the sugar 
donor substrate flexibility of RavGT might be necessary for its successful application in 
combinatorial biosynthesis. It was well established through inactivation  and complementation 
experiments that GilOIII catalyzes the oxidation of the ethyl side chain to the vinyl group (33). 
Despite the presence of a functionally active GilOIII homologue (RavOIII) in the cluster, it was 
not clear why deacetylravidomycin E (29-b) was observed instead of RMV (28) or deacetylRMV 
(29). The results also pose ambiguity over the true function of the potential acetyltransferase 
RavW.  
Comparison of the GV and RMV gene clusters helped to identify the unique genes of 
each cluster. The comparative analyses outlined enzyme candidate candidate (GilN or GilL) to 
be involved in ring contraction reaction during the biosynthesis of the D-fucofuranose moiety of 
GV. We observed several features unique to the RMV cluster. Fusion of two gilR and gilM 
homologous genes into the single orf ravR-M was particularly interesting. This also indicated 
that the products of both genes might work very closely during GV biosynthesis. Unlike the GV 
cluster, two functional ACPs were found in the RMV biosynthetic locus. This raised two 
possibilities: i) the reported ACP of the GV pathway (GilC) does discriminate between 
propionate or acetate starter units; or ii) another ACP is somewhere outside the cluster in the 
genome of the GV producer S. griseoflavus. In this context it is reasonable to speculate that the 
GV pathway could be borrowing the missing ACP from the host to reconstitute GV production 
in S. lividans TK24 while producing GV heterologously through the expression of cosG9B3 (the 
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cosmid that contains all of the hypothesized GV biosynthetic genes). Acyltransferases (ATs) are 
often missing in type II PKS gene clusters. In those cases, ATs are borrowed from the fatty acid 
biosynthetic pathway. Like in the GV cluster, the presence of two RavATs (RavP and RavQ) 
was unique. We suspected that RavP self-loads acetyl-/malonyl-CoA and transfers it to either 
RavC or RavC1. Similarly, RavQ might transfer propionyl-CoA to the remaining ACP.  
In summary, we have cloned and sequenced the gene cluster responsible for the 
biosynthesis of ravidomycin. Heterologous production of deacetylRME in S. lividans TK24 
combined with the results of complementation experiments unambiguously demonstrated the 
functional role of the cluster for RMV biosynthesis. In addition, we discovered a donor substrate 
flexible C-GT capable of utilizing a 5-membered neutral sugar (D-fucofuranose) as well as a 6-
membered basic sugar (D-ravidosamine). The isolated gene cluster could serve as a valuable tool 
to generate GV/RMV analogues through combinatorial biosynthesis. 
Experimental section 
Construction of plasmids and DNA manipulation 
Oligonucleotide primers, plasmids and bacterial strains used in this study are summarized 
in Table 2.2 and 2.3. Routine DNA manipulations, such as cloning, restriction analysis, ligation, 
transformation etc. were carried out following the standard protocols for E. coli (144) and 
Streptomyces (143). High fidelity Pfu DNA polymerase was used to amplify various DNA 
fragments throughout these experiments. PCR products were cloned into PCR-Blunt-II-TOPO 
cloning vector (Invitrogen) and sequenced to confirm that mutation had not been incorporated 
during PCR amplification. For complementation studies, ravOIII was amplified and ligated into 
the pEM4 vector at XbaI and EcoRI sites whereas ravGT was ligated at NdeI and EcoRI sites of 
pUWL201PW (67). 
Bacterial strains and culture conditions 
 Various strains of E. coli were cultured at 37° C in Luria Bertani (LB) broth or on LB-
agar medium supplemented with various antibiotics (kanamycin, 50 μg mL-1; chloramphenicol, 
25 μg mL-1; apramycin, 50 μg mL-1 and ampicillin, 50 μg mL-1) whenever necessary. 
Streptomyces strains were grown on M2-agar or in Soymeal glucose (SG) liquid medium for the 
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metabolite analyses as reported previously.(57) MS-agar medium was used for the transfer of the 
cosmids from E. coli into Streptomyces following a standard protocol (143). Antibiotics 
(apramycin, 50 μg mL-1 and thiostrepton 25 μg mL-1) were supplemented in the medium 
whenever necessary. 
Construction and screening of genomic cosmid libraries 
Genomic DNA of S. ravidus was isolated following a standard protocol (143). The 
genomic DNA was partially digested with Sau3A1, dephosphorylated with calf intestinal 
phosphatase (CIP) and ligated to the pOJ446 vector digested with BamHI and HpaI. The ligation 
sample was transduced into E. coli XL1-Blue MRF using Gigapack III XL packaging extract 
(Stratagene). More than 2300 colonies were obtained as positive clones. Two sets of degenerate 
primers (KS-probe-for and KS-probe-rev, and DH-probe-for and DH-probe-rev, Table 2.2) were 
designed to amplify the internal nucleotide sequences of ketoacyl synthase (KSα) and TDP-
glucose-4,6-dehdyratase from the genomic DNA of S. ravidus (see appendix). The amplified KSα 
fragments were labeled with DIG and used to screen the library. The positive colonies were 
further screened with the TDP-glucose-4,6-dehdyratase probe. The colony hybridization and 
sourthern blot analyses revealed three different cosmid clones. Cosmid cosRav32 was selected 
for the sequencing. 
Sequencing and annotation of the gene clusters 
Sequencing of the cosmids was carried out using a shot-gun approach at the College of 
Agricultural Sciences (University of Kentucky). Phred/Phrap/Consed software package 
(http://www.phrap.org.) was used to process and assemble raw sequence data into the larger 
contigs. The small gaps between contigs were filled up by primer walking. Frame plot 
(http://www0.nih.go.jp/~jun/cgi-bin/frameplot.pl) and ORF finder 
(http://www.ncbi.nlm.nih.gov/projects/gorf/) programs were used to assign ORFs. Functional 
assignment of ORF products was performed through database comparison using various BLAST 
(Basic Local Alignment Search Tool) search tools on the server of the National Center for 
Biotechnology Information, Bethesda, Maryland (http://www.ncbi.nlm.nih.gov). 
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Fermentation and isolation of metabolites 
Streptomyces strains were grown on MS agar for 6 days at 30 °C. An agar chunk full of 
bacterial spores was inoculated into 100 mL SG liquid medium in 250 mL Erlenmeyer flasks and 
incubated for 3 days at 30 °C and 200 rpm to prepare a seed culture. For analysis of metabolites, 
3 mL of the seed culture was used to inoculate 100 mL SG medium liquid culture and grown for 
5 days. The culture was harvested through centrifugation to obtain culture broth and pellet 
fractions. The culture broth was extracted with an equal volume of ethyl acetate two times. The 
combined organic layers were dried in a rotary evaporator. The crude extract was dissolved in 3 
mL of methanol and filtered through a 0.2 μM syringe filter prior to high performance liquid 
chromatography-mass spectrometry (HPLC-MS) analysis. The pellet fraction was resuspended in 
20 mL acetone and sonicated for 10 min. The acetone extract was collected through 
centrifugation and dried under reduced pressure. The prepared extract was dissolved in methanol 
and subjected to HPLC-MS analysis.  
The production of ravidomycins and gilvocarcins by wild/mutant strains were analyzed 
by the aforementioned protocol. For the isolation of the compounds, the production scale was 
increased to 4 L.  The culture was harvested through centrifugation. The cell pellets were 
extracted with acetone as described above and dried off the solvent. The extract was combined 
with the broth and  loaded into the reverse phase silica (RP-C18, 200 g) column (5 × 65 cm), pre-
equilibrated with deionized water. The effluent was discarded and the column was washed with 1 
L of 10% acetonitrile (in water). Elution was carried out using an increasing gradient of 
acetonitrile (20%, 40%, 60%, 80% and 100%, 1L each). The fractions containing the target 
compounds were dried in a lyophilizer. Final purification of the metabolites was carried out 
through preparative scale HPLC. The purity and authenticity of the compound were confirmed 
through 1H and 13C NMR analyses. A linear gradient of acetonitrile and acidified water   (solvent 
A = 0.1% formic acid in H2O; solvent B = acetonitrile; 0-15 min 25% B to 100% B; 16-24 min 
100% B; 25-26 min 100% to 25% B; 27-29 min 25% B) was used to separate compounds.  
SunFire™ prepC18 column (19 × 150 mm, 5 μm) and Symmetry C18 (4.6 × 250 mm, 5 μm) 
columns were used for preparative and analytical scale separations, respectively. The flow rate 
was maintained at 10 mL min-1 and 1.0 mL min-1 for preparative and analytical scale separations, 
correspondingly. Micromass ZQ 2000 (Waters corporation) equipped with HPLC (Waters 
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alliance 2695 model) and photodiode array detector (Waters 2996) were used to analyze the 
compounds. Atmospheric pressure chemical ionization (APCI) and Electrospray ionization (ESI) 
probes were used to detect molecular ions. Electron impact-high resolution mass spectrometric 
(EI-HR-MS) analyses of the compounds were acquired at University of Kentucky mass 
spectrometry facility. 
To isolate deacetyl ravidomycin E, 20 mL of fully grown S. ravidus seed culture was 
grown in SG medium (5 flasks×100 mL) and 100 μl of ancymidol solution (in DMSO) was 
added into the culture to 2 mM final concentration. Only DMSO was used in the control flask. 
The fermentation was carried out for 6 days and the metabolites were analyzed by HPLC-MS. 
Isolation and purification of 4′-O-deacetylravidomycin E was carried out according to the 
aforementioned protocol. The structure of the isolated compound was determined by NMR 
spectroscopy analyses (See NMR data). 
Table 2.2 List of primers used in this study 
Name of the primers Oligonucleotide sequence 
RavOIII_for 5’-AAGTCTAGAAGGAGACGGAGCACCATGGCG-3’ 
RavOIII_rev 5’-CGGAATTCTCTGCTCGTCGGCCGTGGTCACGT-3’ 
RavGT_for 5’-ATCATATGAAAGTCCTGTTCATCGCAGCGGGA-3’ 
RavGT_rev 5’-ATGAATTCTCATCCGCGCACCAGTCCTTCCAG-3’ 
KS_probe_for 5’-GTSTCSACSGGSTGYACSTCSGGS-3’ 
KS_probe_rev 5’-SCCGATSGCSCCSAGSGARTGSCC-3’ 
DH_probe_for 5’-CSGGSGSSGCSGGSTTCATSGG-3’ 
DH_probe_rev 5’-CAGTGGTCSACGTGSAGCCACTCSCG-3’ 
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Table 2.3 List of bacterial strains used in this study 
Strain/ plasmid Characteristics and relevance References 
   
E. coli XL1-Blue-MRF Host for routine cloning works and for the construction of 
genomic libraries 
Stratagene 
E. coli ET12567/pUZ8002 Host for conjugal transfer of plasmid into Streptomyces Danis et al.(145) 
Streptomyces species   
S. ravidus C23201 Ravidomycin producer-wild strain Wyeth Co. 
S. lividans TK24   
S. lividans TK24/cosG9B3-GT¯ Produces defucoGE and defucoGM-the strain harbors the 
GilGT deleted mutant cosmid CosG9B3-GilGT¯ 
Rohr et al.(33) 
S. lividans TK24/cosG9B3-OIII¯ Produces defucoGE and defucoGM-the strain harbors the 
GilOIII deleted mutant cosmid CosG9B3-OIII¯ 
Rohr et al.(33) 
S. lividans TK24/cosRav32 Produces2,3-dehydroUWM6,  2,3-dehydro-HomoUWM6, 
preGV M-o-quinone,  preGV-GE-o-quinone, ravidomycin M, 
4’-o-deacetylravidomycin E -the strain harbors the cosRav32  
This work 
S. lividans TK24/cosG9B3-
GT¯/pRavGT 
Produces GE and GM-pRavGT was introduced into S. 
lividans TK24/cosG9B3-GT¯ 
This work 
S. lividans TK24/cosG9B3-
OIII¯/pRavOIII 
Produces GV and GM-pRavOIII was introduced into S. 
lividans TK24/cosG9B3-OIII¯ 
This work 
Plasmids/cosmids   
pOJ446 Vector for cosmid library construction Schoner et 
al.(104) 
cosRav32 Entire ravidomycin gene cluster cloned into pOJ446 This work 
   
pEM4  Salas et al.(134) 
pUWL201PW E. coli-Streptomyces shuttle plasmid that contains ermEp*for 
the expression of genes in Streptomyces 
Raynal et al.(67) 
pRavGT ravGT cloned into pUWL201PW This work 
pRavOIII ravOIII cloned into pEM4 This work 
PCR-Blunt-II-TOPO To clone PCR products Invitrogen 
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1H and 13C NMR data of deacetylravidomycin E (29-b): 1H NMR (CDCl3, 300 MHz) δ 9.83 
(br, s, 1H, OH 1, D2O exchangeable) 8.51 (s, 1H, H11), 7.97 (d, J = 9.0 Hz, 1H, H3), 7.95 (d, J = 
3.3 Hz, 1H, H7), 7.25 (d, J = 3.3 Hz, 1H, H9), 7.08 (d, J = 9.0 Hz, 1H, H2), 6.01 (d, J = 9.0 Hz, 
1H, H1′), 4.44 (t, J = 9.0 Hz, 1H, H2′), 4.16 - 4.26 (m, 2H, H4′, H5′), 4.15 (s, 3H, OMe12), 4.12 
(s, 3H, OMe 10), 3.35 (dd, J = 9.0, 3.0 Hz, 1H, H3′), 2.95 (s, 6H, N(Me)23′), 2.83 (q, J = 7.5 Hz, 
2H, H1′′), 1.32 (t, J = 7.5 Hz, 3H, H2′′) 1.31 (d, J = 6.0 Hz, 3H ,Me6′); 13C NMR (CDCl3, 75 
MHz) δ 170.2, 161.0, 157.5, 155.0, 152.5, 146.8, 129.8, 125.3, 124.7, 122.4, 122.4, 121.3, 116.0, 
117.7, 114.5, 113.0, 102.8, 79.8, 78.5, 71.6, 69.6, 68.8, 56.6, 43.1, 29.2, 16.95, 15.37.  
 
                                         
 
 
 
 
 
 
 
 
51 
 
Section Three: Characterization of the TDP-D-ravidosamine biosynthetic pathway 
Background 
Glycosylated microbial natural products possess a wide range of pharmaceutical 
properties such as antigenic, chemotherapeutic, and antibiotic (146). The sugar moieties of these 
molecules are often deoxygenated to various extent, and are appended to the backbone through 
O- or C-, and rarely through N- or S-glycosidic linkages. Structural and functional studies have 
demonstrated that these sugar moieties tremendously contribute to the biological activities of the 
parent compounds (147, 148). Due to the large structural diversity of deoxysugars and their 
importance for biological activities, much attention has been paid to the elucidation of their 
biosynthetic pathways (149, 150). Recent progress in understanding and manipulation of these 
pathways has proved the concept that an array of glycosylated natural products can be generated 
through enzymatic glycodiversification (151). However, further application of this concept 
requires an in-depth knowledge of various deoxysugar biosynthetic pathway enzymes that 
includes the identification of the preferred substrate, catalytic activity, and their tolerance for 
other substrates. Thus, the success of generation of new glycosylated natural products largely 
depends on the sugar donor (NDP-sugar) and acceptor substrate flexibility of the dedicated 
glycosyltransferases (GTs) (131). Out of hundreds of GTs reported thus far, a few have shown 
flexibility for the donor(34, 39) or the acceptor substrates, (27, 152, 153) and very rarely for 
both. The majority of the GTs characterized from the secondary metabolite biosynthetic 
pathways are O-GTs such as AveB1(31), GtfD and GtfE (154), KanF (155), AmphD1 and 
NysD1(156). Unavailability of soluble GTs, their sugar acceptor substrates and NDP-sugar 
donor substrates contribute to the slow progress of C-GTs characterization in vitro. Recent 
advancements in understanding deoxysugar biosynthetic enzymes has made it possible to 
engineer a pathway to biosynthesize a target NDP-sugar in an efficient way. This approach is far 
superior than the current chemical synthetic counterpart as it is concerted, less time consuming, 
stereo- and regioselective with high product yield in addition to the environmentally friendly 
protocol (157).  
Ravidomycin (RMV) and gilvocarcin V (GV) differ to each other in their C-
glycosidically linked deoxysugars moieties. RMV comprises the 4′-O-acetyl-D-ravidosamine 
whereas GV contains D-fucoruranose. Earlier studies of structure-activity relationship (SAR) of 
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gilvocarcins and ravidomycins have clearly shown that the deoxysugar moieties are crucial for 
the biological activities (93, 102). Although, there is no direct comparison of biological activities 
among GV class compounds, it has been reported that RMV is the most active compound 
highlighting the unique role of the amino sugar moiety (158). Alteration of the sugar moieties of 
GV/RMV could be very promising to biosynthesize new analogues with potentially better 
pharmacological properties. There are many reports on biosynthesis of unnatural O-glycosides 
through combinatorial biosynthesis (22, 25, 35, 37, 39). Most of them have utilized 6-membered 
neutral sugars for the glycoslation. Glycodiversification utilizing basic sugars (aminosugars) or 
five membered sugars are scarce even though they are highly interesting from a 
structure/interaction point of view. Characterizations of RavGT/GilGT and their donor and 
acceptor substrate biosynthetic enzymes would provide a framework to generate GV/RMV 
analogues with unnatural (for example, a hypothetical 5-membered aminosugar) sugar moieties. 
Such studies in vitro provide a direction to engineer a strain of interest to bioysynthesize the 
target molecule in vivo. In this context, we report the characterization of the TDP-D-
ravidosamine biosynthetic pathway through the in vitro activity assay of the proposed enzymes. 
We also report a two-stage, one-pot enzymatic synthesis of TDP-D-ravidosamine through 
combinatorial biosynthesis, thus providing an efficient route to generate a donor substrate for the 
RMV C-glycosyltransferase RavGT. Furthermore, our efforts to characterize the D-fucofuranose 
pathway in vitro are also discussed in this chapter.  
Results 
Characterization of RavD and RavE 
 Bioinformatic analyses of the ravidomycin biosynthetic gene cluster indicated six open 
reading frames relevant to TDP-D-ravodosamine biosynthesis (Figure 3.1). Homology studies 
indicated that RavD might be an NDP-glucose synthase that could catalyze the first step of the 
ravidosamine biosynthetic pathway i.e. the attachment of TDP at C-1 of the glucose-1-phosphate 
(G-1-P)(16) (Scheme 3.1). Similarly, the encoded product of ravE showed similarity to various 
TDP-glucose 4,6-dehydratases that were well known for deoxygenation at C-6 and oxidation at 
C-4 of TDP-D-glucose (17) to generate TDP-4-keto-6-deoxy-D-glucose (18). The start and stop 
codons of the remainder of the proposed ravidosamine biosynthetic genes (ravNMT, ravIM and 
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ravAMT ) were translationally coupled. RavIM is a unique gene of the RM cluster (see section 2). 
To test their proposed functions, N-terminal His-tag proteins were produced through the  
 
 
Figure 3.1 TDP-D-ravidosamine biosynthetic gene cluster from S. ravidus. 
expression of the genes in E. coli and were purified using immobilized metal affinity 
chromatography (IMAC). The expected sizes of the proteins were observed on SDS-PAGE 
(Figure 3.2). Incubation of RavD with G-1-P and thymidine triphosphate (TTP) resulted in the 
consumption of TTP and concomitant formation of a new peak in HPLC that eluted at the 
identical retention time (37.7 min) of standard TDP-D-glucose (Figure 3.3). The completion of 
the reaction was noticed in 30 minutes. The molecular ion peak observed in low resolution ESI 
mass (at 563) was in good agreement with the calculated value (cal. [M-H]- = 563.075). The 
structure was further confirmed through the comparison of the 1H NMR of the purified 
compound with that of the reported data (Table 3.1).(131) Less than 5% turnover was noticed 
while using UTP, GTP, or CTP indicating TTP to be the preferred substrate for RavD. The 
results clearly demonstrated that RavD was a TDP-glucose synthase and it likely catalyzes the 
first step of the TDP-D-ravidosamine biosynthetic pathway.  
 Incubation of 17 with RavE did not alter the HPLC profile of the reaction mixture, but 
the peak at 37.7 min was broadened over time (Figure 3.3). This indicated a conversion, but the 
substrate and the products might be eluting at the same retention time.  
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Scheme 3.1 A proposed pathway for TDP-4′-O-acetyl-D-ravidosamine biosynthesis. 
                            
Figure 3.2 SDS-PAGE analyses of recombinant RavD (40.37 kDa) and RavE (37.93 kDa). 
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The incubation was continued until 1 h to allow the completion of the reaction and the compound 
was purified through gel filtration. The 1H NMR spectrum of the compound was found to be 
identical to the previously reported data of TDP-4-keto-6-deoxy-D-glucose (18) (Table 3.1) 
(131). It is important to note that 18 is the common intermediate for a variety of deoxyhexoses 
including D-, L-, branched, or amino sugars. The results clearly showed that ravE encodes TDP-
glucose 4,6-dehydratase which catalyzes conversion of 17 to 18 during the biosynthesis of TDP-
D-ravidosamine (19). 
                 
Figure 3.3 HPLC analyses of TDP-sugars generated through the activities of TDP-D-ravidosamine 
pathway enzymes. Trace A: Thymidine monophosphate (TMP, 64) incubated with acetate kinase (ACK), 
thymidine monophosphate kinase (TMK) and adenosine triphosphate (ATP); trace B: Thymidine 
triphosphate (TTP, 66) incubated with glucose-1-phosphate (G-1-P) and RavD; trace C: assay mixture B 
supplemented with RavE; trace D: assay mixture C supplemented with RavIM, RavAMT, L-glutamate 
and pyridoxol-phosphate (PLP); trace E: assay mixture D supplemented with S-adenosyl methionine 
(SAM) and RavNMT. Reactions were carried out for 1 hour prior to the HPLC analyses. The compounds 
on the HPLC traces for B, C, D and E remained unchanged when the commercial TTP was replaced by 
ACK, TMK, acetyl phosphate, TMP and ATP. Three different peaks were observed for commercially 
available SAM indicating the presence of impurities. TDP-D-glucose (17); TDP-4-keto-6-deoxy-D-
glucose (18); TDP-D-ravidosamine (19); TDP-3-keto-3,6-dideoxy-D-galactose (55); TDP-3-amino-3,6-
dideoxy-D-galactose (56); thymidine monophosphate (TMP, 64); thymidine diphosphate (TDP, 65); 
thymidine triphosphate (TTP, 66) 
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Table 3.1 1H NMR data of TDP-D-glucose (17) and TDP-4-keto-6-deoxy-D-glucose (18) (D2O, 500 MHz) 
 TDP-D-glucose (17) TDP-4-keto-6-deoxy-D-glucose 
(18) 
Position number 1H δ [ppm] Multiplicity 
(J/Hz) 
1H δ [ppm] Multiplicity 
(J/Hz) 
1 5.58 dd (7.4, 3.5) 5.4 dd (6.8, 3.3) 
2 3.51 td (9.8, 3.5) 3.51 td (10.07, 3.3) 
3 3.43 t (9.8) 3.63 d (10.07) 
4 3.72-3.78 m - - 
5 3.81-3.90 m 3.93 q (6.5) 
5-CH3 3.72-3.78 m 1.06 d (6.5) 
1’ 6.33 t (6.98) 6.19 t (6.90) 
2’ 2.31-2.38 m 2.23 dd (6.90, 4.85) 
3’ 4.62 m 4.43-4.47 m  
4’ 4.12-4.16 m 3.99-4.06 m 
5’ 4.12-4.16 m 3.99-4.06 m 
5” 1.9 s 1.77 d (0.97) 
6” 7.72 s, br 7.57 d (0.97) 
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Characterization of RavIM and RavAMT 
 RavIM was the only candidate deoxysugar isomerase identified in the RMV gene 
cluster. It showed homology to C-terminal domains of various WxcM domain-containing 
proteins. WxcM from Xanthomonas compestris was proposed to catalyze two steps: i) 
isomerization of TDP-4-keto-6-deoxy-D-glucose to TDP-3-keto-6-deoxy-D-galactose and ii) N-
acetylation of TDP-3-amino-3,6-dideoxy-D-galactose during the biosynthesis of the TDP-N-
acetyl-3-amino-3,6-dideoxy-D-galactose subunit of the surface lipopolysaccharide (LPS). RavIM 
also showed considerable amino acid sequence identities to recently characterized 3,4-
ketoisomerases, such as Tyl1a and FdtA. 
 
Figure 3.4 Multiple sequence alignment of RavIM and its homologues from the database. Srm2, FdtA, 
and WxcM are hexose isomerases identified from Aneurinibacillus thermoaerophillus L420-91, 
Sulfurihydrogenibium yellowstonense SS-5 and Streptomyces ambofaciens, respectively. The sequence 
highlighted by the box indicates the signature motif of FdtA-type isomerases. 
 Both enzymes utilize TDP-4-keto-6-deoxy-D-glucose (18) but generate two different 
products TDP-3-keto-6-deoxy-D-glucose (53 by Tyl1a) and TDP-3-keto-6-deoxy-D-galactose (55 
by FdtA). Holden et al. identified several active site residues of FdtA in this signature region 
through the combined studies of site directed mutagenesis crystal structure.(159) Closer analysis 
of RavIM revealed the presence of the characteristic signature sequence 
[RGXHAH(K/R)X(L/I)XQXGS] (Figure 3.4). This further supported the aforementioned FdtA-
like role of RavIM in 4-O-acetyl-TDP-D-ravidosamine (59) biosynthesis (see section 2 for more 
detail discussion). However, a bifunctional (isomerization/acetylation) role of RavIM could not 
be ruled out. In this context, RavIM might acetylate the amino group of 56 prior to N→O acyl 
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migration, or it could acetylate 4-OH of 55 before or after the transamination at C-3 position. To 
assign the exact functional role of RavIM, the enzyme was heterologously produced in E. coli 
and the protein was purified using IMAC. (Figure 3.5). The enzyme was then subjected to a 
series of enzyme assays. No significant change in the substrate concentration was noticed when 
the assay samples were analyzed after 0 to 2 hours of incubation with 18. However, the 
incubation of 18 with RavIM for 24 hours resulted in the complete consumption of the substrate 
and the appearance of two major compounds TDP (51 min) and a decomposition product, 
presumably dihydroxy-4-keto-2,3-dihydropyran (73, 2.9 min) (data not shown). The UV 
spectrum of the minor compound observed at 43 minutes was identical to that of the thymidine 
chromophore, indicating a possibility of being the product (55) of RavIM. These results showed 
that RavIM might be catalyzing the isomerization (18→55) in a slow rate, and the product might 
be spontaneously decomposing to TDP in the absence of aminotransferase RavAMT. Our several 
efforts to isolate and characterize 55 were unsuccessful due to its poor yield and instability. 
 To carry out the coupled assay with RavIM, RavAMT was overexpressed in E.coli and 
the recombinant protein was purified using IMAC. Incubation of 18 with RavIM and RavAMT 
in the presence of L-glutamic acid and pyridoxol-5-phosphate (PLP) for 30 minutes resulted in 
the appearance of a new peak at 12.8 min as a major compound and TDP peak as a minor 
compound (Figure 3.3). The new peak was collected from the HPLC and desalted through gel 
filtration. Low resolution ESI mass analyses revealed a molecular ion peak at 546 which 
matched with the molecular weight of 56 (molecular formula C16H27N3O14P2, cal. [M-H]- = 
546.096). The negative mode high resolution ESI-MS revealed a molecular ion peak at 546.0922 
which confirmed the suggested molecular formula. The 1H NMR of this compound revealed C-5 
methyl protons as a doublet at δ 1.16. The proton at C-5 position appeared as a quartet at δ 4.25. 
The presence of a broad doublet at δ 3.93 was indicative of an equatorial proton at C-4 position. 
The proton at C-3 position appeared as a double doublet at δ 3.63 with the coupling constants J 
=11.0 Hz and J =3.0 Hz. This further confirmed the presence of an equatorial proton at C-4 and 
axial hydrogen atom at C-2 positions. Likewise in 17 and 18, the proton at C-2 and C-1 appeared 
as a double triplet at δ 3.88 and a double doublet at δ 5.54 ppm, respectively, as a result of 
coupling with the phosphorous atom of the anomeric phosphate group. 
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Figure 3.5 SDS-PAGE analyses of TDP-D-ravidosamine pathway enzymes. The sizes of the observed 
protein bands were in good agreement with the calculated values (RmlB, 40.5 kDa; RavD, 40.37 kDa, 
RavNMT, 31.06 kDa; RavAMT, 41.71 kDa; RavIM, 19.1 kDa; RfbA, 34.54 kDa; TMK, 25.9 kDa; ACK, 
45.41 kDa). 
 The assignment was made by analyzing the coupling constant of the 1H NMR and 1H, 
1H-COSY correlations (Table 3.2). As a positive control, FdtA and FdtB were also expressed 
and purified to compare their activities with RavIM and RavAMT, respectively. Identical HPLC 
profiles were observed when RavIM and RavAMT were replaced with FdtA and FdtB, 
respectively. However, the specific activity of FdtA (201 μM mg-1 min-1) appeared to be ~6 fold 
higher than that of RavIM (31.3 μM mg-1 min-1). These results clearly demonstrated the identical 
biochemical actions of these isomerases and aminotransferases. To test whether RavIM is a 
bifunctional enzyme (i.e. isomerase/acetyltransferase), 18 was incubated with RavIM and acetyl-
CoA. The HPLC profile of the assay product was identical to that of the control mixture without 
acetyl-CoA. Similarly, addition of acetyl-CoA did not alter the products of RavIM and RavAMT. 
These results clearly established that RavIM is not a bifunctional enzyme but it is, in fact, a 3,4-
keto-isomerase that converts 18 to 55. Our further attempts to isolate 55 in large scale using 
FdtA were not successful as the compound decomposed during purification. Comparing the 
active site residues of RavIM with FdtA, we proposed a mechanism of isomerization catalyzed 
by RavIM. His-71 might abstract a proton from the C-3 carbon of 18 to generate ene-diol 63. In 
the next step, His-73 might abstract another proton from the C-3 hydroxyl group of 63 and 
channels to the rear face of C-4 carbon to yield 55 (Scheme 3.2). Alternatively, His-71 could 
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abstract both protons sequentially and His-73 prior to the transfer to the C-4 position. It is not 
clear yet whether or not the same C-3 proton of 18 migrates to the C-4 positon.  
 
 
Scheme 3.2 Proposed mechanism for RavIM catalysis 
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Table 3.2 1H NMR data of TDP-3-amino-3,6-dideoxy-D-galactose (55) (D2O, 500 MHz) 
Position number 1H δ [ppm] Multiplicity (J/Hz) 1H, 1H-gCOSY 
correlations 
1 5.54 dd (6.9, 3.5) 2 
2 3.88 td (11.1, 3.5) 1, 3 
3 3.63 dd (11.1, 3.1) 2, 4 
4 3.93 br, d (3.1) 3, 5 
5 4.25 q (6.4) 4, 5-CH3 
5-CH3 1.16 d (6.4) 5 
1’ 6.28 t (6.8) 2′ 
2’ 2.36-2.28 m 1′, 3′ 
3’ 4.55 br, m 2′ 4’ 
4’ 4.10-4.16 m 5′, 3′ 
5’ 4.10-4.16 m 4′ 
5”-CH3 1.87 s 6′′ 
6” 7.66 br, s 5”-CH3 
 
Biochemical studies of FdtA 
 Although, the functional role of FdtA had been established, the biochemistry of its 
catalysis including the kinetics and the products were not characterized. Because FdtA was 
catalytically superior to RavIM in in vitro assays, it was chosen for a detailed biochemical 
characterization. First, we monitored the FdtA catalysis in various time points. Analysis of the 
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assay mixture from 0 to 110 minutes revealed gradual decrease of 18 with the increasing amount 
of TDP (65) (Figure 3.6). The peak corresponding to 55 gradually increased from 0-55 minutes 
and remained unchanged. However, a new peak at 2.9 minutes increased exponentially 
throughout the incubation. This indicated that 55 was not stable under the experimental 
conditions and it decomposed to TDP and 73. The results were clearly better visualized in the 
graph plotting the normalized area vs the incubation time (Figure 3.7). 
 
                    
Figure 3.6 HPLC analyses of isomerization reaction catalyzed by FdtA. Assay mixtures were quenched 
following increasing incubation periods (0-120 min) and were analyzed in HPLC. Thymidine 
monophosphate (TMP, 64); TDP-4-keto-6-deoxy-D-glucose (18); TDP-3-keto-6-deoxy-D-galactose (55); 
thymidine diphosphate (TDP, 65); (2R,3S)-2-methyl-3,5-dihydroxy-4-keto-2,3-dihydropyran (73). 
 
                 
Figure 3.7 Plot of the normalized HPLC peak area of the compounds in the assay mixture using FdtA. 
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Kinetic studies with FdtA 
 Because the product of FdtA (55) was not stable, the consumption of 18 was monitored 
to determine the initial velocity of the isomerization reaction. Compound 18 was incubated with 
FdtA in the presence of increasing substrate concentrations for different time periods (see 
materials and methods section) and the plot of the initial velocity versus substrate concentration 
was generated (Figure 3.8). The observed values for Km and kcat were 21.89±6.994 (µM) and 
8.95 min-1, respectively. The observed turnover of FdtA was comparable to that of Tyl1a (6.5 
min-1) from the TDP-D-mycaminose pathway. 
 
Figure 3.8 Plot of initial velocity (υ0) vs substrate concentration [S].  
 
Functional characterization of RavNMT 
Homology searches showed that the encoded amino acid sequence of ravNMT is similar 
to other known deoxysugar N,N-methyltransfarases. These homologous enzymes were known to 
methylate the amino group of the deoxysugar twice sequentially using S-adenosyl methionine 
(SAM) as a co-factor. Well known examples are DesVI and OleM1 from the pikromycin and the 
oleandomycin pathways (68, 136), respectively. In context with the RMV biosynthesis, we 
assumed that RavNMT might catalyze a similar reaction (56→19) utilizing the product of 
RavAMT (56) as the substrate. To validate the proposed function of RavNMT, the enzyme was 
heterologously produced in E. coli and purified through IMAC (Figure 3.5). Incubation of TDP-
3-amino-3,6 dideoxy-D-galactose (56) with RavNMT in the presence of SAM resulted in the 
complete consumption of 56 with concomitant production of a new peak at 4.8 min in HPLC 
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(Figure 3.3). The compound pertaining to the new peak was isolated and purified through HPLC 
and gel-filtration.  
 
Table 3.3 1H NMR data of TDP-D-ravidosamine (19) (D2O, 500 MHz) 
Position number 1H δ [ppm] Multiplicity (J/Hz) 1H, 1H-COSY  
1 5.64 dd (6.9, 3.6) 2 
2 4.21 m 1, 3 
3 3.60 dd (11.4, 2.7) 2, 4 
4 4.21 m 2, 5 
5 4.25 q (6.6) 4, 5-CH3 
5-CH3 1.19 d (6.6) 5 
1’ 6.33 t (6.8) 2′ 
2’ 2.29-2.38 m 1′, 3′ 
3’ 4.6 br, m 2′ 4’ 
4’ 4.10-4.16 m 5′, 3′ 
5’ 4.10-4.16 m 4′ 
5”-CH3 1.91 d (1.1) 6′′ 
6” 7.7 d (1.1) 5”-CH3 
 
High resolution ESI mass revealed a quasi molecular ion peak of 574.1227 dalton which 
is in agreement with the molecular formula C18H31N3O14P2 of the proposed product 19 (calcd. 
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MW, [M-H]- = 574.1281). In 1H NMR spectrum, the appearance of a new singlet at δ 2.94 was a 
clear indication of the presence of two methyl groups at the amino nitrogen of 19. Chemical 
shifts for the other protons of 19 were assigned through the analyses of 1H, 1H-COSY 
correlations. The detailed 1H NMR data of 19 are summarized in table 3.3. The negative mode 
high resolution ESI mass spectra of the reaction mixture revealed molecular ion peaks of 
574.1227, 560.1073 and 546.0922 daltons which corresponded to the molecular ions of 19, 60 
and 56 at negative mode, respectively. This indicated that RavNMT catalyzes the transfer of 
methyl groups from SAM to the amino nitrogen of 56 sequentially.  
RavW, a candidate enzyme for O-acetylation 
The product of ravW was the only candidate acetyltransferase identified in the gene 
cluster. Homology searches showed a modest similarity to N-acetyltransferases (GCN5 family 
enzymes). Ravidomycin contains an acetyl group at the C-4′ position, and the amino group at C-
3′ position is dimethylated. However, other RMV analogues FE35a (30) and FE35B (31) which 
contain N-methyl, N-acetyl or N-methyl, N-acetyl and 4-O-acetyl functionalities in their sugar 
moieties have been identified (85). In this context, three different routes could be proposed for 
the biosynthesis of 4′-O-acetyl-TDP-D-ravidosamine: i) acetylation of 4′-OH group of 56 at the 
very last step of the pathway (path I, Scheme 3.1); ii) N-acetylation of 56, acyl shift and 
dimethylation at amino group (path II); iii) N-methylation of 56, N-acetylation of 61, N→O-acyl 
shift and N-methylation of 62 (path III). In order to test these hypotheses, we cloned and 
expressed RavW in E. coli. The protein was expressed only in the form of insoluble inclusion 
bodies. Unfortunately, our several efforts to optimize expression of RavW in soluble form were 
not successful. Further experiments directing the prodcution of soluble RavW would be crucial 
to address the validity of the hypothesized function of RavW. 
One-pot enzymatic synthesis of TDP-D-ravidosamine 
 One of the major goals of this study was to generate a sugar donor substrate for RavGT 
for in vitro glycosylation studies. An identification of sugar donor and acceptor substrates of 
RavGT would set a framework for assessing its substrate flexibility towards substrate variants 
and would also provide a means to generate RMV analogues in vitro as well as substrate 
analogoues. This required an easy protocol to generate the substrate for RavGT. Having all of the 
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biosynthetic enzymes in hand, we attempted to set up a protocol to generate the anticipated sugar 
donor substrate (TDP-D-ravidosamine) of RavGT in a large scale one-pot setup. However, the 
fairly expensive starting material TTP would limit the larger scale production of TDP-D-
ravidosamine. Therefore, we cloned the enzymes necessary for the biosynthesis of TTP from E. 
coli following a reported protocol (160). Thymidine monophosphate kinase (TMK) 
phosphorylates TMP to generate TDP which is further phophorylated to generate TTP through 
the activity of acetate kinase (ACK). ATP serves as a phosphate donor and converts into ADP, 
where acetate kinase regenerates ATP again by transferring the phosphate group of acetyl 
phosphate to ADP (Scheme 3.3).  
                      
Scheme 3.3. Enzymatic synthesis of TTP (66) from TMP (64) using acetate kinase (ACK) and thymidine 
monophosphate kinase (TMK). 
 Both proteins were over expressed in E. coli and purified through IMAC (Figure 3.5). 
Incubation of TMP with acetyl phosphate and catalytic amount of ATP resulted in the production 
of TDP and TTP in quantitive yield. Since these reactions were reversible, the reaction was 
driven forward by adding RfbA and G-1-P in the assay mixture (Figure 3.3). Considering the 
fact that TDP can serve as an inhibitor for the downstream pathway enzymes, overall TDP-
biosynthesis was divided into two stages in the same pot. In the first stage, TMP (0.48 mM), G-
1-P (0.8 mM) and ATP (45 μM) were incubated with ACK, TMK and RfbA. TDP-D-glucose was 
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produced with ~95% yield in 5 minutes using these enzymes (see detail in the experimental 
section). 
 
Figure 3.9 The conversion profile of TDP-4-keto-6-deoxy-D-glucose to TDP-D-ravidosamine at the 
second stage. 
  The enzymes in the assay mixture were denatured by heating at 95 °C for 4 minutes 
and then removed by centrifugation. After several batches of protein production, both of the 
recombinant 4,6-dehydratases (RavE and RfbB) were expressed mostly in insoluble form. 
Therefore, an additional TDP-glucose-4,6-dehydratase (encoded by rmlB) was cloned from E. 
coli, and the protein was produced and purified following the identical protocol described in 
materials and methods. Addition of RmlB in the assay mixture resulted in the complete 
conversion of TDP-D-glucose (17) to TDP-4-keto-6-deoxy-D-glucose (18). RavIM, RavAMT, 
RavNMT, PLP, L-glutamate and SAM were added in the assay mixture to complete TDP-D-
ravidosamine biosynthesis. More than 95% of TDP-4-keto-6-deoxy-D-glucose (17) was 
consumed in 65 minutes (Figure 3.8) with the concomitant productions of TDP-3-amino-3,6-
dideoxy-D-galactose (56) and a mixture of TDP-N-demethyl-D-ravidosamine (60) and TDP-D-
ravidosamine (19). Identical retention times for 60 and 19 prevented us to analyze their 
individual concentrations independently. The productions of 19, 56 and 60 remained unchanged 
from 60 to180 min which was a clear indication of the lack of SAM in the assay mixture. 
Addition of excess SAM resulted in a dramatic increase in production of 19 with the 
Addition of   
SAM 
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consumption of 56 as well as 60 in additional 60 minutes, as evident from 1H NMR analyses of 
the products. The overall yield of TDP-D-ravidosamine was estimated to be 85%.  
Enzymatic synthesis of TDP-D-fucofuranose 
D-fucofuranose is an uncommon sugar moiety found among glycosylated natural 
products. It is particularly interesting for biosynthetic studies because of its crucial role in 
conferring the biological activity of GV, and also due to its unique ring-contraction chemistry. 
Recently, the TDP-D-fucofuranose (22) pathway was characterized from Escherichia coli O52 
where D-fucofuranose is a subunit of surface O-antigen (161). The pathway involved four 
enzymes. The first two enzymes (RmlA and RmlB) were involved in the conversion of 17 to 18 
(Scheme 3.4). Fcf1 then utilized NADPH to reduce the C-4 carbonyl group of 18 to generate 
TDP-D-fucose (67). Fcf2 was the unique gene of the pathway which converted 67 to 22. The 
enzyme did not require any cofactors and the reaction progressed with the contraction of 
pyranose ring to the furanose ring (Scheme 3.4, path A). Since, D-fucofuranose is the component 
of GV, a similar set of biosynthetic genes could be expected in the GV cluster. While GilD, GilE 
and GilU were functionally identical to RmlA, RmlB and Fcf1, respectively, no homologue of 
the fcf2 gene was found in the GV cluster. This indicated that there might be a structurally very 
distinct enzyme in the GV pathway to catalyze the identical reaction, or ring contraction could 
happen after glycosylation (Path B) through the activity of another enzyme whose functional role 
had not been established. Comparison of the GV and RMV gene clusters outlined GilN or GilL 
as candidate enzymes which could be contributing to the ring contraction in the D-fucofuranose 
pathway (discussed in section 2). GilN showed 60-90% homology to GTs from the 
actinomycetes and belonged to the inverting GT-A category. This could be due to the presence of 
a common sugar binding pocket in GilN and GTs. Thus, there could be two routes to establish 
the D-fucofuranose moiety of GV (Scheme 3.4): i) through the contraction of the pyranose ring 
of TDP-D-fucose (67) before the C-glycosylation (path A); ii) through the ring contraction of the 
pyranose moiety of 68 after glycosylation (path B). To test these hypotheses, availability of 
GilN, GilL and GilU was crucial. Therefore, we attempted expression of these enzymes in E. coli 
several times. Unfortunately, all of them were only expressed in insoluble forms. Neither the 
culture induction conditions nor different expression vectors helped to solubilize these proteins. 
Future expression of these genes in homologous hosts such as S. lividans TK24 or S. albus would 
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possibly produce these proteins in the soluble form and would provide a stage to validate the 
proposed hypotheses. 
 
Scheme 3.4 A hypothesized pathway for the biosynthesis of TDP-D-fucofuranose (22) 
 
Discussion 
In vitro assay results clearly demonstrated that RavD preferentially utilizes TTP (66) 
among NTPs to activate G-1-P (16) and the activated sugar converts into TDP-4-keto-6-deoxy-
D-glucose (18) through the activity of RavE. These two steps are common to a variety of 
deoxysugar biosynthetic pathway such as TDP-D-olivose (162), TDP-L-olivose (38), TDP-D-
mycarose (22), TDP-L-mycarose (157), TDP-D-fucose (163) and TDP-L-rhamnose (164). 
Isomerization of 18 to 55 catalyzed by RavIM was the unique feature of the TDP-D-
ravidosamine biosynthetic pathway. Such a conversion was further confirmed by the formation 
of an identical product in a parallel assay involving FdtA. Thus far, no such isomerization has 
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been observed in secondary metabolite biosynthetic pathways. FdtA from Aneurinibacillus 
thermoaerophillus L420-91 was the only enzyme known to catalyze such a transformation 
during the biosynthesis of 3-acetamido-3,6-dideoxy-D-galactose. However, the lack of suitable 
separation conditions for the substrate and product of FdtA hindered the earlier efforts to carry 
out complete biochemical characterization. Taking advantage of the current analytical system, 
we were able to fully characterize FdtA. Kinetic studies showed that the turnover of FdtA (kcat = 
8.95 min-1) was comparable to the recently characterized Tyl1a (kcat = 6.10 min-1) from the 
mycaminose pathway. Notably, the TDP-D-mycaminose biosynthetic pathway was identical to 
the TDP-D-ravidosamine pathway except the isomerization step where Tyl1a converts 18 to 53 
with equatorial facing hydroxyl group at C-4 position (Scheme 3.5). Incorporation of 
ravidosamine in place of the mycaminose moiety of a pikromycin derivative through the 
expression of FdtA in Tyl1a-deletion mutant has further demonstrated the close resemblance of 
these pathways (165). Unfortunately, the small turnover of the isolated RavIM hindered us from 
the determination of its kinetic parameters. RavIM appeared to have ~6.4 fold less specific 
activity compared to FdtA. Therefore, FdtA was used to study the 3,4-ketoisomerization. 
Isolation and characterization of 55 would provide direct evidence for this reaction. We were 
unable to isolate 55 due to its instability under experimental conditions. While monitoring 
FdtA’s activity, continuous production of TDP (65) with the consumption of 18 was observed, 
but the concentration of 55 remained constant after 55 minutes. This suggested a parallel 
isomerization and decomposition reaction sequence in the assay mixture. Compound 55 could 
easily undergo keto-enol tautomerization to generate 72 which could undergo decomposition 
spontaneously resulting in the formation of (2R,3S)-2-methyl-3,5-dihydroxy-4-keto-2,3-
dihydropyran (73) and TDP (65) (Scheme 3.5). There was precedence for the similar 
transformation in the mycaminose pathway where the Tyl1a product 53 spontaneously degraded 
to TDP and (2R,3R)-2-methyl-3,5-dihydroxy-4-keto-2,3-dihydropyran (71).  
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Scheme 3.5 Degradation mechanisms for TDP-3-keto-6-deoxy-D-glucose and TDP-3-keto-6-deoxy-D-
galactose. 
The coupled enzyme assay of RavAMT and RavIM catalyzed production of 56 from 18 
and provided indirect evidence that RavAMT is an aminotransferase which transaminates the 
product of RavIM. Similarly, the conversion of 56 to 19 through the activity of RavNMT 
unambiguously proved the enzyme to be an N,N-dimethyltransferase. Identification of both 19 
and 60 in the assay mixture favored the hypothesis of sequential transfer of methyl groups from 
SAM to the amino nitrogen. DesVI and TylM1 from desosamine and mycaminose biosynthetic 
pathways were other examples of such N,N-dimethyltransferases which catalyze dimethylation 
of a sugar amino group sequentially (68, 166). Whether RavW is involved in 4′-O-acetyl-D-
ravidosamine biosynthesis or whether it serves as a part of RavPKS enzyme complex could not 
be addressed due to the lack of soluble protein. The timing and the sequence of the acetylation 
(path I -III, scheme 3.1) were not clear as well. Clearly, RavIM is not responsible for the 
acetylation. Upon the production of soluble enzyme, it would be highly interesting to clarify 
these ambiguities regarding the functional role of RavW.  
Reports on one-pot enzymatic syntheses of NDP-sugars are rapidly growing. Synthesis of 
TDP-L-rhamnose,(164) TDP-L-mycarose (157), TDP-4-keto-6-deoxy-D-glucose (167) are typical 
representatives. With all of the functional biosynthetic enzymes in hand, we also devised an one-
pot enzymatic synthesis protocol for the quick and efficient production of TDP-D-ravidosamine 
(19) in a cost-effective way. Instead of using expensive commercial TTP, the compound was 
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generated in situ from TMP and acetyl phosphate using acetate kinase (ACK) and thymidine 
monophosphate kinase (TMK) from E. coli. An identical strategy was utilized for the enzymatic 
synthesis of TDP-L-rhamnose (164), TDP-4-keto-6-deoxy-D-glucose (44), and TDP-4-amino-
4,6-dideoxy-D-glucose (167). The first stage synthesis resulted in the production of TDP-D-
glucose (17) in a satisfactory yield (~95%). Further incubation of the 1st stage product with the 
remaining TDP-D-ravidosamine biosynthetic enzymes resulted in the efficient production of 
TDP-D-ravidosamine (~85% at the second stage). Suzuki et al. had developed a chemical 
synthesis protocol for the production of TDP-D-ravidosamine (168). Like the synthesis of other 
TDP-sugars, the reported procedure involved lengthy synthetic steps with overall poor yield. In 
this context, the enzymatic synthesis approach presented in this work would be a better method 
for the mass-production of TDP-D-ravidosamine. 
In summary, all of the proposed biosynthetic enzymes were characterized in vitro to 
achieve the enzymatic synthesis of TDP-D-ravidosamine. Overall, the biosynthetic pathway 
closely resembles the biosynthesis of TDP-D-mycaminose (54), which is different only with 
respect to the isomerization step. The RavIM-mediated isomerization step of the TDP-D-
ravidosamine biosynthetic pathway was further studied using recombinant FdtA. The one-pot 
enzymatic synthesis protocol developed in this study would be a valuable tool to produce TDP-
D-ravidosamine in large scale for routine use of this compound for in vitro activity assay of 
RavGT and other GTs. 
Experimental section 
Cloning and preparation of expression constructs 
Oligonucleotide primers used in this study are summarized in the table 3.4. E. coli XL1 
Blue was used for the routine amplification of plasmid DNA. E. coli BL21 was used for the 
expression of all of the constructs listed in the table 3.5. Genomic DNA of Salmonella enterica 
serover typhimurium LT2, E. coli XL1 Blue and Aneurinibacillus thermoaerophillus L420-91 
were prepared following a standard protocol. The TDP-glucose-4,6-dehydratase gene (rmlB), 
acetate kinase gene (ack) and thymidine monophosphate kinase gene (tmK) were amplified from 
the genomic DNA of E. coli. Similarly, rfbA, rfbB, and fdtA and fdtB were amplified from the 
genomic DNA of Salmonella typhimurium LT2 and Aneurinibacillus thermoaerophillus L420-
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91, respectively. All of the TDP-D-ravidosamine biosynthetic genes were amplified from the 
cosmid cosRav32.  
Expression and purification of proteins 
Pfu polymerase (Stratagene) was used for PCR amplification and the products were 
cloned into the ZeroBlunt-TOPO vector (Invitrogen). Primers used in this study are listed in 
table 3.4. Sequencing of the TOPO clones were carried out to ascertain the perfect fidelity of the 
PCR amplification. The acetate kinase (ACK), ravD, E, IM, AMT, NMT and rfbA were isolated 
from their TOPO-clones with NdeI/EcoRI fragments and ligated at the identical sites of 
pET28a(+) expression vector (Novagen). Similarly, the thymidine monophosphate kinase gene 
(tmk), rfbB and rmlB were ligated at EcoRI/HindIII and BamHI/HindIII and BamHI/XhoI sites of 
pET28a vector, respectively. All the expression constructs generated in this study are 
summarized in table 3.5. The constructs were then transformed into E. coli BL21(DE3) host. A 
single colony was inoculated into 20 mL of LB liquid supplemented with kanamycin sulfate and 
was grown for 4 h to prepare a seed culture. A liter of LB (100 mL × 10 flasks) was inoculated 
with 10 mL of the seed and grown the culture at 37 °C until OD600 reached to 0.5. The culture 
was grown at 23 °C for 12 h following addition of IPTG (0.05 mM final concentration). The cell 
pellets were collected by centrifugation (4000 × g, 15 min) and were washed twice with 20 mL 
of lysis buffer (50 mM KH2PO4, 300 mM NaCl, 10 mM imidazole, pH 7.6). Disruption of the 
pellets was carried out using a French Press (Thermo electron corporation), and the crude soluble 
enzyme fraction was collected through centrifugation (17000 × g). N-terminal His-tagged 
enzymes were purified through immobilized metal affinity chromatography (IMAC) which is 
further desalted through the Profinia protein purification system (Bio-Rad). The concentration of 
the enzyme was determined using the Bradford protein assay method (169). The purities of the 
enzymes were estimated by sodium dodecylsulfate-polyacrylamide genel electrophoresis (SDS-
PAGE) analyses. 
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Table 3.4. List of the primers used in the experiments (deoxysugar biosynthesis) 
Name of the 
primers 
Oligonucleotide sequence 
ACK_ex_for 5′-TCGCATATGTCGAGTAAGTTAGTACTGGTT-3′ 
ACK_ex_rev 5′-TCGGAATTCTCAGGCAGTCAGGCGGCTCGCGTC-3′ 
TMK_ex_for 5′-GCTGAATTCATGCGCAGTAAGTATATCGTCATTGAG -3′ 
TMK_ex_rev 5′-CTGGAAGCTTCATGCGTCCAACTCCTTCACCCA -3′ 
RmlB_for 5' -TTGGATCCATGAAAATACTTGTTACTGGTGGCGCAGGA -3′ 
RmlB_rev 5′-ATTCTCGAGTTACTGGCGGCCCTCATAGTTCTGTTC-3′ 
RavAMT_ex_for 5′-GCGCATATGAAGGTCCCCTATCTGGACCTGAAG-3′ 
RavAMT_ex_rev 5′-GTGGAATTCTCAGACCGCGGCGCGCACCGCTTC-3′ 
RavNMT_ex_for 5′-GCGCATATGAGCACCCTCTCGGTGAGCCAGCCC-3′ 
RavNMT-ex_rev 5′-TCGGAATTCTCATCGCGGTCCCCCGTCGGTCGT-3′ 
RavE_ex_for 5′-CTCCATATGACCTCGACACACATCCTGGTG-3′ 
RavE_ex_rev 5′-TAGGAATTCTCACACCATCGCGCGCTCCTTCAA-3′ 
RavD_ex_for 5′-CCGCATATGAAGGCCCTCGTCCTGTCCGGC-3′ 
RavD_ex_rev 5′-TGTGAAGCTTGGTCATGAGGAGATCTGCACCTT-3′ 
RavIM_ex_for 5′-ACCCATATGACCGACACGACCGCCGCGACC-3′ 
RavIM_ex_rev 5′-AGGGAATTCTCATGGGCGCGCTCCGGCATCCGC-3′ 
RfbA_ex_for 5′-TGCATATGAAAACGCGTAAGGGCATTATTTTA-3′ 
RfbA_ex_rev 5′-TATGAATTCTTATAAACCTTTCACCATCTTCAGCAA-3′ 
RfbB_ex_for 5′-CGGGATCCATGGTGAAGATACTTATTACTGGCGGG-3′ 
RfbB_ex_rev 5′-TCAAGCTTGTCACTGGCGTCCTTCATAGTTCTGTTC-3′ 
FdtA_ex_for 5′- AGAGGATAACATATGGAAAATAAAGTTATTAACT-3′ 
FdtA_ex_rev 5′-TATGAATTCTTATCCTTCTTTTTCTAGATTAATTTTA-3′ 
FdtB_ex_for 5′- TGGGATCCATGATTCCTTTTTTGGATTTAAGACAA-3′ 
FdtB_ex_rev 5′-ATCTCGAGCTAGTATCCATACCTGTTAACAGC-3′ 
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Table 3.5. Bacterial strains and plasmids used in this study. 
Strain/ plasmid Characteristics and relevance References 
E. coli XL1-Blue-MRF Host for routine cloning works and for the 
construction of genomic libraries 
Stratagene 
E. coli BL21 (DE3) Expression host for the various expression 
constructs 
Invitrogen 
Salmonella typhimurium LT2 For cloning deoxysugar biosynthetic genes Liu et al. (131) 
A.neurinibacillus 
thermoaerophillus L420-91 
For cloning deoxysugar biosynthetic genes Messner et al.(132) 
Streptomyces lividans TK24 For expression of gilvocarcin PKS enzymes Wright et al.(170) 
pRfbA rfbA gene cloned into pET28a This work 
pRfbB rfbB gene cloned into pET28a This work 
pRavD ravD gene cloned into pET28a This work 
pRavE ravE gene cloned into pET28a This work 
pRavIM ravIM gene cloned into pET28a This work 
pRavAMT ravAMT gene cloned into pET28a This work 
pRavNMT ravNMT gene cloned into pET28a This work 
pFdtA fdtA gene cloned into pET28a This work 
pFdtB fdtB gene cloned into pET28a  This work 
pACK Acetate kinase gene cloned into pET28a(+) Kim et al.(134, 
164) 
pTMK tmk gene cloned into pET28a(+) This work 
pET28a Expression vector Novagen 
PCR-Blunt-II-TOPO To clone PCR products Invitrogen 
 
Substrates and co-factors 
TMP, TDP, TTP, UTP, GTP, CTP, ATP and TDP-glucose were purchased from Sigma-
Aldrich for analytical scale enzyme assays. Acetyl phosphate, pyridoxal phosphate (PLP), L-
glutamic acid and S-adenosyl methionine (SAM) were also purchased from Sigma-Aldrich. 
 
76 
 
Enzyme assays 
Activity assay of RavD and preparation of TDP-D-glucose 
Enzyme assays for TDP-glucose synthases (RavD or RfbA) were carried out in 200 μL 
mixture composed of 50 mM phosphate buffer (pH. 7.5), 20 mM MgCl2, 5 mM G-1-P, 5 mM 
NTP (ATP, UTP, TTP, GTP and CTP) and 3 μM enzyme. The mixture was incubated for 30 
minutes at 37 °C on the water bath. The reaction was stopped by heating the mixture at 90 °C for 
3 minutes. The precipitated enzymes were removed by centrifugation and the clear supernatant 
fraction was passed through amicon filter (mol. Wt. cut off 3000 Da). The filtrate (50 μL) was 
injected in the HPLC. CarboPackTM PA1 (4×250 mm) column (Dionex co.) was used to separate 
compounds. A gradient of ammonium acetate (500 mM, solvent B) and water (solvent A) was 
used to separate the assay products: 5-20% solvent B from 0-15 min, 20-60% solvent B from 15-
35 min, 60-100% solvent B from 35-37 min, 100% solvent B from 37-40 min, 100-5% solvent B 
from 40-45 min and 5% solvent B from 45-60 min. A control sample without enzyme and 
standard TDP-D-glucose was also injected for the identification of the product peak. For the 
larger scale production of TDP-D-glucose, TMP (5 mM), G-1-P (5 mM), acetyl phosphate (20 
mM) and ATP (5 μM) were mixed in 20 mL solution composed of 50 mM phosphate buffer (pH. 
7.5), 20 mM MgCl2, 4 μM ACK, 6 μM TMK and 5 μM RavD. The mixture was incubated for 1 
hour and the reaction was quenched by heating the mixture at 90 °C for 5 minutes. The mixture 
was centrifuged at 10000×g for 10 minutes and the supernatant was lyophilized. The dry powder 
was dissolved in 5 mL of water and the solution was loaded into the pre-equilibrated Bio-Gel P2 
gel filtration column 100 cm × 25 mm. Separation was carried out at 4 °C with water at flow rate 
of 0.2 mL min-1. Aliquots of 4 mL were collected and the purity of compounds were monitored 
in HPLC at 267 nM. Pure fractions were combined, lyophilized and analyzed by NMR. About 80 
mg of pure TDP-D-glucose was obtained in addition to 125 mg with minor amount TMP and 
TDP mixture. The purity was assayed through HPLC and 1H NMR.  
Activity assay of RavE and preparation of TDP-4-keto-6-deoxy-D-glucose 
To carry out TDP-glucose-4,6-dehydratases assays, the enzymes (4 μM RavE or 3 μM 
RfbB or 3 μM RmlB) were added to 200 μL solution composed of phosphate buffer (50 mM, pH. 
7.5), MgCl2 (20 mM), NAD+ (2 μM) and TDP-D-glucose (5 mM). The mixture was incubated for 
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30 minutes and the reaction was stopped. An enzyme-free solution was analyzed in the HPLC. 
For the larger scale production, a one-pot enzymatic synthesis was carried out in 50 mL volume 
composed of phosphate buffer (50 mM, pH 7.5), MgCl2 (20 mM), glucose-1-phosphate (150 
mM), TMP (98.3 mM), acetyl phosphate (400 mM), ATP (1mM), ACK (0.8 μM), TMK (2.1 
μM), RfbA (2.0 μM). The mixture was incubated for 1 hour at 37 °C and then RavE (final 
concentration of 2.73 μM) or RfbB (2.3 μM) and NAD+ (2 μM) were added and then the 
incubation was continued for additional 2 hours. Surprisingly, after a first few batches of such 
reactions, both RavE and RfbB appeared exclusively in the form of inclusion bodies. Therefore, 
the enzymes were replaced by RmlB (6 μM) in the following batches. The assay mixture was 
heated to denature enzymes. The precipitated fractions were removed by centrifugation. The 
crude product was lyophilized to powder and dissolved in 10 mL water. Separation of the 
products was carried out in the Bio-gel P2 following an identical protocol described earlier. The 
purity of each fraction was analyzed by HPLC. Pure fractions were combined and lyophilized to 
powder. This afforded 700 mg of TDP-4-keto-6-deoxy-D-glucose with ~95% purity and an 
additional 630 mg with about >70% purity. The purity and identity of the compound was further 
confirmed through the comparison of 1H NMR data with the reported literature.  
Activity assay of RavIM alone or coupled with RavAMT 
RavIM (20 μM final concentration) was incubated at 37 °C with TDP-4-keto-6-deoxy-D-
glucose (1 mM) in 500 μL solution composed of phosphate buffer (50 mM, pH 7.5) and MgCl2 
(20 mM) for 60 minutes. An aliquot (60 μL) was drawn from the incubation mixture and flash-
freezed in dry ice/acetone. The enzyme was removed by further heating the mixture at 90 °C for 
3 minutes. The solution was filtered through centricon (MW cut off 3000 Da) and the filtrate (50 
μL) was analyzed by HPLC. In the coupled enzyme assays, RavAMT (30 μM), L-glutamate (10 
mM) and PLP (60 μM) were added in the RavIM assay mixture and progress of the reaction was 
monitored until 60 minutes. The new peak appeared at 12.8 minutes in the coupled assays was 
collected and analyzed by High-resolution ESI-MS. Similarly, FdtA and FdtA-FdtB coupled 
assays were also carried out in parallel as positive controls. For the preparative scale production 
of TDP-3-amino-3,6-dideoxy-D-galactose (56), the substrate and enzyme concentrations were 
doubled and the assay volume was increased to 20 mL. After 2 hours of incubation, enzymes 
were removed and the volume was reduced to 1 mL. Separation of the compounds was carried 
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out in analytical scale HPLC. The compound eluted at 12.8 minutes was collected and separated 
from the ammonium acetate buffer using Bio-Gel P2 column. The pure fractions were combined 
and lyophilized. Through this method, 12 mg powder of TDP-3-amino-3,6-dideoxy- D-galactose 
(56) was purified. The structure of 56 was confirmed through NMR analyses.  
Kinetics study of FdtA  
Enzyme assay carried out in 100 μL solution was composed of phosphate buffer (50 mM, 
pH 7.5), magnesium chloride (20 mM), FdtA (8.4 μM) and various concentrations of 18 ranging 
from 0.05 to 25 μM. Samples with low (0.05 - 2 μM), medium (5 - 15 μM) and high 
concentration (20 - 25 μM) of substrates were incubated for 3 min, 5 min and 8 minutes, 
respectively. Reactions were stopped immediately by chilling dry ice/acetone bath (-90 °C). 
After completion of the assay, the samples were exposed to the boiling water for 5 minutes and 
centrifuged to remove precipated protein. The supernatant fraction (50 μL) was injected in the 
HPLC and the concentration of remaining 18 was determined by using a standard calibration 
curve. This allowed us to calculate decrease in concentration of substrate per unit time. Thus 
generated initial velocity data were plotted versus the concentration of 18. The resulting data 
were fitted into the Michaelis-Menten equation by non-linear regression using PRISM to 
determine kcat and Km values.  
HPLC analyses of FdtA-mediated isomerization and the decomposition of the TDP-3-keto-
6-deoxy-D-galactose  
TDP-4-keto-6-deoxy- D-glucose (18, 1 mM) was incubated at 37 °C with 24.9 μM 
enzyme in 400 μL solution containing 50 mM phosphate buffer and 20 mM magnesium chloride. 
Aliquots (60 μL) were drawn from the assay mixture and quenched the reaction in dry 
ice/acetone bath. The samples were boiled for 4 minutes and centrifuged to remove protein. The 
clear supernatant (50 μL) was injected in to the HPLC and the peak areas under the curve were 
normalized to present data in graph using PRISM. 
Activity assay for RavNMT 
For an analytical scale assay, 200 μL assay mixture containing 50 mM phosphate buffer, 
20 mM MgCl2, 1 mM of 56, 2.0 mM SAM and 10 μM RavNMT was incubated for two hours. 
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Enzyme-free solution was injected in HPLC. The new peak, appeared at 4.8 minutes was 
collected and analyzed by HR-ESI Mass spectroscopy. For the larger scale production, a coupled 
assay was carried out in 20 mL using 18 (2 mM), L-glutamate (14 mM), PLP (80 μM), SAM (4.0 
mM) RavIM (4.8 μM), RavAMT (6.5 μM) and RavNMT (8.0 μM). After two hours of 
incubation, the enzymes were removed and the solution was lyophilized. The dried powder was 
dissolved in 1 mL water and separated by HPLC. The compound eluted at 4.8 min was collected 
and desalted using Bio-gel-P2 column. Lyophilization of the pure fractions afforded 5 mg and 8 
mg of TDP-D-ravidosamine (54) and a 1:1 mixture of 60 and 54, respectively. The structures of 
the compounds were confirmed through the NMR and HR-MS analyses.  
Two-stage one-pot enzymatic synthesis of TDP-D-ravidosamine 
Overall TDP-D-ravidosamine synthesis was divided into two stages. For the first stage, 20 
mL solution containing glucose-1-phosphate (0.8 mM), TMP (0.48 mM), ATP (45 μM), acetyl 
phosphate (2 mM), ACK (5 μM), TMK (10 μM), RfbA (8 μM), phosphate buffer (50 mM, pH 
7.5) and MgCl2 (20 mM) was incubated at 37 °C for 30 minutes. HPLC analyses of the assay 
mixture revealed 0.47 mM of TDP-D-glucose in the solution. Enzymes were precipitated by 
heating the solution to 95 °C and removed through the centrifugation. In the second stage, RmlB 
(5.8 μM) was added to the solution and incubated the mixture for 30 minutes. Broadening of the 
peak at 37.7 minutes indicated conversion of TDP-D-glucose (17) to TDP-4-keto-6-deoxy-D-
glucose (18). RavIM (2.3 μM), AMT (3.9 μM), RavNMT (4.5 μM), L-glutamate (7 mM), PLP 
(42 μM) and SAM (0.7 mM) were then added to the assay mixture and continued incubation for 
5 hours. Considering the fact that SAM degrades in water, an identical amount of SAM was 
added after 3 hours. The profile of conversion was monitored using HPLC. A calibration curve 
was generated varying the concentration of TMP from 62 nM to 15 mM. The concentrations of 
TDP-D-sugars were determined using this calibration curve. The reaction was stopped by heating 
at 90 °C for 4 minutes. The denatured protein was removed through centriguration and the liquid 
fraction was lyophilized. The peak corresponding to the TDP-D-ravidosamine was separated 
through HPLC. The pure fraction was desalted and then analyzed by NMR spectroscopy. 
80 
 
Section Four: Enzymatic synthesis of defucoGM 
Background 
Post-PKS tailoring reactions such as oxidation, dehydration, glycosylation and 
methylation were of our central focus as their in depth understanding was necessary to set 
a framework for successful combinatorial biosynthesis of GV analogues. Incorporation 
studies using 13C-labeled acetate showed the loss of two carbon atoms during GV 
biosynthesis. Furthermore, isotope incorporation patterns were indicative of a C-C bond 
cleavage and an oxidative rearrangement of the backbone (Scheme 4.1) (97). To figure 
out the exact mode of this cleavage and the sequence of the post-PKS tailoring steps the 
entire GV biosynthetic cluster was cloned and sequenced in our lab (71). Most of the 
proposed post-PKS genes were inactivated individually and the metabolites from the 
mutant strains were isolated and analyzed (33, 57, 101, 102).  
 
Scheme 4.1 Incorporation of labeled acetate in gilvocarcin (figure was adapted from Rohr et al.) 
(57).  
GilOI, GilOII and GilOIV were the only candidate monooxygenases for the 
oxidative C-C bond cleavage. ∆GilOI and ∆GilOI-∆GilOII strains accumulated 2,3-
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dehydro-homo-UWM6 (41) as the major metabolite which gradually oxidized to pre-GE-
o-quinone (42-c). Homo-rabelomycin (48) and dehydro-homo-rabelomycin (49) appeared 
to be the major metabolites of ∆GilOIV and ∆GilOIV-∆GilOII, and ∆GilOII mutants, 
respectively (56). All of these accumulated metabolites had an intact angucyclinone 
backbone which confirmed the hypothesis that a C5-C6 bond cleavage of 42 is indeed 
necessary and might require a complex of the all three enzymes. The results also 
demonstrated the bifunctional (dehydratase/monooxygenases) role of GilOI and GilOIV. 
GilOIV appeared to catalyze 2,3-dehydration of 40 to 41 in addition to its oxygenation 
activities namely the hydroxylation at the C-5 position of 41. Similarly, GilOI was able to 
catalyze a 4a,12b dehydration of 2,3-dehydrohomo-UWM6 (41) in addition to its 
oxidation activity, which might be the Baeyer-Villiger oxidation of the carbonyl of 42 or 
12-hydroxylation. Similar set of metabolites was also identified in the closely related 
jadomycin pathway through the inactivation of oxygenase homologues (61). These 
inactivation results were further verified by complementation experiments where 
pWHM1238, a jadomycin PKS expression construct, which is responsible for UWM6 
generation, was complemented with various combinations of gilvocarcin/jadomycin-
oxygenases. Jadomycin A was only detected when pWHM1238 was co-expressed with 
JadF, G, H or GilOI, OII, OIV in the presence of L-isoleucine. This was a clear indication 
for the requirement of all three-oxygenases to form a complex for the oxidative C-C bond 
cleavage in both pathways (56). These results also showed that the biosynthesis of both 
antibiotics proceed through common intermediates up to 44/44-a. Based on these results, 
a pathway for the oxidative cleavage was proposed. GilPKS and other associated 
enzymes synthesize the presumed intermediate homo-UWM6 (40), where GilOIV 
catalyzes its 2,3-dehydration and then subsequent hydroxylation at C-5 position. Further 
oxidation of 42 through the activity of the yet unknown enzyme results in the formation 
of pre-GE-o-quinone (42-c). Most likely, GilOI might serve as a Baeyer-villiger 
monooxygenase which could introduce an oxygen atom between C-5 and C-6 of 42. 
Spontaneous hydrolysis of the lactone moiety of 43 could provide the acid-aldeyde 
intermediate 44, which could be further oxidized by anthrone oxygenase homologue 
GilOII.  
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Scheme 4.2 Proposed pathway for the biosynthesis of gilvocarcins  
Inactivation of GilOIII and GilGT clearly showed their direct roles in the 
formation of vinyl group and the C-glycosylation, respectively. Various attempts to 
produce metabolites from a GilMT deleted-mutant cosmid (cosG9B3-∆gilMT) were not 
successful. However, the enzyme was proposed to catalyze the methylation of phenolic 
hydroxyl groups. The ∆GilM mutant abolished the production of GV and accumulated 
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the biosynthetic shunt product homorabelomycin (48) in addition to a yet 
uncharacterized, highly unstable compound. Inactivation of GilR resulted in the 
accumulation of the pathway intermediate pre-GV (47) indicating its dehydrogenase 
activity. The functional roles of gilN, gilV and gilL were not assigned as the 
corresponding gene deleted mutant cosmids failed to express in S. lividans TK24. 
Several previous in vivo studies had indicated that angucycline post-PKS tailoring 
reactions were often accompanied by follow up bioconversion events in Streptomyces. As 
a result, accumulated products deviated from the pathway toward shunt products with 
unexpected alterations in the structures (30, 61, 125, 171-174). In addition, the 
involvement of non-enzymatic reactions was proposed as well as unusual bifunctionality 
combined with an atypical enzymology associated with these biosynthetic steps. These 
posed challenges to the separation of the real associated biosynthetic events from 
nonspecific spontaneous or host-contributed endogenous reactions, and also complicated 
the functional assignment of individual enzymes. Despite having many results from gene 
inactivation experiments in hand, the GV biosynthetic pathway remained largely unclear. 
The exact functional roles of GilOI, GilOII and GilOIV appeared to be the central 
question. Although the results indicated the necessity of these three enzymes for the C5-
C6 bond cleavage, these studies failed to address the possible contributions from host 
enzymes. The results clearly showed the contribution of GilGT, GilM, GilR and GilOIII 
to GV biosynthesis. However, their substrates and mechanisms of actions were not 
identified. Similarly, the sequence of the entire post-PKS biosynthetic events remained 
unclear. Expression of the entire post-PKS enzymes and reconstitution of the pathway in 
vitro would not only provide new insights into the sequence of biosynthetic events and 
the involved intermediates, but would also provide a means to test the substrate flexibility 
of the individual enzymes. In addition, the assay system would be free of the the host 
enzymes, and thus could provide cleaner results which could be applied to engineer the 
pathway to biosynthesize novel GV derivatives. Since defucoGM (50-b) possesses all 
structural elements of GV except the vinyl group and the sugar moiety, its biosynthesis 
could be used as a model for in vitro studies.  
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Prejadomycin (41-a), the dehydration product of UWM6 (40-a), was first isolated 
from the mutant lacking JadH, an oxygenase of the jadomycin pathway (61). Through 
feeding experiments, it was proven that compound 41-a was also a jadomycin 
biosynthetic pathway intermediate (30). The compound was later isolated as a minor 
compound from the ∆GilOI mutant (57). Further inactivation and complementation 
experiments had concluded that 41-a was likely an intermediate of the GM biosynthetic 
pathway. However, the hypothesis could not be tested through feeding experiments due 
to the lack of a GilPKS-deleted mutant strain. Therefore, we have chosen this compound 
as the starting point to biosynthesize defucoGM through enzymatic synthesis in vitro. A 
detail of the experimental approach and the results are discussed below.  
Results 
Activity assay of the post-PKS enzymes using 2,3-dehydro-UWM6 (41-a, 
prejadomycin) as a substrate 
As discussed earlier, the complex of GilOI, GilOII and GilOIV might be 
necessary to catalyze conversion of 41/41-a to the hypothetical acid-aldehyde 
intermediate 44/44-a. To test this hypothesis, all of the three enzymes were expressed in 
E. coli. Unfortunately, GilOIV appeared in the form of inclusion bodies. Various attempts 
to express the protein in soluble form were unsuccessful. Given the fact that the 
jadomycin pathway oxygenase (JadF) could complement the GV biosynthesis, which was 
halted by the deletion of GilOIV (56), identical activity of both enzymes was expected. 
Therefore, JadF was overexpressed in E. coli and purified using IMAC. JadF and GilOI 
were eluted as intense yellow proteins indicating them being flavo-proteins. The 
molecular weights of the expressed proteins observed in SDS-PAGE were in good 
agreement with their calculated weights (Figure 4.1). 
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Figure 4.1 Expression and purification of post-PKS tailoring enzymes. Theoretical molecular 
weights of these enzymes are as follows: GilOI, 55.23 kDa; JadF, 53.72 kDa; GilOII, 27.78 kDa; 
GilM, 29.35 kDa; GilMT, 39.99 kDa; GilR, 56.15 kDa. 
 HPLC analyses of cofactor released from GilOI and JadF clearly showed the 
presence of non-covalently bound FAD. Incubation of prejadomycin (41-a), FAD and 
NADPH with JadF or JadF and GilOII at various conditions did not reveal any change in 
the HPLC profile of the assay mixture compared to that of the control sample (Figure 
4.2). To provide excess of FADH in situ, NADH, FAD and NADH-FAD reductase were 
added in the assay mixture, and the assay products were analyzed in parallel. Most of the 
prejadomycin (41-a) was converted into dehydrorabelomycin (49-a) when GilOI was 
added in place of JadF. The reaction involved a C4a-C12b dehydration and an 
oxygenation at the C-12 position of 41-a. Dehydrorabelomycin (49-a) was the only new 
compound observed when 41-a was incubated with GilOI and JadF, GilOI and GilOII, or 
GilOI, JadF and GilOII (data not shown). The results raised two questions: i) was 
prejadomycin not a true intermediate? ii) were other post-PKS enzymes (GilM, GilR, 
GilMT) necessary to catalyze the C5-C6 bond cleavage of 41-a and then further convert 
the cleavage product to defucoGM (50-b)? To address these issues, the remainder of the 
defucoGM post-PKS biosynthetic enzymes were cloned, expressed and purified (Figure 
4.1). Incubation of 41-a with three oxygenases (GilOI, GilOII and JadF), GilM, GilMT 
and GilR in the presence of all anticipated cofactors did not reveal any new product, 
except again the formation of 49-a. Notably, co-incubation of the assay mixture with 
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Expression of PKS enzymes in vitro 
Gilvocarcin PKS genes identified in the cluster represented typical type II PKS 
genes. The encoded GilPKS enzymes [GilA (KSα); GilB (KSβ); GilC (ACP); GilP (AT); 
GilF (KR); GilK (cyclase); GilG (cyclase)] had been proposed to biosynthesize the 
anticipated earliest intermediate, UWM6 (40-a) of the GM/defucoGM pathway (Scheme 
4.3). The malonyl-CoA-ACP acyltransferase (GilP) picks up the starting building block 
(acetyl-CoA) or the extending blocks (malonyl-CoA) and loads then on to the ACP 
(GilC). Thus, this enzyme along with GilABC constitutes a minimal PKS whose 
activities would condense nine molecules of malonyl-CoA to an acetyl-CoA to generate a 
20-carbon poly-β-keto-acyl intermediate, where the associated keto-reductase (GilF) 
would reduce the keto-group at the C-8 carbon of 77 to a secondary alcohol. The 
associated cyclase/aromatase (GilK) and cyclase (GilG) could catalyze intramolecular 
aldol condensations of the poly-β-keto-ester which could set up the first, second, the third 
ring, respectively. The GilG-catalyzed cyclization/dehydration would immediately follow 
the second cyclization to produce UWM6 (40-a). 
 To reconstitute the biosynthetic pathway of 40-a, these genes were cloned into 
pET28a (+) expression vector and thus generated constructs were expressed in E. coli. 
GilA and GilB were expressed together to allow their hetero-dimer formation. 
Unfortunately, none of the constructs except pGilP and pGilF could produce enzymes in 
soluble form. GilP and GilF were produced in 8-10 mg/L and 6-9 mg/L culture, 
respectively. To improve their solubilities, gilC, gilK, gilG and gilAB were cloned into 
pXY200 (175) and expressed under the control of a thiostrepton-inducible promoter 
(ptipA) for Streptomyces enzymes in a genetically more friendly host S. lividans TK64. 
Surprisingly, 29 mg/L of soluble GilAB could be produced through the expression of the 
construct pGilAB. Purity and size of proteins were estimated on SDS-PAGE (figure 4.3). 
However, the productions of GilK and GilG were still poor (0.4-0.7 mg/L culture). 
Several attempts to produce soluble GilC were unsuccessful. Therefore, homologues of 
these enzymes from closely related pathways were cloned and expressed. Thus, pJadD 
(contains the homologue of gilK) and pRavG (contains the homologue of gilG) were 
generated using jadomycin and ravidomycin biosynthetic pathway genes, respectively. 
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Scheme 4.3 Biosynthesis of UWM6 (40-a) through the activity of GilPKS enzymes. 
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Figure 4.3 SDS-PAGE analyses of PKS enzymes and malonyl-CoA synthetase (MatB). 
Theoritical molecular weights of the enzymes are as follows: GilA, 43.85 kDa; GilB, 40.33 kDa; 
GilP, 33.75 kDa; GilF, 26.9 kDa; JadI, 12.4 kDa; JadC, 11.7 kDa; RavC1, 10.8 kDa; RavC; 11.3 
kDa; RavG, 12.48 kDa; JadD, 34.74 kDa.  
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In addition, jadI (another homologue of GilG) from jadomycin gene cluster was 
also cloned and expressed. As discussed earlier in Section 2, there were two putative 
ACPs (RavC and RavC1) in the RMV cluster, unlike GilC and JadC of the GV and 
jadomycin pathways, correspondingly. Considering the potential role of either or both of 
these RavACPs in defucoGM biosynthesis, both were cloned into pET28a vector to 
generate the expression constructs  pRavC and pRavC1. In addition, JadC expression 
construct (pJadC) was also generated and expressed in E. coli. While RavG (10 mg L-1 
culture) and JadD (9 mg L-1 culture) were produced from E. coli BL21 (DE3), 5-9 mg L-1 
of each of the ACPs were also produced from the same host. The sizes of proteins 
observed in SDS-PAGE were relevant to the calculated molecular weight of the proteins 
(Figure 4.3). 
It was well established that post-translational modification of apo-ACP was 
crucial for the activities. Such modification involved the phosphopantetheinylation of the 
active site serine residue of the apo-ACP. The reaction was catalyzed by 
phosphopantetheinyl transfearase (PPTase) which transfers phosphopantetheine moiety 
of co-enzyme A (CoA) to the hydroxyl group of a serine residue of the apo-ACP to 
generate the functionally active holo-ACP (Scheme 4.4). The phosphopantetheine arm of 
the ACPs provides an anchor site to tether starter/extender units. Since E. coli harbored a 
functional PPTase to generate holo-ACPs for its fatty acid biosynthesis, it was possible 
that RavC, RavC1 and JadC were expressed in their holo forms, but that was not sure. 
Therefore, each enzyme was purified, desalted, and then subjected to the MALDI-TOF 
analysis.  
 
Scheme 4.4. Conversion of apo-ACP to holo-ACP. 
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Table 4.1 MALDI-TOF analyses of ACPs 
Enzymes Apo-ACP (Mol Wt.) Holo-ACP (Mol. Wt.) Holo-ACP-Acetyl-CoA (Mol. Wt.) 
 Calculated Observed Calculated Observed Calculated Observed 
RavC 11197 11203 11537 11550 11585 11593 
RavC1 10732 10735 11072 11085 11115 11128 
JadC 11613 11619 11953 11964 11996 12007 
 
Only molecular weights of the apo-ACPs were observed in the spectra with reasonable 
accuracy (± 10 amu) ruling out the phosphopantetheinylation of RavC, RavC1 and JadC 
through the activities of the host enzymes (Table 4.1). Thus, to produce these enzymes in 
their holo-forms, the genes were expressed in the E. coli BAP1 host (176), which was 
generated through the integration of the promiscuous phosphopantetheinyl transferase 
(sfp) gene from Bacillus subtilis into the genome of E. coli BL21(DE3), thereby 
generating a mutant strain capable of efficiently expressing ACPs in their holo form. The 
amount of production of ACPs from E. coli BAP1 host was similar to that from E. coli 
BL21 host. MALDI-TOF analyses of the purified proteins revealed the presence of both 
apo- and holo-forms in about equal proportions. (Table 4.1). 
Activity assay of PKS enzymes: an enzymatic synthesis of angucyclines 
With all of the anticipated PKS enzymes in hand, enzyme assays were conducted 
in analytical scale and the assay products were analyzed by HPLC-MS. Malonyl-CoA 
was synthesized in situ using sodium malonate, CoA and malonyl-CoA synthetase 
(MatB) (see details in materials and methods). Preliminary screening for the efficient 
production of polyketides was conducted using a “mix and match” approach. The 
experimental design using various combinations of ACPs (RavC, RavC1 and JadC), 
CYCs (RavG, JadD) and other PKS enzymes (GilF, GilP, GilAB) are summarized in 
Table 4.2. 
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Table 4.2 An experimental design for the preliminary PKS enzyme assay 
Enzymes Experiment no. 
 1 2 3 4 5 6 7 8 
GilA/GilB + + + + + + + - 
RavC + + - - + + + + 
RavC1 + - + - + + + + 
JadC - - - + - - - - 
GilF + + + + - + + + 
GilP + + + + + + + + 
RavG + + + + + - + + 
JadD + + + + + + - + 
+ and – indicates presence or absence of enzymes, respectively. 
 
 
A cocktail of acetyl-CoA, malonyl-CoA and NADPH in phosphate buffer was 
incubated with eight different combinations of PKS enzymes in 200 μL solution. 
Rabelomycin (48-a) was produced as the major compound from assay no. 1 through 4 
(Figure 4.4). The authenticity of the compound was confirmed through the comparison 
of retention time, UV spectrum and mass data with an authentic sample compound. This 
clearly demonstrated that GilABFP, JadD, RavG and either of the ACPs (JadC, RavC or 
RavC1) were sufficient to biosynthesize rabelomycin from acetate and malonate building 
blocks. Surprisingly, UWM6 (40-a) was not observed in any of these experiments while 
48-a was produced as the major product. This could be due to the instability of 40-a 
under the experimental conditions, where it could convert to 48-a spontaneously. Such a 
non-enzymatic conversion was reported previously while producing UWM6 in S. lividans 
TK24 using jadomycin PKS biosynthetic enzymes (177). Since the reaction was carried 
out in a small scale, UWM6 could be present in the assay mixture in undetectable small 
amounts. The new peaks a, b and c which were detected in assay no. 5 and 6 were not 
identified. However, their UV spectra were not typical to those of angucyclines. This 
indicated that a, b and c could be aroused from the partial cyclization of the newly 
formed poly-β-keto-ester. No new peak was detected from experiment 7 that lacked 
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cyclase JadD. This could be due to the spontaneous cyclization of the newly formed 
polyketide to several products not sufficient enough to appear in the HPLC 
chromatogram. As expected, no new compounds were detected in experiment 8 (the 
control experiment that lacked GilAB). In summary, assay no. 2 and 4 appeared to be the 
best enzyme combinations for the production of rabelomycin (48-a). Therefore, GilAB, 
RavC, GilF, GilP, RavG and JadD (assay no. 2) were chosen for the production of 
angucyclines in larger scale which potentially could synthesize UWM6 besides 
rabelomycin, and for the coupled assay with the post-PKS enzymes to biosynthesize 
defuco-GM. 
 
 
Figure 4.4 Analyses of the PKS enzyme assay products. Traces 1 through 8 correspond to the 
experiment 1 through 8 described in table 4.2. Compounds were detected at 380 nm. The peaks 
a-c were not identified. Compound 48-a represents rabelomycin. 
 
The assay volume was increased to 10 mL and the experiment was conducted 
under identical conditions. HPLC-MS analyses of the assay products revealed 48-a as the 
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major product (Figure 4.5). Compound 40-a was not observed in any of the experimens. 
However, a new peak (peak X, Figure 4.5) with the UV spectrum typical of 40-a was 
detected. The compound was purified through HPLC. Low resolution ESI-MS revealed a 
molecular ion [M-H]¯ peak of 383 daltons at negative mode suggesting a MW of 384. A 
molecular ion peak of 383.1113 daltons corresponding to C20H16O8 observed in high 
resolution ESI-MS (at negative mode) further confirmed the MW of the compound to be 
384 daltons. However, we were unable to further characterize this compound through 
NMR due to its poor yield. 
 
Figure 4.5 Enzymatic synthesis of rabelomycin and other angucyclinones. Trace A: control 
sample without enzymes; trace B: GilABFP, RavCG and JadD incubated with acetyl-CoA, 
malonyl-CoA and NADPH; trace C: standard rabelomycin (48-a). Compound X was the 
unknown compound with MW=384 g Mol-1. 
 
Enzymatic synthesis of defuco-GM 
Production of the biosynthetic shunt product rabelomycin as the major product 
through the activity of the PKS enzymes suggested that the PKS and post-PKS oxygenase 
complex might function intimately to catalyze the oxidative ring opening of a in situ 
formed angucycline intermediate, e.g. 40-a. The product of the oxygenase complex could 
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be further processed by other enzymes, presumably GilM, GilMT and GilR, to yield 
defuco-GM. Successful reconstitution of the entire defuco-GM pathway would be highly 
interesting as it would outline the minimum number of enzymes required to biosynthesize 
this compound. Identification of the compounds generated from various combinations of 
PKS and post-PKS enzymes would also provide a platform to identify the pathway 
intermediates as well as the sequence of biosynthetic events. Therefore, we attempted the 
co-incubation of PKS and post-PKS enzymes and analyzed the metabolites in HPLC-MS.  
 
Figure 4.6 HPLC analyses of the enzyme assay products: trace A, control sample without GilAB; 
trace B, assay sample with GilA, B, F, P, OI, OII, R, M, MT, RavC, G, JadD and JadF; trace C, 
standard defucoGM. X1 and X2 represent yet uncharacterized compounds. They were also 
observed in the culture broth of the ∆GilGT mutant. 
Acetyl-CoA and malonyl-CoA were incubated with GilA, GilB, GilF, GilP, 
GilOI, GilOII, GilM, GilMT, RavC, RavG, JadD, JadF, NADPH, FAD and SAM. Here, 
NADPH could serve as a co-factor for the PKS-associated ketoreductase GilF, and for the 
FAD-dependent oxygenases GilOI and JadF. GilF could utilize NADPH directly whereas 
the oxygenases would utilize it to generate chemically reactive FADH in situ. Similarly, 
SAM served as a methyl donor for the MTs (GilMT, GilM). Overnight incubation of the 
assay mixtures at 37 °C resulted in the formation of several new compounds besides 
rabelomycin. Formation of defuco-GM in the assay mixture was confirmed through the 
comparison of retention time, UV spectrum and ESI-MS with the standard compound 
(Figure 4.6). UV spectra and retention times of the other two unknown minor products 
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were also observed in culture extract of the defuco-GM producer ∆GilGT mutant (33). 
This further indicated that defuco-GM production in vitro indeed had an identical 
biosynthetic fingerprint to that of the in vivo production. As expected, no defucoGM or 
rabelomycin were observed when GilAB were removed from the assay mixture.  
Discussion 
 Polyketide-derived metabolites show tremendous structural diversity. A majority 
of their structural and functional variations are aroused from post-PKS tailoring reactions. 
Biosynthetic pathway of most of the bio-active compounds such as GV (71), jadomycins 
(61), urdamycins (106), landomycins (178), kinamycin D (179) and marmycins (178) 
utilize identical building blocks and functionally identical PKS enzymes to generate an 
angucycline backbone, presumably UWM6, which is further processed through the 
activity of specialized post-PKS tailoring enzymes to furnish their final structures. 
Oxygenases and dehydratases have appeared to be the earliest post-PKS modifying 
enzymes in many biosynthetic pathways of angucycline-derived natural products (30, 59, 
171). Oxygenases have drawn special interest in biosynthetic studies due to their 
tremendous capacities to alter structures through hydroxylation, C-C bond cleavage, 
rearrangement of the backbone and desaturation that ultimately lead to the generation of 
highly complex biologically active compounds, whose biosyntheses are often difficult to 
decipher without the study of the involved enzymes. For instance, the oxygenation 
cascade of jadomycin biosynthetic pathway has been labeled as a “biosynthetic black 
box” as in vivo and in vitro experiments attempted so far failed to address the exact 
functional roles of the oxygenases JadFGH (61). The biosyntheses of GV and GM also 
involve such modifications, for instance, C-C bond cleavage, a series of oxygenations, a 
glycosylation and methylations. Previous experiments concluded that GilOI, GilOII and 
GilOIV were the earliest post-PKS tailoring enzymes that could convert the anticipated 
intermediate UWM6 (40-a) and homo-UWM6 (40) to GM (12-b) and GV (12), 
respectively, through the presumed intermediates prejadomycin (41-a) and 2,3-dehydro-
homo-UWM6 (41), respectively. However, the exact catalytic actions of these enzymes, 
the sequence of their actions and the fate of the involved intermediates were not clear. 
Therefore, the first task of this study was to demonstrate 41/41-a to be the intermediates 
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of the GV/GM pathway. There were three advantages in focusing on GM instead of on 
GV. First, the pathway did not require a desaturation step to install the vinyl side chain, 
which makes the study simpler. Second, prejadomycin could be obtained easily in large 
amounts from a landomycin oxygenase (LndE)-deletion mutant. Lastly, the jadomycin 
pathway oxygenases JadF and JadH could be used in place of GilOIV and GilOI, 
respectively, whenever necessary. Here, it was important to note that JadF and JadH 
completed GV biosynthesis that was disrupted by the deletion of GilOIV and GilOI, 
respectively, indicating their functional identities. 
 To unravel the molecular details of the GV oxygenation cascade, prejadomycin 
(41-a) was incubated with various combinations of oxygenases. Surprisingly, the 
substrate remained unchanged in all cases except those involving GilOI, where the 
compound was converted into the shunt product 2,3-dehydrorabelomycin (49-a). The 
results clearly outlined two possibilities: the first, 41-a might not be an appropriate 
substrate of GilOIV or GilOI; the second, the downstream post-PKS enzymes might be 
necessary for the oxygenases to carry out their optimal functions. The product 49-a was 
originally produced in vivo from the ∆JadG mutant from the jadomycin pathway, and 
later from the ∆GilOII mutant as well (30, 56, 61). Identical transformation was observed 
in vitro when the GilOI homologue JadH was incubated with prejadomycin (166). JadH 
and GilOI had been proposed to be bifunctional dehydratase/oxygenase enzymes where 
they could catalyze dehydration to establish a double bond between carbons 4a and 12b 
(101). It was not clear whether C-12 oxygenation could happen spontaneously after 
4a,12b dehydration, or whether JadH might contribute to or is responsible for this 
oxygenation. The observed activity of GilOI was identical to that of JadH and it did not 
reveal any new insights into the exact functional role of this enzyme in the context of the 
GV/GM biosynthesis. The FAD-dependent monooxygenases could be one component or 
two component enzymes. One component enzymes can produce FADH2 themselves 
utilizing NADPH whereas two component oxygenases require the second enzyme that 
utilizes NADH or NADPH to generate FADH2 to carry out their activities. In this 
context, GilOI and JadF could be two component enzymes and FADH2 might not be 
available to carry out their oxygenation activities. To provide access of FADH2, NADH, 
FAD and NADH:FAD reductase were supplied to the assay mixtures. Such extra supply 
98 
 
of FADH2 in situ did not alter the product profiles except the inhibition of conversion of 
41-a to 49-a. It is possible that the robust production of FADH2 could induce 
conformational change in GilOI which could prevent the docking of 41-a to the active 
site, thereby preventing the 4a,12b dehydration as well as C-12 oxygenation or 
NADH:FAD reductase might block the substrate from docking into the active site of 
GilOI. The results again indicated that prejadomycin was not an appropriate substrate for 
GilOI and JadF or that the oxygenases might need to form a complex with the other post-
PKS enzymes to convert 41-a to defucoGM (50-b). To test the second possibility, 41-a 
was incubated with GilOI, GilOII, JadF, GilM, GilMT and GilR in the presence of 
cofactors SAM, FAD, NADH/NADPH and NADH:FAD reductase. As a result, the 
substrate remained unchanged. This result revealed that 41-a was not a defuco-GM 
pathway intermediate, and that PKS and post-PKS enzymes might form a giant multi-
enzyme complex, where the nascent yet unknown PKS product could be utilized 
immediately by the post-PKS enzymes to convert to defucoGM. Alternatively, these 
enzymes might not be forming a complex but need to be physically close enough to 
transfer the nascent PKS product to the post-PKS enzymes, as hypothesized earlier for 
the gaudimycin biosynthetic pathway (59).  
To reconstitute the entire defuco-GM pathway in vitro, we had further cloned and 
expressed PKS enzymes from GV, RMV and jadomycin pathways. Preliminary screening 
for the production of UWM6 was conducted using a “mix and match” approach. 
Interestingly, rabelomycin (48-a) was produced as the major product when GilA, B, F, P, 
JadD and RavG were incubated with any of the three ACPs (JadC or RavC or RavC1). 
This clearly demonstrated that the three ACPs are functionally identical. It was an 
interesting result for several reasons: i) it was the first report on the successful 
reconstitution of an angucycline pathway in vitro; ii) rabelomycin was produced through 
a one-pot enzymatic reaction; iii) the assay demonstrated that PKS enzymes (GilABFP, 
RavC, RavG and JadD) were sufficient to generate rabelomycin, presumably through the 
spontaneous oxidation of UWM6 after cleaving off from the ACP (RavC); iv) GilA and 
GilB could accept ACPs from other angucycline pathways without discrimination; v) it 
indicated that PKS enzymes might require post-PKS enzymes to channel the PKS-
product into the defuco-GM biosynthetic pathway thus preventing it from converting to 
99 
 
shunt product rabelomycin. Interestingly, incubation of the PKS and post-PKS (GilOI, 
GilOII, JadF, GilM, GilMT, GilR) enzymes with acetyl-CoA, malonyl-CoA (generated in 
situ), FAD, NADPH, SAM, NADH and NADH:FAD reductase resulted in the formation 
of defucoGM (50-b) and rabelomycin (48-a) in addition to other minor yet 
uncharacterized compounds. Several conclusions could be drawn from this results: i) the 
enzymes used in this assay were sufficient for the production of defuco-GM; ii) post-PKS 
tailoring enzymes must be coupled with PKS enzymes to convert the nascent PKS 
product to defuco-GM; iii) several other unknown gene products (GilN, GilL and GilV) 
of the GV pathway did not contribute to the biosynthesis of defuco-GM (50-b); iv) the 
imperfect stochiometry of the PKS and post-PKS enzymes might result in the production 
of rabelomycin (48-a) where the post-PKS enzymes might not be able to sufficiently 
utilize the products of the PKS enzymes leading partly to a spontaneous decomposition of 
the yet uncharacterized intermediate. 
Overall in vitro results were in agreement with the current hypothesis that post-
PKS tailoring reactions often require a close synchronization between steps to prevent 
intermediate degradation or shunt product formation. The post-PKS oxygenation cascade 
catalyzed by the pathway oxygenase (PgaE) and the bifunctional oxygenase/dehydratase 
(PgaM) in the gaudimycin C biosynthetic pathway represents another typical example 
(59). Through in vitro assays, it was demonstrated that both enzymes are required to be in 
close vicinity, not in the form of a non-covalent complex, to convert UWM6 to 
gaudimycin C through a oxygenation/dehydration cascade. However, such a phenomenon 
can not be responsible in the GV post-PKS oxygenation cascade, as both the in vitro 
reconstitution of the post-PKS oxygenases and the entire post-PKS enzymes failed to 
convert the hypothesized intermediate prejadomycin (41-a) to any compound except to 
the shunt product 2,3-dehydrarabelomycin (49-a). In light of an emerging new class of 
oxygenases that work on ACP-tethered substrates, combined with the results of this work, 
which showed the formation of defuco-GM only after reconstitution of the entire PKS 
and most of the post-PKS enzymes, we suggest to revise the GV pathway as described in 
Scheme 4.4. According to this, an ACP-tethered angucycline, presumably 79-a/79, might 
serve as the true substrate of JadF/GilOIV. Similar oxygenation activitiy has been 
discovered recently in the biosynthetic pathway of the antitumor antibiotic C-1027, where 
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the two-component monooxygenases SgcC catalyzes hydroxylation of the β-tyrosine 
moiety covalently attached to the peptidyl carrier protein (SgcC2) (180). GilOIV/JadF 
might also catalyze C2-C3 dehydration as well as C-5 hydroxylation of 79/79-a to 
generate the 80/80-a which could undergo GilOI-catalyzed Baeyer-Villiger oxidation to 
generate a lactone-type intermediate 81/81-a. Opening of the 7-membered lactone ring 
might take place before or after hydrolysis from the ACP and subsequent 
decarboxylation. GilOII might catalyze the hydroxylation at the napthol moiety of 44/44-
a. GilM or GilMT might methylate one of the two p-hydroxyl groups which would 
protect the compound from spontaneously converting to the quinone, as assumed for 
jadomycin biosynthesis, in whose gene cluster no GilM homologue is found. 
Desaturation of C-8 ethyl side chain could be catalyzed by GilOIII, along the way, 
although the exact substrate for this enzyme remains elusive. The hemiacetal moiety of 
82, 82-a and 82-b might form spontaneously through the rotation of the C-C bond and the 
high reactivity of the aldehyde function. Methylation of the other hydroxyl group 
followed by dehydrogenation of the hemiacetal would generate the defucogilvocarcins 
(50, 50-a, 50-b), however, glycosylations might precede these events to yield 
gilvocarcins. Further in vitro activity assays would be necessary to validate this 
hypothetical pathway. In this context, co-incubation of individual or combinations of 
post-PKS enzymes with PKS enzymes, and the identification of the products of these 
assays would be the most crucial experiments.  
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Scheme 4.5 A revised hypothetical pathway for GV biosynthesis. Note that the key-oxidative 
events occur, while the oxygenase substrates are still tethered to the ACP GilC 
Rabelomycin was first isolated from Streptomyces olivaceous ATCC21549 (181). 
The compound was later isolated from oxygenase deficient mutants from the jadomycin 
pathway (∆JadF), urdamycin (∆UrdM) and gilvocarcin (∆GilOIV) biosynthetic pathways 
(56, 57, 61, 180, 182). In addition, the compound was also produced in vivo through the 
engineering of PKS enzymes or through the expression of a cryptic pathway (125, 174, 
177). Rabelomycin was recognized as an antibiotic, it displayed an activity comparable to 
tetrangomycin against gram-positive bacteria. Several synthetic routes to produce 
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rabelomycin and related compounds had been developed over the past decades (183-187). 
Similarly, several chemical synthesis routes for the preparation of defucoGM (187-190) 
have been developed. However, all of these methods involve multistep syntheses and 
suffer from poor overall yields. Enzymatic total syntheses of defucoGM and rabelomycin 
presented in this work provide alternative approaches, which are environmentally 
friendlier, more efficient and cost-effective than any of the previously reported synthetic 
approaches. In addition, the enzymatic synthesis of defucoGM, to our knowledge, 
represents the first successful one-pot enzymatic synthesis of a natural product that 
involves consecutive activities of more than 12 functionally distinct enzymes.  
Lactone generation by GilR as the last step of the GV biosynthetic pathway 
GilR was one of the unknown genes of the GV cluster. Homology searches 
showed that the enzyme GilR (498 aa) belongs to an oxidoreductase family enzyme, 
whose amino acid sequence displays its identity/similarity to various putative 
dehydrogenases from various species: 43%/57% (identity/similarity) to StfE (CAJ42334) 
from Streptomyces steffisburgensis, 41%/55% to a dehydrogenase (ZP_00377889) from 
Brevibacterium linens BL2 and 41%/58% to BusJ and SpnJ from butenyl spinosyn and 
spinosyn producer Saccharopolyspora pogona and Saccharopolyspora spinosa, 
respectively. The conserved domain analysis revealed two hits: the N-terminal FAD-
binding domain (pfam01565) and the C-terminal berberine-like domain (pfam08031). 
Pfam01565 family proteins belong to plant enzymes that utilize FAD as a co-factor and 
catalyze oxidation reactions, whereas pfam08031 family enzymes oxidize the N-methyl 
group of S-reticuline into the C-8 methylene bridge carbon of (S)-scoulerine in presence 
of FAD.  
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To deduce its functional role in the GV biosynthesis, the gene was inactivated and the 
∆GilR mutant accumulated preGV (47) which contains a hemiacetal moiety instead of the 
lactone moiety of GV (68). PreGV was completely converted into the GV when fed in the 
culture of early pathway enzyme-blocked mutant thus, proving the former compound an 
intermediate of the GV pathway. Chemically, the conversion requires elimination of two 
protons along with two electrons from preGV. Although many dehydrogenases that 
catalyze such reactions were reported in primary as well as secondary metabolism, none 
of them were obseverd in the context of hemiacetal oxidation. To deduce the exact 
function of the gilR-product, the gene was cloned into the pET28a vector, expressed in E. 
coli, and the generated N-terminal His-tagged protein was purified using IMAC (figure 
4.7). The intense yellow color of the purified enzyme and its typical FAD-like UV 
spectrum clearly indicatied the presence of bound FAD (Figure 4.8).  
 
 
Figure 4.7 Separation of purified GilR at denaturating conditions (SDS-PAGE, A) and at native 
conditions (native gradient PAGE, B) 
To figure out whether FAD is covalently bound or not, the enzyme was denatured using 
different techniques and the protein-free supernatant liquid was analyzed (see materials 
and methods for the detail). UV analyses of the liquid did not reveal the presence of FAD 
indicating a covalently bound FAD. The results were further supported by the 
visualization of intense golden yellow protein pellets. To determine the quaternary 
structure of GilR, the enzyme was separated in native 15% polyacrylamide gel (Bio-Rad). 
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A single band was observed in between 50 and 60 kDa. A similar size was observed 
when the protein was separated in 12% SDS-PAGE (Figure 4.7). This was a clear 
indication for the monomeric existence of GilR in its natural form. 
 
 
Figure 4.8 UV spectrum of the purified GilR (200 μL, 4.0 mg mL-1 concentration). Desalting 
buffer was used as a reference.  
 
Activity assay of GilR 
The pathway intermediate 47 was incubated with GilR both in presence or 
absence of FAD. The HPLC/MS analysis of the assay mixture revealed a dramatic 
decrease of the substrate with concomitant formation of 12 (Figure 4.9, traces A and B) 
in the both cases. The addition of FAD did not alter the GilR catalysis indicating the 
saturation of GilR with FAD. The results confirmed that GilR catalyzes the oxidation of 
the hemiacetal moiety of 47 to the lactone found in 12. The accumulation of significant 
amount of defuco-GV (50) by both the GilGT (C-glycosyltransferase)- and GilU 
(deoxysugar ketoreductase)-deletion mutants indicated that GilR might be capable of 
oxidizing defuco-PreGV (83) to 50, and the tethered defucofuranose residue might not be 
required for its activity (102). The accumulation of 47 by the GilR-deletion mutant 
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suggested the occurrence of the C-glycosylation prior to the lactone formation. These 
results raised a question, which one (47 or 83 ) is the true substrate of GilR? To address 
this ambiguity, and to address the sequence of biosynthetic events, 83 was prepared semi-
synthetically through one-step diisobutyl aluminium hydride (DIBALH) mediated 
reduction of 50, and the kinetics of GilR catalysis were compared for both substrates. 
Interestingly, GilR was capable to oxidize 83 to 50. However, the reaction rate was much 
slower as compared to the reaction with substrate 47 (Figure 4.9, trace C, D and E). The 
Km values of GilR were determined to be 117.0 µM and 93.4 µM for 47 and 83, 
respectively (Table 4.3, Figure 4.10, 4.11). However, the kcat for 47 was found to be 
more than four fold higher than for 83. The ratio of kcat and Km for 47 was 3.5 fold higher 
than for 83 clarifying the former compound to be the true substrate of GilR. 
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Figure 4.9 HPLC profile of enzyme assay mixtures: trace A; preGV (0.1 mM) incubated with 
GilR (1 μM) for 10 minutes, trace B; a control sample (without GilR) at the identical conditions, 
trace C; standard defuco-preGV, trace D; defucoGV, trace E; defuco-preGV (0.1 mM) incubated 
with GilR (0.5 μM) for 8 minutes. 
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Figure 4.10 Kinetic profile of GilR with preGV. 
 
 
Figure 4.11 Kinetic profile of GilR with defuco-preGV. 
108 
 
 
 
Scheme 4.6 Chemical preparation of preGV and analogues through the reduction of the 
corresponding natural lactones. 
 
 
Table 4.3 Kinetic parameters for GilR 
Substrate km (µM) 
akcat (min-1) kcat/km Sp.activity (U mg-1min-1) 
PreGV (47) 117.0 ±24.8 268.31±40.77 2.29±0.03 3.62±0.88  
Defuco-PreGV (83) 93.4 ±12.73 61.24±6.28  0.65±0.086 0.84 ±0.10 
PreChryV (85) nd nd nd 1.4×10-3 
nd; not determined, aone active site was assumed per enzyme 
 
Substrate specificity of GilR 
One of the major objectives of biosynthetic pathway studies is to generate 
unnatural derivatives of natural products through the exploitation of the substrate 
flexibility of pathway enzymes. In this context, alteration of the deoxysugar moiety of 
GV provides a good means to generate GV analogues by combinatorial biosynthesis. 
This requires relaxed substrate specificity of both GilGT and GilR. To test the flexibility 
of GilR regarding the C-glycosidically linked deoxysugar moiety, prechrysomycin A (85) 
was prepared through chemical reduction of chrysomycin A (32). Surprisingly, the 
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incubation of 85 with GilR under identical assay condition barely generated 32, limiting 
the complete kinetic study of the reaction. However, the specific activity of the enzyme 
with 85 was determined to be 2500 and 600 fold lower than those with 47 and 83, 
respectively, thus indicating its poor specificity for a substrate analogue with a branched 
pyranose moiety. We were previously able to generate a GV analogue with an extra 
hydroxyl group at 4’ position of the D-fucofuranose moiety through the targeted 
inactivation of the dedicated ketoreductase gene gilU (102). This analogue maintained a 
five-membered sugar residue, and the poor conversion of 85 could be due to the presence 
of the branched pyranose (D-virenose) which could impose some sterical hindrance in the 
binding pocket of GilR that appeared optimal for substrates with a 5-membered sugar 
residue. 
 
Significance 
Lactones are often found in varieties of bioactive natural products such as PKS-
derived gilvocarcin (GV, 12), lovastatin (3), erythromycin A (5), FK-506 (4), 
amphotericin B (7), as well as in terpene-derived natural products, such as 
pentalenolactone and artemisinin. In many cases lactones modulate the biological activity 
of the molecules directly by interacting with target sites (as in camptothecin)(191, 192) or 
indirectly by providing structural rigidity to the molecule (as in erythromycin). Lactones 
were also found or proposed as intermediates of various biosynthetic pathways such as 
jadomycin, gilvocarcin, mithramycin and urdamycin, where the formation of a lactone 
intermediate is crucial for the installation of polar residues of the final structures (54, 171, 
193). Interestingly, the ways through which nature installs lactones in secondary 
metabolites are found to be limited to two general routes (Scheme 4.6): (i) through the 
intramolecular condensation between a hydroxyl group and a carboxylic acid or an ester 
(route A) and (ii) through Baeyer-Villiger oxidatation of a cyclic ketone (route B). The 
vast majority of the macrolide lactones are generated through thioesterase (TE)-domain 
mediated intramolecular condensation of thioester and alcohol (route A),(194-196) 
whereas the lovastatin lactone formation is truly pH-dependent (route A) (197). Literature 
report on Baeyer-Villiger monooxygenases (BVMO)-catalyzed lactone formation in 
natural products is rapidly growing (54, 58, 198). In addition, lactone generation through 
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the oxidation of a hemiacetal moiety is well established, but was limited so far to primary 
metabolism, and plays a role especially in the pentose phosphate pathway (route C). We 
observed such unique chemistry for the first time in the secondary metabolism, in the GV 
biosynthetic pathway. 
Previous gene inactivation results clearly demonstrated that none of the four 
candidate oxygenases of the GV pathway (GilOI, GilOII, GilOIII, GilOIV) contribute to 
the formation of the lactone moiety of GV. Complementing the previous gene 
inactivation results, the current in vitro assay results have clearly established that GilR is 
an FAD-dependent oxidoreductase and is responsible for oxidizing hemiacetal 47 to 
lactone 12 (Scheme 4.7, route I). In the pentose phosphate pathway, glucose-6-phoshate 
(G-6-P) dehydrogenase catalyzes a similar reaction converting G-6-P to 6-phospho-D-
gluconolactone (199). However, unlike GilR, this enzyme utilizes free standing NADP+ 
thereby placing GilR into a new class of oxidoreductases. Since FAD is bound covalently 
to GilR, and no other reducing equivalent was used in the in vitro assay, we anticipate 
that FADH2 reacts with dissolved oxygen to regenerate FAD. The results also clarify that 
the lactone generation is the last step of the post-PKS tailoring steps of GV biosynthesis, 
and the enzyme is flexible enough to handle both sugar-tethered and sugar-free 
substrates, while its flexibility is limited by the nature of the linked deoxysugar. 
Understanding the substrate binding mode of GilR and widening its substrate specificity 
through site-directed mutagenesis might be necessary to generate further GV analogues 
by combinatorial biosynthesis. The results of this study also show indirectly that defuco-
preGV, and not defuco-GV as previously assumed, is the substrate of GilGT, the C-GT of 
the GV pathway. 
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Scheme 4.7 General routes for lactone formation in natural products. 
 
 
Scheme 4.8 Proposed pathway for GV biosynthesis. 
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Experimental section 
Bacterial strains, culture conditions 
 Streptomyces strains S. griseoflavus Gö 3592, GilGT-minus mutant S. lividans 
TK24 (cosG9B3-GT¯), GilR-minus mutant S. lividans TK24 (cosG9B3-R¯) and S. 
albaduncus AD819 were cultured on M2 agar (56) or in SG liquid medium (56) at 28 °C 
and 200 rpm. E. coli strains were grown in Luria Broth (LB) or on agar at 37 °C. 
Kanamycin sulfate (50 μg mL-1) and apramycin sulfate (50 μg mL-1) were supplemented 
to the media, whenever necessary. Standard pregilvocarcin V was isolated from the S. 
lividans TK24 (cosG9B3-R¯) mutant following the previously reported procedure (56). 
The compound was generated in larger scale by chemical reduction of GV (described 
later in this section). Chrysomycin A was isolated from S. albaduncus AD819. Spores of 
each Streptomyces strain were inoculated into 100 mL of SG medium in 500 mL- 
Erlenmeyer flasks, and the culture was grown for 3 days to prepare a seed. The seed 
culture (3% by vol) was then taken for inoculation of production scale SG medium (5 L; 
100 mL × 50 flasks) and grown for 7 days.  
Preparation of expression constructs 
All of the anticipated defucoGV biosynthetic genes (gilA, B, C, F, K, P, OI, OII, 
OIV, OIII, R, M, MT) were amplified from cosG9B3 using specific primers (Table 4.4) 
and pfu polymerase (Stratagene). Similarly, some of the ravidomycin (ravG, C, C1) and 
jadomycin PKS (jadC, D, I) genes were amplified using cosRav32 and pJV779, 
respectively. PCR products were cloned into Zero-Blunt TOPO vector (Invitrogen) and 
sequenced. Jadomycin oxygenase (encoded by jadF) was also cloned following an 
identical protocol and gilA and gilB were amplified together. Topo clones were digested 
with NdeI and EcoRI to excise the gene fragments and ligated at the identical sites of 
pET28a vector for all genes except jadI which was cloned at NdeI and HindIII site. GilAB 
fragments were cloned at NdeI and EcoRI sites of pXY200. Expression constructs 
generated in this study are summarized in the Table 4.5. 
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Table 4.4 List of primers used in this study 
Name of the primers Oligonucleotide sequence 
GilOIV_ex_for 5′-GGGCATATGACGGAGCCCGAGACCTCGGAC-3′ 
GilOIV_ex_rev 5′-GAGAATTCTCACCGCGTCACCTCGGGTTCCA-3′ 
GilOII_for 5′-GGCCATATGCCGATCATCGAGCCCGAGAAC-3′ 
GilOII_rev 5′-CGGGAATTCTCACGACGCGTACCCCTCGACCGA-3′ 
GilR_ex_for 5′-CGCCATATGACCGCTTCCGTACCGCCGTTCACGGTG-3′ 
GilR_ex_rev 5′-CCAGAATTCTCAGAGTCCTATGGACATGCTGTG-3′ 
GilM_ex_for 5′- CGCCATATGCCAACGGGCAGCACGGAGAAGATC-3′ 
GilM_ex_rev 5′-CGGGAATTCTCATGCCGGGCTCTCCGATCGGGT -3′ 
GilMT_ex_for 5′-GACCATATGACCATTACTGCATCGGGATCG-3′ 
GilMT_ex_rev 5′-CGGGAATTCTCACCGGCTGCGGGGAGAGCCCGG-3′ 
JadF_ex_for 5′-ATTCATATGACGGAGCCCCGCCGGGCAGGA-3′ 
JadF_ex_rev 5′-TTAGAATTCTCAGAGGTGGGTGGGGGCGCC -3′ 
GilA_exp_for 5′- ATTCATATGAGCCGCAGGGTCTTCATCACC-3′ 
GilB_exp_rev 5′-ATTGAATTCTCATTTCCCGACGATCAGGGCCGA-3′ 
GilC_exp_for 5′- ATCCATATGTCCGCACGCGTCACCATGGAC-3′ 
GilC_exp_rev 5′-ATGAATTCTCACGATGCCGCCGCCTGACGC-3′ 
GilF_exp_for 5′- ATTCATATGACCTCTCCCCGTCATGCCCTG-3′ 
GilF_exp_rev 5′-ATGAATTCCTAGAAGTTGCCGAGGCCGCC-3′ 
GilK_exp_for 5′-ATCATATGGCCGATCCGGCTCGCACAGAC-3′ 
GilK_exp_rev 5′-ATGAATTCTCACCTCTGCGACACGGCGGTG-3′ 
GilP_exp_for 5′-ATCATATGAGAGCGTTCCTGTTCCCCGGT -3′ 
GilP_exp_rev 5′- ATGAATTCTCACCAGCCCGTCACGCC -3′ 
RavC1_for 5′- ATTCATATGACCACCGGCACGTTCACC-3′ 
RavC1_rev 5′- ATTGAATTCTCACGCCGCGTTGACCAGCTC-3′ 
RavG-for 5′-ATTCATATGCACAGCACCCTGATCGTCGCC-3′ 
RavG-rev 5′-ATTGAATTCTCAGTCCTGCTGCCAGTGGTA-3′ 
RavC_for 5′-ATTCATATGAGCAGCTTCTCGATCGACGACCTC-3′ 
RavC_rev 5′-ATTGAATTCTCAGCCGCGCGGCGCGGG -3′ 
JadC_for 5′-ATTCATATGAGCAGCAAGACCTTCACCCTC-3′ 
JadC_rev 5′-ATTGAATTCTCAGGCGGCGGCGACGGC-3′ 
JadI_for 5′-ATTCATATG CACAGCACTCTGATCGTGGCC-3′ 
JadI_rev 5′-ATTAAGCTTTCACGCGTTCGCCTCCCAGTT-3′ 
JadD_for 5′-ATTCATATGACGACCCGTGAGGTCGAGCAC-3′ 
JadD_rev 5′-ATTGAATTCTCAGCGCTTGCCCTCGGCGTA -3′ 
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Table 4.5 List of plasmids constructed/used in this study. 
Strain/ plasmid Characteristics and relevance References 
E. coli XL1-Blue-MRF Host for routine cloning works and for the construction 
of genomic libraries 
Stratagene 
E. coli BL21 (DE3) Expression host for the various expression constructs Novagen 
E. coli (BAP1) Expression of holo ACPs Pelzer et al.(176) 
S. lividans TK24 For expression of gilvocarcin PKS enzymes Hopwood et 
al.(170) 
S. lividansTK24/cosG9B3-
GilGT¯ 
For the production of defucoGV Rohr et al.(33) 
S. albandancus For the production of chrysomycin A Asheshov et 
al.(200) 
pGilL gilL gene cloned into pET28a This work 
pGilN gilN gene cloned into pET28a This work 
pGilU gilU gene cloned into pET28a This work 
pGilOI-1 gilOI gene cloned into pET28a This work 
pGilOII-1 gilOII gene cloned into pET28a This work 
pGilOIV-1 gilOIV gene cloned into pET28a This work 
pGilR-1 gilR gene cloned into pET28a This work 
pGilM-1 gilM gene cloned into pET28a  This work 
pGilMT-1 gilMT gene cloned into pET28a  This work 
pGilGT-1 gilGT cloned into pET28a(+) This work 
pGilF gilF cloned into pET28a(+) This work 
pGilK gilK cloned into pET28a(+) This work 
pGilP gilP cloned into pET28a(+) This work 
pGilAB gilA and GilB cloned into pXY200 This work 
pGilC gilC cloned into pET28a(+) This work 
pRavC ravC cloned into pET28a(+) This work 
pRavC1 ravC1 cloned into pET28a(+) This work 
pRavG ravG cloned into pET28a(+) This work 
pJadC jadC cloned into pET28a(+) This work 
pJadD jadD cloned into pET28a(+) This work 
pJadI jadI cloned into pET28a(+) This work 
pWJ292 Malonyl CoA synthetase expression construct Tang et al(201). 
pET28a Expression vector Novagen 
pXY200 Thiostrepton inducible expression vector Zabriskie et 
al.(175) 
PCR-Blunt-II-TOPO To clone PCR products Invitrogen 
 
Expression and purification of enzymes 
All of the genes were expressed with N-terminal polyhistidine tag. pET-28a-
expression constructs were expressed in E. coli BL21 (DE3) following the protocol 
discussed in section 3. Purification of protein was achieved using IMAC through the 
Profinia protein purification system (BioRad). Enzymes were purified occasionally using 
metal talon affinity resin (BD Biosciences). Concentrations of proteins were determined 
by the Bradford method using a calibration curve of the known concentrations of BSA 
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(169). Purified enzymes were stored in 50 mM phosphate buffer (pH 7.5) supplemented 
with glycerol (25% final volume). Protoplasts of S. lividans TK64 were transformed with 
pGilAB following the standard protocol (143). The transformants were selected for 
apramycin resistance (50 μg mL-1) phenotypes. A single transformant colony was 
inoculated into a 500 mL Erlenmeyer flask containing 100 mL TSB medium. The culture 
was grown for 3 days at 28 °C with constant shaking at 250 rpm. A fully grown seed 
culture (2 mL) was inoculated into 100 mL (× 40 flasks) of R2YE medium. After 24 
hours of incubation, thiostrepton (20 μg mL-1) was added in the culture to induce the 
expression of GilA-GilB complex. Incubation was continued for another 48 hours and the 
culture was harvested through centrifugation (4000 × g, 15 min). Cell pellets were 
washed twice with lysis buffer prior to their lyses. Disruption of cells was carried out in a 
French Press (Thermo Electron Corporation) and the crude enzyme was separated from 
the cell debris through centrifugation (15000 × g, 60 min). Thus obtained crude enzymes 
were filtered through 0.5 μM syringe filter (Millipore) and the filtrate was subjected to 
the purification using the Profinia (Bio-Rad).  
Preparation of holo-ACPs 
Holo form of ACPs (RavC, RavC1 and JadC) were achieved directly by 
expressing the enzymes in the genetically engineered E. coli BAP hosts. Purified 
enzymes (5-8 mg) were subjected to the PD10 desalting column (GE Healthcare) pre-
equilibrated with water. Water was used to elute the enzymes and aliquots of 200 μL each 
were collected and analyzed in a UV spectrophotometer. The first fraction containing 
enzyme was analyzed by MALDI-TOF mass at University of Kentucky Mass 
Spectrometry facility. 
Co-factor analyses of GilOI and JadF 
GilOI and JadF were eluted as intense yellow enzymes. To identify the enzyme 
bound cofactors, 1 mL enzyme solution (4 mg mL-1) of each enzyme was boiled for 5 
minutes to release the cofactor from the enzyme. The precipitated enzyme was removed 
by centrifugation (12000 ×g, 5 min) and the yellow solution was analyzed by HPLC. 
Standard solution (1 μM) of FAD and FMN were used in parallel for comparison. 
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Carbopac PA1 (Dionex Inc.) analytical column (4 × 250 mm) was injected with 50 μL 
sample. A gradient program of ammonium acetate (500 mM) and water (ammonium 
acetate: 5 to 20% over 15 min, 20 to 60% over 20 min, 60 to 100 % over 2 min, 100% 
over 3 min and 100% to 5% over 5 min and 5% over 15 min) was used to elute 
compounds. The flow rate and detector were set to 1 mL min-1 and 267 nm, respectively. 
FMN and FAD were eluted at 35 min and 50 min, respectively. 
Preparation of malonyl-CoA in situ 
Malonyl-CoA was prepared enzymatically from sodium malonate, ATP and 
coenzyme A (CoA). Assay mixtures of variable volumes (200 μL- 20 mL) composed of 
sodium malonate (5 mM), magnesium chloride (5 mM), ATP (25 mM), CoA (1.5 mM) 
and MatB (6 μM) were incubated for 30 minutes. The formation of malonyl-CoA was 
monitored by HPLC. CarboPackTM PA1 (4×250 mm) column (Dionex co.) was used to 
separate compounds. A gradient of ammonium acetate (500 mM, solvent B) and water 
(solvent A) was used to separate the assay products: 5-20% solvent B from 0-15 min, 20-
60% solvent B from 15-35 min, 60-100% solvent B from 35-37 min, 100% solvent B 
from 37-40 min, 100-5% solvent B from 40-45 min and 5% solvent B from 45-60 min. 
The flow rate was maintained to 1 mL min-1 throughout the separation. ATP, CoA and 
malonyl-CoA were eluted at 52.5, 33.0 and 31.5 minutes, respectively. 
PKS Enzyme assay 
One-pot PKS enzyme assays were carried out in two scales. For the analytical 
scale, assay mixtures composed of phosphate buffer (pH 7.5, 50 mM), sodium malonate 
(5 mM), magnesium chloride (5 mM), ATP (25 mM), CoA (1.5 mM), MatB (6 μM), 
acetyl CoA (100 μM) were added with various combinations of PKS enzymes [GilAB, 
~0.2 μM; RavC, 2.1 μM; RavC1, 2.0 μM; JadC, 2.5 μM; GilP, 3.1 μM; GilF, 0.1 μM; 
RavG, 0.15 μM; JadD, 0.06 μM, JadI, 0.2 μM] and the final volume of the assay mixture 
was maintained at 200 μL. Incubation of the assay mixture was carried out at 28 °C for 4 
hours and the reaction was stopped by thorough mixing with 400 μL of ethyl acetate. The 
organic layer was collected and dried in a speed vac. The extract was dissolved in 
methanol (150 μL) and then filtered through a syringe filter (pore size 0.25 μM) prior to 
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the HPLC/MS analyses. Separation and MS analyses were carried out following the 
procedure described in Section 2. For larger scale assays, the volume was increased to 20 
mL and the mixtures were incubated for 12 hours. 
Enzymatic synthesis of defucoGM 
One pot enzymatic synthesis of defuco-GM was carried out using PKS, post-PKS 
enzymes and the anticipated cofactors. The assay mixture (10 mL) containing phosphate 
buffer (pH 7.5, 50 mM), sodium malonate (5 mM), magnesium chloride (5 mM), ATP 
(25 mM), CoA (1.5 mM), MatB (6 μM), acetyl CoA (100 μM), GilAB (~ 0.2 μM), RavC 
(2.1 μM), GilP (3.1 μM), GilF (0.1 μM), RavG (0.15 μM), JadD (0.06 μM) GilOI (1.58 
μM), GilOII (0.9 μM), JadF (0.95 μM), GilM (0.15 μM), GilR (0.10 μM), JadI (1.35 μM), 
FAD (12.5 μM), NADH (0.62 mM), NADPH (0.5 mM), SAM (25 μM), NADH:FAD-
reductase (10 μM) was incubated at 28 °C for 8 hours. The reaction was stopped by 
extracting the products with 40 mL ethyl acetate. The organic layer was dried under 
reduced pressure and dissolved in methanol. Then the sample was passed through a 0.25 
μM syringe filter for the HPLC-MS analysis. In the control experiment, buffer was added 
in place of GilAB. 
Cofactor analysis of GilR 
The UV spectrum of the purified enzyme was typical to that of FAD (Figure 4.8). 
To analyze the bound cofactor, the enzyme (2.37 mg) was boiled for 5 minutes and 
centrifuged (12000 × g, 15 minutes). Interestingly, the supernatant was a clear solution, 
and a yellow solid residue was noticed at the bottom of the tube. No UV-absorption was 
found for the supernatant but a typical of FAD spectrum found when the solid residue 
was dissolved in 100 μL of 10% SDS solution and analyzed in a spectrophotometer. The 
protein was precipitated again with the addition of trichloroacetic acid (TCA, 400 μL) 
and then centrifuged to obtain the supernatant. Again, the supernatant did not absorb in 
the UV, but the pellet fraction remained yellow. The results clearly indicated that FAD is 
covalently bound to the enzyme.  
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Kinetic study of GilR catalysis 
A typical assay mixture (105 μL) composed of 0.1 mM substrate, 9.5 mM MgCl2, 
50 mM phosphate buffer and 0.1-1 μM enzyme and 15% DMSO (final concentration) 
were incubated at 20-45 °C for 4-10 minutes to estimate the optimal assay conditions for 
the kinetic analysis. The reaction was terminated through flash freezing at -80 °C. The 
product was extracted twice with 300 μL of ethyl acetate, and the extract was combined 
and dried in vacuom. The extract was then dissolved in 100 μL of acetonitrile and filtered 
through 0.2 μM membrane. 70 μL of the filtrate was injected in the HPLC/MS. The 
amount of product formation was estimated through plotting the product peak area in the 
standard calibration curve. For the kinetic analysis, 8 different substrate concentrations 
(4.76 to 714 μM final concentration) were incubated with the enzyme (0.23 μM final 
concentration) for 5 minutes at 37 °C. The resulting data were fitted into the Michaelis-
Menten equation by nonlinear regression using GraphPad Prism 5.0 to determine the kcat 
and Km values. Three replicates of each sample were analyzed and the average was taken 
as a result. 
Isolation and purification of chrysomycin A, defuco-gilvocarcin V and gilvocarcin V 
 The fully grown culture of S. albaduncus was harvested by centrifugation (4000 
× g, 15 min). The cell pellets were resuspended in 400 mL of acetone, sonicated for 20 
min and centrifuged to obtain the acetone extraction fraction. The process was repeated 
twice, the acetone fractions were combined and the solvent was removed using a rotary 
evaporator. Finally, the extract was resuspended in 200 mL of water and mixed with the 
culture broth. Reverse phase silica (Rp18, 200 g) was loaded into a column (5 × 65 cm) 
and equlibrated with deionized water. The culture broth was passed through the column 
and the effluent was discarded. The column was washed with 1 L of 10% acetonitrile (in 
water). Elution was carried out using an increasing gradient of acetonitrile (20, 40, 60, 80 
and 100%, 1L each). HPLC/MS analyses revealed that chrysomycin A was the major 
compound in the 40% to 60% fractions. Acetonitrile was removed from these fractions 
and the aqueous fractions were combined and dried in a lyophilizer. The dried extract 
was dissolved in 30 mL dimethylsulfoxide (DMSO), filtered through a 0.25 μM filter, 
and the filtrate was subjected to preparative HPLC separation. Fractions containing pure 
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chrysomycin A were collected and dried. The purity and authenticity of the compound 
was confirmed through 1H and 13C NMR analyses. A linear gradient of acetonitrile and 
acidified water  (solvent A = 0.1% formic acid in H2O; solvent B = acetonitrile; 0-15 min 
25% B to 100% B; 16-24 min 100% B; 25-26 min 100% to 25% B; 27-29 min 25% B) 
was used to separate compounds. SunFire™ prepC18 (19 × 150 mm, 5 μm) and 
Symmetry C18 (4.6 × 250 mm, 5 μm) columns were used for preparative and analytical 
scale separations, respectively. The flow rate was maintained at 10 mL min-1 and 1.0 mL 
min-1 for preparative and analytical scale separations, respectively. Micromass ZQ 2000 
(Waters corporation) equipped with HPLC (Waters alliance 2695 model) and photodiode 
array detector (Waters 2996) were used to analyze the compounds. Atmospheric pressure 
chemical ionization (APCI) probe was used to detect molecular ions. A similar procedure 
was followed to isolate defucogilvocarcin V and gilvocarcin V from S. 
lividansTK24/cosG9B3-GilGT¯ and S. griseoflavus, respectively.  
Preparation of pregilvocarcinV (preGV, 47), defuco-preGV (83) and 
prechrysomycin A (85) 
O
O
OH
HO
HO
Me
OH OMe
OMe
OH
47  
Pregilvocarcin V (47). A solution of DIBALH (1M in hexane, 0.4 mL, 0.4 mM) 
was added dropwise to a stirred solution of gilvocarcin V (1) (20 mg, 0.04 mM) in THF 
(7 mL) at - 78 °C. After 1 h ethyl acetate (10 mL) was added to quench the reaction. The 
solvent was removed in vacuom and the mixture was purified through reverse phase 
HPLC (Symmetry Prep C187μm column, 19 × 150 mm) using a linear gradient of 
acetonitrile and water to afford 11 (14 mg, 70%) as colorless solid. The structure was 
confirmed through the comparison of NMR and MS data with the standard compound 
isolated from the GilR-minus mutant (56).  
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Defuco-pregilvocarcin (83). A solution of DIBALH (1M in hexane, 0.4 mL, 0.4 
mM) was added drop wise to a stirred solution of defuco-gilvocarcin V (9) (30 mg, 0.09 
mM) in THF (10 mL) at -78 °C. After 1 h ethyl acetate (10 mL) was added to quench the 
reaction. Solvent was removed in vacuom and the mixture was purified through reverse 
phase HPLC (Symmetry Prep C187μm column, 19 × 150 mm) using a linear gradient of 
acetonitrile and water to afford 12 (22 mg, 73%) as light yellow solid. 1H NMR (DMSO-
d6, 500 MHz) δ 9.48 (s, 1H, 1-OH), 8.03 (s, 1H, H11), 7.72 (d, J = 8.0 Hz, 1H, H4), 7.37 
(t, J = 8.0 Hz, 1H, H3), 7.32 (d, J = 5.5 Hz, 1H, 6 -OH), 7.28 (s, 1H, H9), 7.19 (s, 1H, 
H7), 6.82 (d, J = 8.0 Hz, 1H, H2), 6.80 (dd, J = 17.0, 11.0 Hz, 1H, H1˝), 6.37 (d, J = 4.0 
Hz, 1H, H6), 5.98 (d, J = 17.0 Hz, 1H, H2˝E), 5.35 (d, J = 11.0 Hz, 1H, H2˝Z), 4.06 (s, 
3H, -OMe), 4.02 (s, 3H, OMe); 13C NMR (DMSO-d6, 125 MHz) δ 156.2, 153.8, 149.3, 
140.6, 137.8, 136.2, 134.8, 128.1, 127.2, 116.4, 116.3, 115.0, 114.3, 113.1,111.0, 109.9, 
103.6, 92.3, 56.2, 56.1.    
 
O
OH OMe
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OH
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Prechrysomycin A (85). A solution of DIBALH (1M in hexane, 0.4 mL, 0.4 
mM) was added dropwise to a stirred solution of chrysomycin A (10) (20 mg, 0.04 mM) 
in THF (7 mL) at - 78 °C. After 1 h ethyl acetate (10 mL) was added to quench the 
reaction. Solvent was removed in vacuom and the mixture was purified through reverse 
phase HPLC (Symmetry Prep C187μm column, 19 × 150 mm) using a linear gradient of 
acetonitrile and water to afford 13 (11 mg, 55%) as colorless solid. It exists as 1:1 
mixture of two diastereomers. 1H NMR (DMSO-d6, 500 MHz) δ 9.81 and 9.78 (2 × s, 
1H, -OH, D2O exchangeable), 8.00 and 7.94 (2 × s, 1H, H11), 7.75 and 7.73 (2 × d, J = 
8.5 Hz, 1H, H3), 7.30 and 7.08 (2 × d, J = 6.5 Hz, 1H, -OH, D2O exchangeable), 7.27 (2 
× s, 1H, H9), 7.18 (2 × s, 1H, H7), 6.83 (2 × d, J = 8.5 Hz, 1H, H2), 6.80 (2 × dd, J = 17, 
11 Hz, 1H, H1˝), 6.46 and 6.33 (2 × d, J = 9.0 Hz, 1H, H1΄), 6.28 (2 × d, J = 5.0 Hz, 1H, 
H6), 5.99 (2 × d, J = 17.0 Hz, 1H, H2˝E), 5.36 (2 × d, J = 11.0 Hz, 1H, H2˝Z), 4.67 (d, J = 
8.0 Hz, 1H, -OH, D2O exchangeable), 4.67 and 4.51 (2 × s, 1H, -OH, D2O exchangeable), 
4.25 and 4.20 (2 × q, J = 7.0 Hz, 1H, H5΄), 4.06 (2 × s, 3H, -OMe), 4.01 and 4.00 (2 × s, 
3H, -OMe), 3.97 and 3.61 (2 × d, J = 8.0 Hz, 1H, -OH, D2O exchangeable), 3.38 and 3.28 
(2 × d, J = 9.5 Hz, 1H, H2΄), 3.13 (2 × d, J = 8.0 Hz, 1H, H4΄), 1.25 and 1.21 (2 × s, 3H, 
3΄-OMe), 1.13 and 1.08 (2 × d, J = 7.0 Hz, 3H, 5΄-OMe); 13C NMR (DMSO-d6, 125 
MHz) δ (156.2, 156.1), (153.2, 153.0), (149.8, 149.7), (142.5, 142.2), (137.9, 137.8), 
(136.3, 136.2), (135.6, 134.5), (130.2, 129.9), (127.9, 127.3), (127.2, 127.0), 117.0, 
(116.8, 116.6), (116.1, 115.8), (115.3, 115.2), (114.7, 114.6), (111.0, 110.9), (110.1, 
109.9), (103.7, 103.6), (92.5, 91.8), (76.5, 76.4), (76.1, 75.8), 74.2, (73.5, 73.2), (71.1, 
71.0), 56.4, 56.1, (23.5, 23.4), 17.2.  
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Summary and future studies 
In summary, the studies reported in this dissertation cover the cloning and 
characterization of the ravidomycin biosynthetic gene cluster. Functional roles of many 
of the PKS, the post-PKS and the deoxysugar biosynthetic enzymes involved in the 
biosynthetic pathway of this antibiotic were established. The insights gained into the 
activities of these enzymes provide a framework for the generation of gilvocarcin 
V/ravidomycin V analogues through combinatorial biosynthesis. 
In Specific aim 1, we cloned and sequenced the entire gene cluster responsible for 
ravidomycin biosynthesis. The implication of this cluster in ravidomycin biosynthesis 
was demonstrated through the production of 4′-O-deacetylravidomycin E in a 
heterologous host. The functional role of RavOIII that generates the vinyl side chain of 
ravidomycin was established. An unprecedented sugar donor substrate flexibility of the 
RavGT that is capable of utilizing 6-membered amino sugar as well as 5-membered 
neutral sugar was also demonstrated. 
In Specific aim 2, in vitro enzyme assays of the recombinant enzymes established 
the functional roles of all of the proposed TDP-D-ravodosamine biosynthetic genes ravD, 
ravE, ravIM, ravAMT and ravNMT. Kinetics of keto-isomerizations catalyzed by RavIM 
and its homologue FdtA were studied in detail. An efficient protocol for one-pot in vitro 
enzymatic synthesis of TDP-D-ravidosamine was developed through a combination of 
suitable biosynthetic enzymes from various pathways.  
In specific aim 3, the angucyclinone rabelomycin was enzymatically synthesized 
in vitro using enzymes from GV, RMV and jadomycin pathways. The requirement of 
synchronous actions of PKS and post-PKS enzymes to biosynthesize GV was 
demonstrated in vitro through the one-pot enzymatic synthesis of defucoGM, and thus 
outlined the minimal set of enzymes necessary to biosynthesize the benzo[d]naptha[1,2-
b]pyran-6-one moiety of GV. Through the enzyme assay and kinetic studies, GilR was 
determined to be a dehydrogenase and was shown to be responsible for dehydrogenation 
of the hemiacetal moiety of preGV at the last step of the GV biosynthetic pathway. 
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Future studies will focus on the characterization of the remaining GV/RMV post-
PKS tailoring enzymes. Analyses of the products generated through co-assay of the 
aforementioned PKS enzymes with the individual post-PKS enzymes in all possible 
combinations will potentially generate all of the intermediates of the defucoGM pathway. 
In this context, co-assay of PKS enzymes, the oxygenases (GilOI, GilOII or GilOIV) and 
GilM or GilMT will be the first experiment to test. The isolation and characterization of 
the products (pathway intermediates or shunt products) will help to assign the exact 
functional roles of GilM and GilMT as well as their sequence of action. In addition, these 
intermediates can be tested as sugar acceptor substrates of RavGT. The sugar donor 
substrate of RavG, presumably TDP-D-ravidosamine, can be routinely produced 
following the protocol developed in this study. Having all of the biosynthetic enzymes in 
hand, a one-pot enzymatic synthesis of ravidomycin M (RM) will be an interesting 
experiment to try as the successful reconstitution of the pathway. This will not only set up 
a framework for the in vitro biosynthesis of RMV/GV analogues but also demonstrate the 
tremendous power of biosynthesis to generate highly complex molecules, which are 
otherwise impossible to generate in such a concerted way using currently available 
technology.  
Given the fact that the C-8 vinyl side chains of GV/RMV serve as a warhead of 
these antibiotics, future experiments will involve the characterization of the dedicated 
enzymes GilOIII/RavOIII. In this context, acetyl-CoA will be replaced by propionyl-CoA 
and a potential propionyl-CoA:ACP acyltransferase (GilQ/RavQ) will be included in the 
assays. As discussed earlier, co-assay of the PKS and the post-PKS enzymes will result 
GV/RMV pathway intermediates with ethyl side chain instead of methyl group. These 
compounds will potentially serve as substrates for GilOIII/RavOIII. Successful 
characterization of GilOIII/RavOIII together with the other enzymes (Gil/RavM, MT and 
GT) will clarify all of the current ambiguities regarding the structure of the intermediates 
and the sequence of the biosynthetic events. In addition, the results will provide an 
opportunity to assess the gatekeeping vs promiscuity of the individual enzymes with 
regard to their unnatural substrates. Promiscuity of these enzymes can be exploited to 
generate new GV analogues through mutasynthesis as demonstrated earlier in generating 
enterocin,(202) rapamycin,(203) or lacticin 481 analogues.(204) The unusual sugar donor 
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substrate flexibility of RavGT observed in this study is particularly promising for its 
application in generating GV/RMV analogues with diverse sugars. In this context, 
experiments involving the co-expression of ravGT with various deoxysugar biosynthetic 
plasmids in the GilGT-deletion mutant (∆GilGT) seem promising to generate novel 
GV/RMV analogues. 
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Appendices 
 
 
 
 
Figure A1.  Multiple sequence alignment of ketoacyl synthase (α) from several angucycline 
biosynthetic pathways (CmmP from chromomycins, GilA from GV, PgaA from gaudimycins, 
UrdA from uradamycins and Stfp from steffimycin biosynthetic pathways). Consensus amino 
acid sequence (highlighted by arrow) were used to design conserve primers for the amplification 
of internal gene sequence of ketoacyl synthase (α) from S. ravidus. The expected amplification 
(~0.65 Kb) is shown in the DNA agarose gel picture. 
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Figure A2. Multiple sequence alignment of 4,6-dehydratases from several deoxysugar 
biosynthetic pathways (CosH from cosmomycin, RhoH from rhodomycin, Gra-ORF1 from 
granaticin, LanH4 from landomycin and SchS5 from Sch47554 and Sch4755 biosynthetic 
pathways). Consensus amino acid sequences (highlighted by arrow) were used to design conserve 
primers for the amplification of the internal gene sequence of 4,6-dehydratase from S. ravidus. 
The expected amplification (~0.60 Kb) is shown in the DNA agarose gel picture. 
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Apo-RavC1
Expected mass:
10732.85
 
Figure A3. MALDI-TOF analysis of apo-RavC1 
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Apo-RavC
Expected  mass:
11197
 
Figure A4. MALDI-TOF analysis of apo-RavC 
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Apo-JadC
Expected mass: 11613
 
Figure A5. MALDI-TOF analysis of apo-JadC 
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Apo-RavC
Holo-RavC
+383
+340
 
Figure A6. MALDI-TOF analysis of holo-RavC 
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Apo-RavC1
Holo-RavC1
+341
+384
 
Figure A7. MALDI-TOF analysis of holo-RavC1 
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Holo-JadC
Apo-JadC
+340
+383
 
Figure A8. MALDI-TOF analysis of holo-JadC 
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Figure A8. 1H NMR spectrum of deacetylravidomycin E in CDCl3(300 MHz, Varian) 
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Figure A9. 1H NMR spectrum of TDP-3-amino-3,6-dideoxy-D-galactose (55) in D2O (500 MHz, 
Varian) 
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Figure A10. 1H NMR spectrum of TDP-4-keto-6-deoxy-D-glucose (18) in D2O (500 MHz, 
Varian) 
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Figure A11. 1H NMR spectrum of TDP-D-ravidosamine (19) in D2O (500 MHz, Varian) 
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